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Abstract 
DNA profiling has become a universal technique for identifying individuals for evidential use in 
courts of law. In more complex cases such as sexual assaults, identifying the origin of a stain or 
sample offers valuable information as to the events that occurred. Currently, many ‘in service’ 
body fluid identification (BFID) techniques are presumptive, require significant sample volumes 
and generate false positives. As such, the development of a highly specific and reliable BFID 
technique would be highly beneficial to forensic scientists in provide more informative and 
reliable evidence.  
MicroRNAs (miRNA) are short, stable, non-coding RNA’s which modulate gene expression. 
Expression of some of these miRNA are body fluid specific, making them a potentially robust 
tool for BFID. The possibility for the integration of a robust, miRNA based BFID technology for 
forensic casework employing stem-loop reverse transcription and qPCR analysis was the theme 
of the research presented here. To be incorporated into the workflow of current forensic 
laboratories, the protocol must be able to be carried out alongside current techniques with 
limited addition of cost, equipment, analysts and time.  
A range of custom designed miRNA markers were analysed on vaginal material, menstrual 
blood, saliva, venous blood, semen, seminal fluid and skin. Screening indicated specificity of 
hsa-mir-124 to vaginal material, hsa-mir-10a, 135a and 888 to semen, hsa-mir-412 and 507 to 
menstrual blood, hsa-mir-144-3, 144-5, 142 and 451 to blood and although highly expressed in 
saliva, hsa-mir-205 was also observed in vaginal material. Universal expression was observed in 
hsa-mir-93, 508, 1260b and SNORD 47 providing a means of normalisation through the 
designation of these markers as endogenous controls. A combined panel of markers are 
presented which were capable of identifying all body fluids, excluding skin from single stains. 
The panel was successful at identifying certain mixtures such as semen within vaginal material 
but was unable to confirm saliva presence within vaginal material. Screening of hsa-mir-205 
within vaginal material uncovered the observation that hsa-mir-205 was impacted by the use 
of female contraception.  
Once a full BFID panel was generated the robustness of the markers was further analysed across 
the menstrual cycle. No significant difference (p>0.001) was seen in markers highly expressed 
in vaginal material during screening (hsa-mir-124, 203a, 205). Expression of non-specific 
markers highlighted the importance of the optimisation of input miRNA. Differential extraction 
of genetic material was found to be detrimental to miRNA sample integrity. As such, total DNA 
extraction was employed for vaginal swabs obtained from volunteers following unprotected 
sexual intercourse, markers hsa-mir-10a, 135a and 888 were able to successfully detect semen 
presence for up to 96 hours.  
The data generated to date has highlighted a number of miRNA markers that provide a platform 
for BFID. The developed protocol is reliable and robust; requiring minimal optimisation and is 
capable of integration with current laboratory workflow with minimum implications to time and 
cost. The markers identified for BFID have been implemented within studies that are 
representative of real case scenarios, and have demonstrated their ability to be stable, specific 
and successful in the identification of certain body fluids. Overall, this research showcases a 
reliable and body fluid specific protocol capable of being performed alongside DNA profiling. 
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PBMC - Peripheral Blood Mononuclear Cells  
PRC - Police Recorded Crime 
Pro K – Proteinase K  
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qPCR – Quantitative polymerase chain reaction  
RASSO – Rape and Serious Sexual Offences 
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RISC - RNA-induced silencing complex  
RNA - Ribonucleic acid  
rRNA - Ribosomal RNA 
RT – Reverse Transcription  
rt-PCR – real time polymerase chain reaction  
RT-qPCR - Quantitative reverse transcription PCR 
RTS – Rape Trauma Syndrome  
SARC - Sexual Assault Referral Centre 
SDS - Sodium Dodecyl Sulphate  
SEM – Standard Error of Mean  
siRNA – Small interfering RNA 
SNORD RNA – Small nucleolar RNA  
SOA - Sexual Offences Act 
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SOCO - Scene of Crime Officer 
Tris HCl - Tris(hydroxymethyl)aminomethane hydrochloride  
tDMRs - tissue-specific differentially methylated regions  
tRNA - Small transfer RNA 
UPSI – Unprotected sexual intercourse 
WBC – White blood cells 
W/B – White British 
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1. Sexual Assaults 
and Offences 
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 Sexual Assault 
Sexual assault is a crime that occurs worldwide, despite prevalence of this crime reporting 
and conviction rates are universally low [1]. Although many individuals experience an 
incident that meets the legal definition of sexual assault, many do not label their experience 
as such; these individuals are typically described as unacknowledged victims. Research 
shows that a large proportion of rape victims are unacknowledged [2]. The Sexual Offenses 
Act of 2003 (SOA) relates to sexual offences that were perpetrated within England and Wales 
later than May the 1st, 2004; If an offence occurred earlier the SOA of 1956 would apply. The 
SOA 2003 defines various levels of sexual assault. The statutory definition states that an 
individual has committed the offence of rape if he deliberately penetrates an orifice, such 
as the vagina, mouth or anus with his penis without the consent of the other individual, 
usually with force or a threat of force [3, 4]. Life imprisonment is the maximum sentence for 
rape cases however the majority of sentences administered in a court of law are around 5 
years [5]. Cases where aggressive or forceful aspects are involved can increase the custodial 
sentence imposed by the Judge.  
The SOA 2003 states that consent is only valid if the individual has the freedom and capacity 
to consent, therefore if an individual feels pressurised, threatened, incapacitated by 
drugs/excessive alcohol or a certain disability they cannot legally consent to sexual 
intercourse [4]. The SOA 2003 states that penile penetration would lead to a charge of rape, 
whereas penetration of an orifice using a foreign object or another part of their body, such 
as a digit or tongue should face charges of assault by penetration. Therefore under UK law 
only a male can commit the act of rape [4]. Sexual assault encompasses the full range of 
sexual acts, the majority of which are forceful or controlling in nature. Sexual assault 
includes acts of rape but is broadened to sexual acts such as unwanted sexual touching, 
kissing, cunnilingus and grooming [6]. 
The correct case level for sexual assault is difficult to define due to various factors 
surrounding case details that can alter the severity of the sexual offence. The Metropolitan 
Police define sexual assault on two levels; standard and serious. Standard sexual assaults 
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involve occurrences such as the intentional sexual touching of another individual without 
their consent, while a serious sexual assault involves penetration of the vagina or anus of 
another individual with an object or any part of the body without consent [7]. The physical 
action of a sexual assault, known as the actus reus, occurs when an individual performs 
sexual actions against a man or woman when consent has not been provided. The mental 
aspect of criminal activities, known as the mens rea or ‘guilty mind’, was re-defined by the 
SOA 2003. The SOA requires a negative answer to two questions; whether the defendant 
held a belief that the individual provided consent, and if that belief was reasonable. Prior to 
SOA 2003 a lack of mens rea could be argued if the suspect provided an entirely 
unbelievable reasoning for why they believed consent was provided [4, 5]. The prosecution 
must prove the actus reus, a standard for most crimes as well as mens rea.  
The difficulties that courts of law face when dealing with cases of sexual assault is that a 
large range of actions; from verbal or light touching to full penetrative intercourse are 
categorised as a sexual offence. It can therefore be difficult to identify case level, prove that 
consent was absent, or for a judge to assign a correct sentence. Within sexual assault cases 
the burden of proof usually lies on the defendant, as opposed to other crimes such as theft 
or murder where burden of proof must come from the prosecution [5]. The defence have 
only to provide reasonable doubt the sexual assault did not occur or the complainant 
consented for a jury to likely provide a non-guilty verdict.  
The creation of the rebuttable presumption in the SOA 2003, supports victims of sexual 
assault and states that consent was absent and the suspect had mens rea if; violence or the 
threat of violence was carried out against the victim or another party, the victim was being 
held against their will, they were asleep, had a disability or were incapacitated by an 
administered substance [5]. Despite the changes within the SOA 2003, victims can often feel 
very ashamed of their traumatic event or feel that will not be believed or supported by 
authorities. It has also been seen in many sexual assault cases that assailants go unpunished 
even when a case reaches the courts. Victims facing such uncertainly and public attention 
may choose not to report their traumatic experience [8].  
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Measurement of crime within England and Wales is constructed from two main statistical 
sources: the Crime Survey for England and Wales (CSEW), associated with the Office for 
National Statistics (ONS) and the Police Recorded Crime (PRC) data, collected from 44 forces 
across England and Wales. These two data sets in combination provide an informative 
perspective on crime rates and actual reporting of crime. The CSEW is conducted via face-
to-face interviews, due to the sensitivity and discomfort of discussing instances of sexual 
assault the CSEW excludes sensitive cases such as murder and sexual assault. To obtain the 
most reliable overview of sexual assault based crime rates, self-administered electronic 
surveys are performed by adults aged 16-59. Participants are asked to describe any 
experiences involving domestic abuse, sexual abuse or severe violent crime. Reports for 
crime statistics are gathered through the PRC for each financial year of April to March. Crime 
statistics have the benefit of displaying actual crime figures but do not provide information 
on sexual assaults where the victim did not inform the police [9].   
Within both reports, sexual offences include instances of rape, sexual assault, grooming, 
indecent exposure and any illegal sexual act such as touching involving adults and children. 
The self-administer section of the CSEW observed no significant difference in the estimated 
percentage of individuals who were victims of sexual assault or attempted sexual assault 
within that period of April to March. Current data suggests that instances of sexual assault 
have fallen over the last 10 years (Figure 1.1). This reduction however, appears to be as a 
result of fewer instances of less serious sexual assault, where the instances of rape including 
attempts has remained consistent.  
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Figure 1.1: Trends in victims of serious and standard sexual assaults from 2002 to 2013 observed as a percentage of total 
sample base. Data was collected throughout each year with crime data published in April obtained from the CSEW self-
completed crime survey [9] 
PRC statistics include data from all reported cases of sexual offence, the data is however 
only representative of cases where individuals have reported the crime and it has been 
recorded. Total values of sexual offences recorded can be observed in figure 1.2. In March 
2016 the total recorded number of sexual offences was 106,378, consisting of 35,798 reports 
of rape and 70,508 other sexual offences. This was an increase of 21% from the recorded 
crime figures of 2015 (increase 22% rape and 20% sexual offenses) and a significant increase 
from 2011/2012 figures of 52,760 total sexual offences, 16,038 rape cases and 36,722 other 
(an increase of 97%, 125% and 85% respectively [10-12]).  
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Figure 1.2: Volume of sexual offences reported and recorded to 44 police forces over the financial year of April – March, 
recorded from 2002 to 2016. Data is represented in thousands and obtained from yearly PRC figures [11, 12]. 
The CSEW results display opposite trends to PRC figures. The CSEW includes residents that 
at the time of the survey were dwelling in households in England and Wales. The range of 
sexual offences included in the survey is significantly less than those recorded by the police 
and participants are not included if they reside in large residencies, such as care homes or 
campus residences or if they are only visiting the country as a tourist. The most at risk group 
of sexual assaults are adolescents in environments such as universities and the elderly or 
mentally ill therefore if sexual assaults occurred within these higher risk groups it would not 
be included within the survey [8].  
The significantly increased observation of all sexual offences including rape within the PRC 
statistics over the past 5 years is not necessarily representative of the true number of crimes 
reported. A number of factors have shown a positive impact on the willingness of sexual 
assault victims to come forward and report their experience to the police.  
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1.1.1. High profile reports into sexual assault recording 
In 2014 Her Majesty’s Inspectorate of Constabulary (HMIC) and the HM Crown Prosecution 
Service Inspectorate (HMCPS) published investigative findings from 2012 that analysed the 
various police forces management and recording of sexual assault reports [13]. The report 
stated there was a significant nationwide problem of under reporting of many types of 
crime. A large scale audit of available records determined that across England and Wales, 
19% of cases that should have been recorded as a criminal offences were not, with a 
national under reporting of sexual assaults at 26% (1 in 4 reports). The extensive 
investigation discovered the procedures of specialist rape and sexual assault units for 
recording were highly unsuitable, especially when charged with underage or vulnerable 
individual’s cases. The investigation uncovered a multitude of cases that had not be 
properly transferred to the appropriate crime recording system and therefore were not used 
within the national official statistics. This report highlighted the need for improvements 
within reporting and recording of sexual assault cases and set a high precedent for police 
forces. This increase in recording and care of transfer of information will undoubtedly 
increase the national statistics for sexual offence occurrence.  
1.1.2. Large scale investigations into historical allegations 
of sexual abuse 
The active investigation into large scale sexual abuse cases such as ‘Operation Yewtree’ saw 
a prolific number of sexual offences being uncovered [14]. Operation Yewtree was an 
extensive investigation of alleged sexual abuse mainly against children, predominantly 
focusing on the sexual acts performed by Jimmy Savile and other well-known public figures. 
By July 2014 the investigation had uncovered a large volume of sexual assault allegation 
against a further 16 public figures, with individuals such as Gary Glitter, Max Clifford and 
Rolf Harris being convicted of multiple accounts of sexual assault [15]. When these alleged 
sexual assaults occurred, victim’s stated they felt they could not come forward and 
therefore their cases were not included in the recorded crime of that year, the significant 
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volume of occurrences uncovered by Operation Yewtree would cause a significant increase 
in reported figures for that year [14].  
Current investigations into historic allegations of sexual abuse of youth football players by 
coaches have been launched by 15 police forces into 148 football clubs1. 429 alleged victims 
have been identified, the majority of which ranged in age between four and twenty years 
old. Such a large-scale investigation would therefore contribute a significant increase in 
recorded sexual assault for 2016/17 when these cases occurred years beforehand [16, 17]. 
1.1.3. Creation of independent inquires for sexual abuse 
The report of the HMIC and the extensive investigation of Yewtree saw an increased need 
to determine if individuals in positions of authority had shown true duty or care or abused 
their power. The ‘Independent Panel Inquiry into Child Sexual Abuse’ was produced to 
investigate public authoritative bodies and their ability to protect children and higher at-
risk groups [14].  
The CSEW collected feedback from all police forces which stated that both current and 
historical sexual offences continued to rise in the year ending March 2015 when compared 
with March 2014. Police forces did however indicate that the major contribution to this 
increase was believed to be caused from present-day sexual offences. The lack in significant 
change over CSEW data compared to the continual increased in reported cases of police 
recorded data supports the hypothesis that victims of sexual abuse are more willing to 
come forward about their experiences. This increase in willingness is likely due to the high-
profile coverage when investigations occur, the observed serious response that the police 
have shown in dealing with historic cases of abuse and the significantly improved recording 
and reporting procedures of all police forces [12, 14].   
 
 
                                                          
1 Correct as of December 2016 
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 Vulnerable and High Risk Groups 
The PRC provided case details for all reported cases of sexual assault from April 2014 to 
March 2015. Within this year there was a reported rate of 29,265 rape offences, of these 90% 
(26,339 cases) were females of varying ages. Across the 29,265 rape offences almost 25% 
were aged between 15 and 19 years old, with 16% aged ten to fourteen and 14% aged 20-
24 [18]. The predominance of reported rape in young adults and children was clearly 
observed when 73% of all recorded rape cases involving women were aged below 30 years 
old with a third of those females being children under the age of 16. Although rape offences 
involving males accounted for 10% of all rape cases 88% of these males were under 30 years 
with 60% falling under the age of 16. The data represented highlights that young 
adolescents are more at risk of experiencing sexual assault than individuals over 30 [18]. The 
overall statistics for all rape victims, regardless of age group displayed women in a higher 
risk category than males. This could be due to accurate representation of data or that males 
who experience rape may be less likely to report their experience. Figure 1.3 displays the 
proportion of rape offences categorised by the gender and age of each victim. The trends 
that can be observed are that the highest incidents occur in individuals under the age of 30 
with a significant majority being female, however when a sexual offence involves a male 
they will likely be under the age of 16 [18].  
In cases of sexual assault the age of victims decreased with individuals more frequently 
aged between 10 and 14 [18]. This age group, as seen in Figure 1.4, made up 28% of all 
sexual assault cases, compared to the 16% in all rape cases, while 15-19 years old comprised 
19% of all sexual assaults and 23% of all reported rapes. Of the 28% aged 10-14, 83% were 
female and 17% male further supporting females as the highest risk group of sexual 
assaults. Approximately half all reported sexual assault cases involving children aged 10-14 
were recorded as sexual activity involving children such as indecent exposure or 
pornographic images with the remaining involving a physical form of sexual assault. The 
data showed female victims under the age of 30 made up 78% of all female sexual assault 
cases while male victims under the age of 30 made up 84% of male sexual assault offences. 
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Combined over 50% of all male and female offences occurred when the victim was under 
16 [18]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Proportion of rape offences, categorised by age and sex of the victim, provided by the Home Office Data Hub (13 forces), April 
2014 to Mar 15. The highest volume of rape occurred in females aged 15-19 [18] 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.4: Proportion of sexual assault offences, by age and sex of the victim, provided by the Home Office Data Hub (13 forces), April 
2014 to Mar 15. The highest volume of sexual assault occurred in females aged 10-14 [18].   
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The PRC data for both reported rape and other sexual assault offences display a clear trend 
of individuals at higher risk, females under the age of 30 comprised the complainant in a 
significant volume of cases compared to all other incidences in both reported rape and 
sexual offences. With both males and female being categorised as high risk of sexual assault 
below the age of 16 [18].   
 Common Perpetrators of Sexual Assaults  
In 2013, a collaborative review on sexual offending was performed by the Ministry of Justice, 
Home Office and the ONS. The review gathered all available statistics and reported an 
extensive summary on sexual offending throughout England and Wales [19]. The data 
reported that approximately 90% of individuals who experienced a serious sexual assault 
throughout the previous year knew who committed the assault. In cases of other sexual 
offences, for example voyeurism or exposure, the percentage of victims who knew their 
attacker decreased to below 50% [19].  
The review combined recorded data from 2009-2012 to assess the female based victim-
offender connection within serious and less serious sexual assault cases (Figure 1.5). The 
observable trend throughout 2009-2012 is that in cases of serious sexual assault only 10% 
of cases were committed by a stranger, while 56% of cases displayed a current or ex-partner 
as the perpetrator. The majority of cases (52%) of other sexual assaults were perpetrated by 
someone unknown to the victim [19].  
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Figure 1.5: Percentage of female victim based sexual assaults, categorised by severity and relationship to victim [19]. 
The reviews analysis of the self-completion survey, completed by females aged 16-59 from 
2009-2012 also showed the most frequently reported perpetrators were males aged 20-39. 
Table 1.1 shows that in no incidents were women the perpetrator with the highest number 
of sexual assault being committed by young to middle aged adults. This data is not entirely 
comprehensive as cases involving multiple perpetrators were not included however a 
distinct trend in the perpetrators of female victim-based sexual assaults is clear [19].  
Age Male perpetrator Female perpetrator 
<16 1 0
16-19 29 0
20-39 47 0
40-59 20 0
>60 2 0
 
Table 1.1: Results of self-completion module completed by female victims (aged 16-59) of a serious assault. Results of 
2009/10- 2011-2012 were combined with a sample base of 62. Incidents involving more than one perpetrator are not 
included in the results [19].  
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As previously discussed, the most at risk group of sexual assaults are young females. Of 
female victim based crime the perpetrator is highly likely to be male and aged below 40 
years old. In cases of rape and serious sexual assaults the victim is highly likely to have a 
known connection with the perpetrator, either through an intimate relationship or another 
acquaintance. In instances of less serious sexual offences, where no penetration occurred 
the perpetrator is more likely to be unknown to the victim.  
 Prosecution and Defence of a Sexual Assault  
Once the CPS has been provided with evidence from forensic scientists and medical 
examiners and have been provided the key data such as age and vulnerability of the victim, 
the sexual assault can progress to a court of law. The prosecution must then decide the 
offence level that they wish to assign to the case. The SOA 2003 states that a serious sexual 
assault includes rape and even the unclothed touching of genital organs whereas the 
prosecution can assign a lower level in instances where touching was performed through 
clothing or where the vagina or anus were not penetrated. Case level can be heightened 
however in cases where factors that have previously been discussed are involved, such as 
alcohol or violence [4] 
Once case level is assigned the prosecution would provide a prosecution hypothesis that 
that the complainant performed these sexual acts without the consent of the victim while 
the defence would provide an alternate hypothesis in which the complainant’s testimony 
would be taken into account. The outcome would be either the sexual assault never 
occurred or that the events described by the victim happened but they had provided 
consent for every action. Depending on the defence hypothesis the forensic evidence can 
be vital. If the former defence is provided any DNA or BFID evidence would show strong 
support for the prosecution however if the latter is utilised the same evidence would 
support both hypotheses as consent cannot be addressed by any DNA and BFID forensic 
evidence. 
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 Under-reporting and low convictions rate 
Figures for the UK show it has one of the lowest conviction rates for rape in Europe [1]. A 
report by Amnesty International suggested that these low conviction rates could be due to 
“rape myth” ideology held by members of the jury or judges. Over a third of their study 
population (1,000 people) believed that ‘women may be partially or wholly accountable for 
being raped if her actions included flirtatious behaviour and therefore they cannot be declared 
a victim’. 250 of the 1,000 interview participants also believed that wearing inappropriate 
clothing or becoming intoxicated meant partial or complete blame fell on the victim. The 
majority of the individuals surveyed had no awareness of the prevalence of sexual offences 
within the UK [20]. If these views are held by a large percentage of the population, victims 
are less likely to receive justice in a court of law.  
Research has however been performed to show low conviction rates are not solely due to 
victim blaming and rape myths but due to high attrition rates and lack of belief shown by 
police forces [14]. Rape cases are complex and views held by people in positions of power 
will affect how a sexual offence is reported. If a rape occurs where a young female has been 
drinking at a university party, police officers may have doubts as to whether consent was 
provided, due to intoxication and possible regret when sober. If, however, rape occurs by a 
stranger in a public area, the police are more likely to believe the victim [14]. In 2007, 14% 
of reported cases resulted in trial. Approximately 9%, all involving those aged 16-25, were 
categorised as false allegations. Over 33% of these reported that they did not proceed to 
trial as a result of victim credibility, or issues with evidence. A large proportion of the 
remaining reports were retracted due to the stigma they would face, or fear of being 
disbelieved [21].  
Research into attrition of police forces in England and Wales propose that only a marginal 
number of rapes are reported to the police [1]. Of those that are reported, the bulk do not 
result in prosecution of the suspect, or conviction. Retraction of statements from victims is 
highly likely during the early stages of case construction, highlighting that the way police 
officers approach and interact with victims of sexual assault may not be suitable and likely 
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to cause withdrawal of statements. The belief from an authority figure after a traumatic 
ordeal will have a significant impact on whether a victim of sexual assault is likely to pursue 
the prosecution of the offender [1]. Research into rape allegations reported to the London 
Metropolitan police suggested attrition was influenced by rape myths but also heavily by 
ethnicity of the victims and offenders, if the offender was a stranger, discrepancies within 
the victim’s statement, the opinion of the police and prosecutors on the level of significance 
the evidence will provide or any prior notification of false accusations by the victim. Overall 
the research determined that a range of factors influence the level of importance that police 
deal with some sexual assault cases. These include the relationship of the victim and 
offender, the resistance shown by the victim and the injuries they obtained, the length of 
times that elapsed before reporting, their mental health and one of the largest influences 
involved alcohol consumption [21]. 
The in-depth review of the HMIC 2013 inspection into how England’s and Wales police 
forces dealt with sexual assaults showed 26% of sexual assaults were not recorded by the 
police, therefore victims reported their experiences to the police and were incorrectly 
informed it did not meet the criteria to be recorded as a sexual assault offence. The 
inspection also investigated the police protocol of recording a sexual offence and 
subsequently cancelling the report and classifying it a ‘no-crime’. The data from the report 
highlighted 664 reports that were incorrectly voided due to labelling as ‘no-crime’, of these 
200 were rape charges. Overall the statistics for a ‘no-crime’ cancellation was stated at 3.1%, 
however for crimes recorded as rape the level of ‘no-crime’ was 7.3% suggesting that police 
forces are more likely to ‘no-crime’ a case if the charge involves rape [13]. 
1.5.1. Reporting rates within the UK  
The Department of Justice produced data that states approximately 344 of every 1,000 
cases of sexual assault results in the police not being informed, leaving a large proportion 
of victims as unacknowledged. The data showed that only 28% of elderly patients and 20% 
of young females reported sexual abuse to the police. The reports questions victims who 
did report their experiences and discovered the majority did so to protect a loved one from 
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further attacks, to prevent reoccurrence of abuse or they believed it was their duty to 
protect their community from the offender. The majority of victims who did not report their 
experiences stated they did so out of panic of retaliation, to protect the perpetrator, they 
believed the police would do nothing or it was a personal issue that should be dealt with 
without police intervention [22, 23]. 
There are a multitude of additional factors that could prevent victims from reporting sexual 
assaults [8] 
 Fear of social stigma: The fear of what the surrounding community or family may think 
of them if their experiences were known. If their surrounding communities were 
receptive to rape myths there is a possibility the victim may be blamed for causing 
their own sexual assault. 
 Acceptance:  Some victim may feel so traumatised they feel they cannot accept the 
events that happened to them and thus do not share their experience with anyone. 
 Fear of retribution or repeat offences: If the assault is reported and not taken seriously 
the fear that the offender may punish them in a manner far worse than the original 
offence may silence some victims.  
 Pressure from offender not to speak out: In situations where the offender is a close 
family member or friend of the family, they may tell the victim that it will hurt the family 
if the assault was revealed or threaten to hurt someone they care about if they speak 
to anyone.   
 Previous trouble with authority: Individuals who may have had negative interaction 
with the police prior to the sexual assault may feel they would not be shown due care 
if they reported their experiences. 
 Disability: Individuals may lack the physical or mental capacity to explain that they 
were the victims of sexual assault or feel ashamed they were unable to prevent the act 
from occurring.  
 Domestic sexual abuse: Partners may feel it is their duty to have sexual interactions 
with their partners regardless of their wishes and thus not deem their experience rape.  
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 Fear of honour killing or being disowned: In certain regions around the world and 
within the UK, the loss of virginity caused by sexual acts with an individual who is not 
their married partner is considered a great dis-honour to their family. The fear that 
severe familial consequences may occur from revealing their assault would lead them 
to not reporting their offence [24]. 
The ONS looked at abled and disabled individuals under the age of 16 who experienced 
rape or penetration and whether they felt like they could inform anyone of their experience, 
as seen in table 1.2. The results showed that disabled individuals only told someone, not 
necessarily the police in 32% of occurrences, with this number decreasing to 23% in 
individuals with no disability. In all individuals the majority heavily favoured keeping their 
experiences to themselves.  
Within England and Wales Individuals aged 16 to 59 
 Informed Did not inform number of adults 
  Percentages
Long-standing illness or disability  32 68 180 
Limits activities 34 66 156 
Does not limit activities - - 24 
No long-standing illness or disability 23 77 298 
   
Total 26 74 478 
Table 1.2: Proportion of victims of sexual assault by rape or penetration (including attempts) while under the age of 16 
informed anyone about the abuse at the time, by disability, year ending March 2016 [25] 
1.5.2. Increases in reporting rates  
There has been significant efforts through many governing bodies and law reforms to 
increase reporting and conviction rates with the goal of protecting sexual assault victims. 
Prior to 2003, the acts involved to be concluded as sexual assault were very vague. The 
enhanced definition of rape, including factors such as consent, domestic rape and smaller 
sexual offence improved the police and prosecutions ability to assign case level. The 
construction of Sexual Assault Referral Centres (SARC) allowed for dedicated and specially 
trained staff to provide the appropriate medical care and support toward victims of sexual 
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assault, prioritising their emotional and physical needs to support them after experiences 
traumatic events such as rape [1, 4] 
In 2014 the CPS created a National Scrutiny Panel, involving a large scale discussion 
between police forces, prosecutors, respected academics and victims of sexual assault. In 
2015 the CPS then went on to collaborate with the Association of Chief Police Officers 
(ACPO) The result of both of these events was strict new guidelines and a ‘rape action plan’ 
being implemented within police protocols that improved the management and recording 
practices as well as the attitudes towards rape [1, 26, 27]. The new protocols demonstrated 
dramatic improvements were required from every police force with regards to every 
reported sexual assault case. 
 Section 3.1: ‘’The Police will appoint a Rape Champion and the CPS will appoint a 
Rape and Serious Sexual Offences (RASSO) Unit Head who will ensure that the 
investigation and prosecution of rape is co-ordinated between the agencies’’  
 Section 6.1: ‘’Any forensic medical examination of the victim should take place in a 
dedicated examination suite to maximise victim care and the integrity of the 
evidence. Special requirements for victims with special needs must be considered 
and may involve assistance with transportation or the use of hospital facilities for the 
medical examination’’ 
 Section 9.3: ‘’Rape specialists will assist in making a provisional assessment of the 
case, and participate in discussion around lines of further enquiry, identification of 
the likely charges and of the evidence required to support them. They will be 
proactive in identifying, and where possible rectifying evidential deficiencies and in 
bringing to an early conclusion those cases that cannot be strengthened by further 
evidence. In addition the investigating officer and rape prosecutor can discuss 
questions to be put to suspects in interview, any pre-charge court procedures and 
any strategy for a likely prosecution’’[27]. 
These improvements are all aimed at providing support to victims so they feel they will be 
properly represented if the case is carried forward. The attitudes of the police forces are also 
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required to be supportive and non-judgemental when assessing cases of alleged sexual 
assault. It is likely these improvements as well as large scale investigation such as Operation 
Yewtree are the biggest influences in the increase in reporting rates. 
1.5.3. Conviction rates within the UK 
The PRC data for 2005/2006 displayed over 60,000 reported sexual offences, consisting of 
nearly 15,000 instances of rape. Although a steady increase in reporting was observed in 
Figure 1.2, the conviction rates for rape were constantly low with successful conviction 
observed in 6% of cases in England and Wales and 4% in Scotland [9, 21]. Improvements in 
conviction rates have been observed, the CPS released a report in 2016 stating the current 
conviction rates against violent crimes against women. The results state a 57.9% increase in 
the number of convictions for cases involving rape. Within that year the CPS prosecuted 
over 4,600 individuals for charges of rape with conviction being successful in over 2,500. 
Although these figures are promising when compared to the 5.7% observed in the 2005 
Home Office report [28], the volume of reported sexual assaults reported by police forces 
surpassed 100,000 with the CPS only prosecuting 4,600 cases. Of those cases only 60% 
achieved a successful conviction [29]. This low conviction rate, although steadily increasing 
discourages victims of sexual assault from reporting. The criminal justice process can be 
long, humiliating and invasive for a victim. If the chance of conviction is approximately 5% 
many victims may view the process not worthwhile.   
 Rape Myths 
The societal views surrounding rape and sexual assault can have a serious effect on the 
awareness, reporting and the investigation of sexual assault claims. Rape myths are narrow 
and descriptive views about sexual assault such as the cause, context and people involved 
that could provide justification for the act [30]. Rape myths involve false beliefs about the 
victim, perpetrator and the act itself revolving around a stereotypical view of a likely victim 
that shows disbelief and reduced credibility to victims that do not fit that ideal [31]. Barnett 
et al. undertook a study to determine how aspects such as religion and gender effects 
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societal views towards rape. Participation by 653 University students aged 18-30 was 
fulfilled through competition of a questionnaire. The results suggested that people who 
viewed themselves as atheist or agnostic endorsed rape myth acceptance at a significantly 
lower level than individuals within the Roman Catholic or Protestant faith. Individuals of 
these faiths may hold a stronger belief on views such as appropriate clothing and the 
protection provided from their religion. Males were the most likely to endorse rape myth 
ideology however no significant link was determined between gender and religion. Due to 
the high volume of female victims in sexual assault offences is it likely males would be more 
open to the ideology that females put themselves in bad situations than females who may 
have friends that have suffered some form of sexual assault [32].  
The most commonly circulated rape myth is that the majority of sexual assaults and rapes 
involve an unknown individual that violently attacks, usually with a weapon, a woman. 
These attacks cause serious injuries to the victim and occur when the victim is in a remote, 
open area [33]. The common factor within all rape myths is that the victim is to blame for 
the act occurring, such as provocative clothing, travelling alone, visiting unsafe places or 
that the victim is after revenge and thus accuses an alleged suspect with rape [30].  
Previous studies have determined these myths are acknowledged by individuals of all sex, 
age and race, McGee et al. reported that above 40% of their sample population believed 
that a claim of rape was invented by the alleged victim [34]. It is therefore simple to 
understand why victims of rape may not wish to share details to police or the people 
surrounding them. Clay-Warner and McMahon-Howard observed victim reporting patterns 
and discovered a two fold increase in victim report rates if the attack occurred in a public or 
communal area or if the perpetrator invaded the victim’s dwellings. Their results also 
indicated an increase in reporting rates in attacks where an unknown individual was 
involved as opposed to someone familiar to the victim, however the rate of an outside party 
reporting the act increased if the perpetrator was known to the victim. The main cause for 
an influx in reporting rates was however linked to whether a weapon was involved/ serious 
injuries were caused to the victim [35].  
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  Sexual Assault Forensic Medical Examination 
Within the United Kingdom a specialist unit was created to deal with the intricate and 
complex process of sexual assault examination. The sexual assault referral centre (SARC) 
comprises of highly trained and committed individuals, with the knowledge and experience 
to identify possible injuries or consequences of a sexual assault.  The examination is 
performed using a rape kit and must place the medical, physical and psychological 
requirements of the victim as paramount while identifying the key forensic features that 
would be required by the CPS to form a case for the courts [3].  
The SARC examination involves a thorough examination of the individual’s psychological 
and physical condition.  Forensic evidence is obtained from examining the entire body for 
trauma as well as a comprehensive genito-anal examination. The intimate exam starts with 
a visual examination of the external areas surrounding the genitals followed by an exterior 
swab. A speculum is them utilised to cause the least discomfort to the patient while 
obtaining an endocervial swab, if a speculum is too traumatising for the victim a blind 
vaginal swab can be obtained. During the examination it is important to collect swabs from 
the vagina and cervix, with high vaginal swabs (HVS) being taken before the low vaginal 
swabs (LVS). The final swab is obtained from the individual’s anal canal [36, 37] 
If unprotected penile penetration followed by ejaculation occurred, a SARC team would 
utilise various tests that would assess whether spermatozoa were present, if the results were 
positive it would support the prosecution hypothesis that penile penetration occurred.  As 
previously discussed the reporting rates of sexual assaults are low, and victims are rarely 
examined immediately after the assault occurred [3]. Currently there is no defined time 
period for utilising a rape kit after an assault however collection of evidence becomes 
challenging after 48 – 72 hours [38]. The likelihood of finding identifiable spermatozoa 
decreases when the length of time or reporting increases. A medical exam taken two weeks 
after an assault may struggle to identify any wound that occurred or identify the presence 
of spermatozoa and thus provide support for the defence hypothesis that intercourse did 
not occur.  
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 The Aftermath of Sexual Assault 
Sexual assault can cause immediate and long term damage to the victim, the immediate 
damage usually encompasses physical trauma that requires treatments such as provision of 
emergency contraception, medical care to injuries and tests for sexually transmitted 
infections (STI). As time progresses more emotional and psychological effects tend to 
emerge [8, 38]. 
1.8.1. Physical trauma and medical health 
Family general practitioners and doctors care for survivors of sexual offences immediately 
after the event and for many years to come. Sexual assaults involving penetration of the 
vagina can, dependant on the force used and resistance displayed cause significant injuries 
to genitalia as well other areas of the body. Since the highest risk group for sexual assault is 
young females Baker et al. investigated the relationship between age and the genital 
injuries that were observed following rape [39]. They reviewed 234 medical recorded 
obtained from the emergency department of a special rape unit, all cases involved woman 
ages 14 – 29, including multiple ethnicities. Their findings showed genital damage among 
62.8% of cases, higher instances (65.7%) were observed in 14-21 year olds compared to the 
58.5% observed in young adults (22-29). The volume of injuries within each case was also 
assessed, with one survivors suffering 24 distinctive injuries in various locations. The 
average number of genital injuries was approximately 1.8 with the highest frequencies seen 
in 14-21 year olds. Overall the study indicated that although younger age groups did not 
display significantly more injuries than slightly older age groups, the frequency of injuries 
to the thighs, labia and vagina were higher per younger child compared to young adults. 
The injuries survivors display are not always genital, if force such as strangling or a knife is 
used to make the victim comply then significant bruising or laceration may also be present 
requiring further medical care. In addition to physical injuries there are immediate and long-
term medical issues that could arise from sexual assaults, if a condom was not worn by the 
offender tests for STIs will need to be administered and treated if positive. In the months 
following a sexual assault wounds could become infected or the victim may fall pregnant 
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and have the associated medical issues surrounding pregnancy. In certain cases, such as a 
sexual assault between two men there will be a higher risk of being infected with hepatitis 
B or HIV [40]. 
1.8.2. Emotional and psychological trauma 
Research into the emotional state of survivors of sexual assault has shown a severe negative 
impact of psychological well-being following the experience, with the most damage seen 
in young adolescents. Survivors often suffer from depression, self-harm, anxiety, post-
traumatic stress syndrome (PTSD) and can become more submissive to further oppressive 
behaviour from partners or strangers [41]. Victims can also feel self-loathing due to guilt or 
shame of the event. Mental disorders such as PTSD and Rape Trauma Syndrome (RTS) are 
common within survivors of sexual assaults, where RTS is the intense fear and distress that 
they will be killed during a sexual assault. Burgess et al. interviewed more than 600 victims 
of sexual assault and identified RTS as prevalent in the majority of case. The recommended 
requirement of care was crisis intervention counselling with physiatrist evaluation if 
improvements was not observed [42]. A number of interviews with survivors of sexual 
assault disclosed that they were physically repulsed by the idea of engaging with sexual 
activity with new or current partners and they became withdrawn in situations where 
intimacy and physical interaction occurred [43].   
1.8.3. Social stigma 
Despite the internal feelings victims may deal with there is a high possibility of stereotypical 
judgements and negative reactions caused by the prevalence of rape myths and victim 
blaming [44]. If survivors are struggling emotionally and physically with the aftermath of 
sexual assaults, the effects will only be heightened if their surrounding community believe 
that the individual is at least partially to blame for its occurrence. The fear of these 
judgements may lead to victims not informing the police of their action and further 
escalating their negative emotional and psychological behaviour.  
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1.8.4. Re-victimisation 
Survivors of sexual assault are at a higher risk of re-victimisation during their life.  Research 
by Najdowski et al. observed that women suffering from PTSD or RTS were more likely to 
use destructive coping mechanisms such as alcohol, drugs or sexual activities and therefore 
are at a higher risk of being involved in a subsequent sexual assault. Results from a one year 
survey of 555 women who had experienced childhood sexual assault, showed that 
approximately 45% suffered re-victimisation within that year [45].  
1.8.5. Crime reported effects of serious sexual assault 
Data from 2015 PRC and crime survey indicated that approximately 45% of victims of a 
serious sexual assault suffered physical trauma and injuries, with 30% displaying minor 
bruising. Data showed 2 out of 5 victims reported severe trust issues and problems 
developing personal relationships while 3 of 5 victims reported mental and/or emotional 
disorders. Of all incidents of serious sexual assault 9% of victims attempted suicide, 3% 
contracted an STI and 5% fell pregnant [8]. As previously discussed physical trauma and 
mental health influenced attrition and rape myth belief. If the 25% of victims who did not 
show physical signs of trauma displayed psychological conditions while dealing with the 
experience they may experience a lack of belief and assistance from the police and their 
community. 
In summary, the implications of sexual assault are numerous. The physical effects are 
immediate but when coupled to emotional impacts the harm can last throughout the 
victim’s life, with devastating effects on their health and emotional wellbeing.  
 Consent 
Forensic science involves the application of scientific principles to provide evidence that 
aids with queries associated with the law. The issue that forensic scientists face is that 
consent is not a factor that can be addressed, the definitions within the SOA 2003 means 
that the scientific evidence provided cannot determine rape, only the likelihood that an 
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event such as sexual intercourse occurred [46]. The theme of any definition for sexual 
assault is that of consent and can change the verdict of a sexual assault case dramatically.  
Consent is however, very difficult to prove and falls into many categories; it can be revoked 
at any time, it can be conditional, and alcohol and drugs have an effect on the ability of an 
individual to provide consent. Prior to the introduction of the SOA 2003, the SOA 1956 did 
not state a definition for consent. Here, the members of a jury were simply reminded at the 
start of a trial that submission and consent were different and should be taken into 
consideration. Consent was however readdressed in the SOA 2003 and states that consent 
has only been given when a person agrees to participate in a sexual act while having the 
capability and free-will to make that decision [4, 47].  
Numerous factors have an effect on whether it is deemed consent has been provided. 
 An Individual may feel they are mature enough for sexual intercourse however may 
change their mind during the activity and withdraw their consent. If the activity 
continues after this withdrawal then according to SOA 2003 an offence has been 
committed [4]. 
 An individual may state they only feel comfortable with vaginal intercourse, if 
consensual vaginal intercourse occurred followed by anal intercourse. The anal 
intercourse would be considered a sexual offence. 
 Individuals may willingly consume a large volume of alcohol or drugs that could 
inhibit their mental and physical capacity to consent. It would then be up to a court 
of law to decide if the individual consented or was assaulted while in a vulnerable 
state. 
 A sexual partner or spouse of the victim may force sexual intercourse on an 
unwillingly partner, the defence used could suggest that since they are in a 
relationship consent has always been given for sexual acts.  
 Two adolescents under the legal age of consent may both state they provided 
consent to sexual intercourse with each other [4] 
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1.9.1. Verbalised non-consent 
In many case studies of sexual assault involving adolescents, individuals wish to engage in 
a relationship with another individual. In these cases, one of the individuals may feel the 
other party is willing and consenting to performing intimate acts. When told they do not 
wish to perform them the situation can escalate and victims may feel powerless to stop 
what is happening, if they have made their feelings clear and they are ignored and forced 
into sexual acts they may feel there is nothing they can do to stop the situation. This 
however falls into the SOA 2003 definition of rape, if consent is known to not be provided 
the individual continuing the act is committing a sexual offence fulfilling actus reus and 
mens rea.   
Case Study 1-1: Pandora’s survivors stories 2015: Elizabeth was always considered a “full of 
life individual” with a happy outlook on life, this part of Elizabeth was ripped away from her 
when she was sexually assaulted. She described the event as splintering her world and 
feeling broken and alone, she wasn’t sure she would ever feel happiness again. During her 
first week at University she met a young male she described as witty, clever and admired by 
his peers, she described how excited she felt that he would want to kiss her while at a party. 
Elizabeth agreed to enter his room but explicitly said she did not want sex, this was however 
not acknowledge and she felt she had lost control of the situation. He asked Elizabeth if he 
should find a condom to which her reply was a firm no. He refused to acknowledge this and 
proceeded to sexual assault her, thus taking her virginity. As with many victims Elizabeth 
didn’t want to acknowledge what had happened and therefore tried to convince herself 
and friends it had been a loving, wonderful experience. She managed to convince herself 
for three months before realising how much this trauma had affected her life [48].   
The fact that consent was explicitly not given before any sexual interaction occurred means 
that under the law, this case would be deemed as rape. However in a court of law consent 
within this case is hard to prove, the defence would state she consented while the 
prosecution would state she did not. The fact that she willingly entered his room, stated to 
friends that it had been consensual and the time that lapsed before reporting the assault 
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would all support the defence hypothesis leaving the prosecution with limited viable 
evidence. Body Fluid Identification (BFID) would likely not be useful in a case such as this, 
after three months the likelihood of finding external body fluids present from a penile swab 
or vaginal swab would be very low. If the defence stated that sexual intercourse did occur 
however it was consensual BFID would provide no additional support to either case 
hypothesis. 
The application of BFID would be extremely useful in sexual offences where the prosecution 
state the victim verbalised non-consent or the suspect understood consent was not 
provided while the defence state sexual assault did not occur. Semen identification within 
the victim’s vaginal material samples or the identification of vaginal material from the 
suspect’s penile swab would provide substantial support to the prosecution.  
1.9.2. Automatically void consent 
Under certain circumstances the prosecution is not required to prove absence of consent, 
the SOA 2003 states strict regulations on scenarios and individuals where consent is 
automatically void. The criteria needed for such cases focuses mainly on individuals that are 
deemed vulnerable or at risk or on perpetrators in a position of power [4]. 
 Any child below the age of 13: Any sexual activity has voided consent. 
 Individuals with a mental disability. For example, if that disorder debilitates choice, 
if they engage in a sexual activity with their carer or if they are mental manipulated 
or threatened into sexual activity. 
 Individuals with a physical disability: If that disability removes their ability to stop or 
defend themselves from a sexual assault: If a carer takes advantage of a patient in a 
paraplegic state.  
 Children below the age of 18: If sexual activity occurred with a member of their 
family who is above the age of 13 or who is in a position or authority or trust [4]. 
Khalifeh et al. performed a study to identify the prevalence of sexual offences against 
patients with severe mental illness. 303 randomly selected patents diagnosed with severe 
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mental illness who had been in contact with community services at any point in 51 years 
provided information using the British Crime Survey domestic/sexual violence 
questionnaire. Data was compared to 22,606 people in a control group consisting of the 
general population participating in the 2012 national crime survey. As observed in Figure 
1.6, a serious sexual assault happened to 40% of females with mental illness compared to 
7.1% of the general population, the figures were still high for men where prevalence was 
12.5% compared to 0.5% of the general population. 61.2% of all females stated a form of 
sexual assault had occurred since the age of 16, compared to 21.1% of the general 
population. The conclusions from this study are that individuals with severe mental illness 
are at a higher risk of sexual assaults relative to the general public and therefore more 
observance and support must be provided to protect patients with mental illnesses [49].  
 
Figure 1.6: Prevalence of sexual assaults against males and females with severe mental illness. Data shows a high 
prevalence of serious sexual assaults in women suffering mental illness compared to the control group [49]. 
BFID would be an essential tool in cases where consent is automatically void. In cases where 
a careers DNA is found on a patient the defence could state that the DNA was transfer during 
routine care of the patient, possibly washing or restraining if the patient became agitated. 
DNA evidence alone would therefore not be substantial enough for the prosecution, if 
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however BFID ran alongside DNA profiling, and the DNA present could be linked with 
semen the prosecution hypothesis that the patient had been involved in a sexual would be 
proven and due to void consent could not be argued.  
1.9.3. Age of consent  
Sexual abuse of children includes any act that the law defines as sexual with a child who is 
below the current legal age of consent, these acts could be a lone occurrence or be 
recurrent over many years. Sexual abuse of children can occur from strangers, adults or 
peers however the offender in most cases is an individual who has obtained a position of 
trust or authority with the child. 
Current UK legislation identifies two classifications of offence which contain different 
stipulations dependent upon the age of the child: the categories classify sexual offences 
against children that are below the age of 13 and 16. Worldwide statutory rape is defined 
as sexual intercourse with an unmarried individual who is below the legal age of consent of 
that country. Force is not a pre-requisite; the crime lies exclusively with the age of the victim. 
The law presumes that adolescents lack the maturity and are included in the vulnerable 
category and therefore cannot provide valid consent to sexual intercourse. These laws 
attempt to safeguard young individuals by discouraging those who might take advantage 
of the lack of maturity. The laws governing statutory rape punish those who have 
committed sexual abuse against young people, however they also act as a deterrent for 
consensual sexual intercourse amongst young individuals. The law surrounding statutory 
rape provides no support for a defence hypothesis, a defendant’s claim of being unaware 
of their sexual partner’s age will not be acknowledged in a court of law [4, 50]. 
1.9.3.1.  Offences against children below 13 
In case where sexual activity has occurred with a person over the age of 18 and a child below 
the age of 13 the prosecution must only prove that sexual activity occurred and the age of 
the individual on the date the event occurred. The SOA 2003 states that a child below 13 
years old cannot legally consent to any sexual activity, regardless of any surrounding 
circumstances [4]. Upon conviction a prison term not exceeding 14 years can be imposed. 
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BFID of semen/saliva within or surrounding intimate areas of a child below 13 years old 
would provide highly supportive evidence that sexual assault occurred and therefore the 
suspect would be charged with rape. 
1.9.3.2. Offences against children below 16 
Within the UK the lawful age of consent in 16, this applies to both sexes and sexual activity 
between different or matching genders. The SOA 2003 states that a sexual offence has 
occurred if the victim is under 16 and the suspect does not reasonably believe the victim is 
16 or over. Upon conviction a prison term not exceeding 10 years can be imposed. The law 
applies in a similar fashion to prosecution of assaults of children under 13 in that consent 
cannot be provided, however in cases such as two 15 year old engaging in consensual 
sexual intercourse the court are unlikely to deliver a custodial sentence. 
1.9.3.3. Offences against children below 16 when perpetrated by an individual 
below 16 
Regardless of consensual sexual activities occurring between two young adolescents the 
SOA 2003 states that sexual activity with an individual under 16 is still a sexual offence, 
however leniency dependent on the situation is more likely. When determining the 
legislation for the sexual assault act 2003 key priority was to protect victims of sexual 
assault. During the passage of the Sexual Offences act, Lord Falconer stated "Our overriding 
concern is to protect children, not to punish them unnecessarily. Where sexual relationships 
between minors are not abusive, prosecuting either or both children is highly unlikely to be in 
the public interest. Nor would it be in the best interests of the child ..."[51]. If however one 
individual is below the age of 13, statutory rape would still be applied regardless whether 
the other party was below 16. 
Case Study 1-2: Supreme Court Case ID: UKSC 2016/0083: At the age of 14, an individual 
was charged with showing pornography and indecently exposing himself to other children 
his age. The Scottish police did not carry forward with any charges. At the age of 19 however 
the individual was arrested and charged with engaging in sexual intercourse with a female 
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under the age of 16. In certain cases the defence could state that the individual reasonably 
believed that the female was over the age of 16. However section 39 of the Scottish SOA 
2009 state that this defences cannot be applied to individuals who have previously been 
charged with a relevant sexual offence [52].  This case is still be deliberated in the courts as 
to whether the defendant can plead ignorance of knowledge of age considering he was not 
charged with a sexual offence at the age of 14 [53]. 
In cases involving individuals under the age of 16 the law surrounding consent can become 
convoluted. In certain cases, a defence can be made that there was no reasonable 
knowledge the individual was under 16, however every case may have implicating factors 
that will change the prosecution’s defence hypothesis meaning all evidence can alter the 
outcome of a case within a court room. In cases where the individual is below the age of 13 
years old, or sexual intercourse occurs when the suspect is aware their partner is below 16 
years old, the only thing that must be proven by the prosecution is that sexual assault 
happened. BFID would be essential to providing this evidence, if saliva or semen is identified 
on intimate areas of a 13-year-old child it would indicate sexual activity occurred.  
1.9.4. Revoked consent 
Penetration is an on-going act and as such consent can be withdrawn at any time after initial 
penetration has begun. Individuals may feel they are ready to take their relationship to a 
more intimate level and thus consent to sexual intercourse, if however they regret this 
decision and verbally or physically make their partner aware they wish the action to cease 
and the act does not, it transforms from consensual intercourse to rape  [4, 54]. A qualitative 
study performed by the NSPCC stated that approximately 40% of young people engage in 
sexual texting with peers [55]. In these cases individuals may feel safe and confident with 
expressing sexual thoughts or ideas, however these feelings may change when faced with 
physically performing them with a partner who believes they are willing. 
Case Study 1-3: March 23, 2000: Laura T, a 17 year old female finished her job at a 
supermarket. At approximately 6.30pm she picked up a gentleman she had met two weeks 
prior called Juan and drove them to a small gathering at a friend’s house. Everyone present 
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consumed alcohol with the exception of Laura. Laura states that at 8.10pm she declared 
that she wished to leave but was persuaded to join Juan and his 16 year old friend John in 
the bedroom. After they entered the dark bedroom Laura, Juan and John engaged in 
consensual sexual interaction, this included the removal of Laura’s garments, the fondling 
of her breasts and digital penetration. Laura was then asked if she would like to ‘’have two 
guys at the same time’’ to which Laura said she did not. Following this John left the room 
while Juan opened and put on a condom. Noticing this Laura verbally and physical objected 
and resisted to sexual intercourse with Juan, however despite this Juan used force to have 
sexual intercourse with Laura. Laura’s consistent resistance resulted in Juan ceasing 
intercourse and leaving the room to which Laura then got up to find her clothes. During this 
time John entered the room naked, he complimented and kissed Laura and asked if she 
would be his girlfriend. Laura then kissed John, to which he responded by climbing on top 
of her and engaging in sexual intercourse. Sexual intercourse lasted from approximately 10 
minutes, during this time Laura physically struggled and repeated three times that she 
“needed to go home”, John’s response was always “just give me a minute”. Following the 
termination of sexual intercourse John turned to Laura and stated “Well, I didn’t rape you 
so you cannot call the cops” indicating that he felt no criminal action had been committed 
[54]. 
In this case study BFID would only prove sexual intercourse occurred, since the victim 
accepted consensual intercourse occurred but then revoked her consent the BFID of his 
semen would provide no support to the prosecution. This case would rely on DNA profiling 
and prosecution to provide evidence that consent was not provided.  
1.9.5. Drunken consent  
The matter of capacity to consent in cases of sexual assault where a large volume of alcohol 
has been voluntary consumed by the victim is difficult to prove in court.  
Case Study 1-4: R v Bree [2007]: Bree visited his brother at University and consumed a large 
volume of alcohol over the course of the evening. Bree heavily drank with another female 
he had met that night and they proceeded back to Bree’s home. She recalled having sexual 
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intercourse with Bree and that although she had not stated no, she did not provide consent. 
Bree’s defence states that he held reasonable belief that they were undertaking consensual 
sexual intercourse due to her taking her own clothes off and appearing to be willing and 
awake throughout the event. Bree was sentenced to a custodial sentence for rape, however 
the court of appeals overturned this decision stating drunken consent is still consent and 
that the evidence provided was not substantial enough to prove consent was not provided 
[56].  
In this case the Court of Appeal addressed capacity to consent and stated that if a 
complainant, due to intoxication lost her capacity to decide to willingly engage in sexual 
intercourse then consent was not provided and the act would be charged as rape. If 
intercourse occurred where a complainant had voluntarily consumed alcohol but remained 
capable of making decision and provided consent it would not be rape [57]. In cases where 
alcohol is involved the capacity to consent of the victim is difficult to prove and must be 
properly assessed with each individual case. The court of appeal suggested that if the victim 
was incapable of making decisions, as would be the case if unconscious then rape had 
occurred, however the recollection of events due to unconsciousness could have a negative 
impact on prosecution support.   
Case Study 1-5 R. v. Dougal, 2005: A 21-year-old student drank vodka with her friends 
before attending a University party on campus where she continued to drink with friends. 
Due to intoxication, she began to feel ill and ask a nearby security guard to take her back to 
her dorm. The female recalled very little from the evening except briefly emerging from 
unconsciousness to become aware she was lying in the hallway outside her door and 
something was happening to her. When police interviewed Mr Dougal he stated intercourse 
did occur however it was consensual, the victim stated she was adamant she would not 
have provided consent and if that were the case they would have entered her flat. The High 
Court Judge in this case directed the jury to reach a verdict of not guilty, stating drunken 
consent is still equivalent to consent. The case was subsequently abandoned [58]. 
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Since the victim has no recollection of providing consent there is reasonable cause that it 
was provided, be it in an intoxication state and therefore sexual assault is incredibly difficult 
to prove. BFID would only be required in cases where the defence stated that no sexual 
activity occurred. If the defence of Bree or Dougal had stated they did not have intercourse 
with these women but intimate swabs detected the presence of semen the support would 
be towards the prosecution. 
The impact of alcohol consumption and the recollection of events while intoxicated varies 
between individuals and research into the effect alcohol has on memory loss is ongoing. A 
study by Hagsand et al. analysed the accuracy of testimony under various alcohol 
consumption levels, their results suggested that alcohol does not always have a negative 
impact on memory and that although intoxicated witnesses may recall fewer details there 
were many who displayed recall as accurate as sober witnesses [58]. Current research 
however does not take into account the context of the traumatic event, such as a sexual 
assault that occurred and how mentally processing while intoxicated could impact memory 
recall. This lack of recollection by a victim may provide stronger evidence to the defence, as 
observed in case study 1-5 however BFID can add an additional aspect to the evidence that 
may, in cases where the suspect denies intercourse occurred be essential to supporting the 
victims account.  
1.9.6. Conditional consent 
In certain cases, the capacity to consent is not addressed but the conditions stated before 
sexual activities occurred are. If an individual states they wish to engage in vaginal 
intercourse however do not feel comfortable with anal intercourse they are conditionally 
consenting to sexual intercourse. If the partner decided to penetrate the anus then a sexual 
act without consent has occurred. In other cases oral intercourse may be consensual 
between partners but not vaginal penetration. If this is known and penetration occurs then 
consent is removed and a sexual offence has been committed. 
Case Study 1-6: EWHC 945, 2013: The complainant stated that following their Islamic 
marriage her husband exerted substantial control over her, he regularly demanded sexual 
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intercourse which often included physical aggression. The complainant was submissive to 
these demands as she felt it was her duty and therefore provided consent. Throughout a 
year of marriage the court heard a pattern of sexual aggressiveness had become 
established, and although her husband knew it was reluctant acceptance he concluded 
consent was given.  In February 2010, her husband demanded sexual intercourse with his 
wife. The complainant knew she did not want any further children and due to medical 
reasons preventing hormonal contraception and her husband’s aversion to condoms, 
withdrawal was their accepted method of contraception. The complainant stated clearly 
before intercourse occurred than she would only be happy if he withdrew and did not 
ejaculate. After intercourse began her husband told her that he would ejaculate inside her 
‘’because you are my wife and I’ll do it if I want’’. The results of these events were that 
complainant became pregnant [60].  
If conditional consent is provided on the basis that ejaculation does not occur or a condom 
will be worn the application of BFID would be beneficial to the prosecution. The 
identification of semen, where in both situations it should not be present would conclude 
that the conditions of consent have been breached and therefore was not provided by the 
victim.  
 Drug Related Sexual Assaults 
The voluntary consumption of alcohol and drugs has previously been described however 
drug facilitated sexual assaults (DFSA) are defined as sexual activity that occurred due to the 
administration of drugs by the suspect. DFSA are classed as pro-active or opportunistic, 
relating to whether an individual purposefully administers substances such as sedatives to 
victims with the intention of committing a sexual assault or if while an individual is 
incapacitated they take advantage of this debilitation and perform sexual acts [61].  
The ONS CSEW collected data from 26 forces where alcohol was involved in a sexual offence 
claim, the results for alcohol related sexual offences can be observed in Figure 1.7. Across 
all the cases observed over 20% of cases recorded rape of a female over the age of 16 
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involved alcohol. Values were not much greater than the percentage of male victims 
observed. It was observed that as the victim age decreased, the less alcohol was involved. 
This could be due to adolescents over the age of 16 being present in an environment where 
alcohol is abundant and that children do not have access to alcohol [18]. 
 
Figure 1.7: Prevalence of sexual assault cases involving alcohol [18]. 
Many reports of sexual assault involve females that recall being out with other people for a 
night out and their next memory involves waking up somewhere unfamiliar. 
Case Study 1-7: B-Heard survivor’s story: A young female, between the age of 18 -25 went 
out for her best friend’s birthday with a group of friends. A space was rented and invites 
were sent out to a large number of individuals from different academic institutions. The 
female recalls having one glass of champagne and then states ‘everything went black’. She 
woke up in the morning in an unrecognised apartment with no recollection of the previous 
evening. She was completely naked and had no idea where she was. She recalled that she 
was menstruating and was aware that her tampon had been removed and felt general pain 
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and discomfort especially around her vagina and anus. She woke up to a note wishing she 
had a good night and to help herself for breakfast. The female felt too scared and ashamed 
to tell anybody but felt extreme discomfort around her genitals so went to the hospital. An 
intimate exam confirmed that she had been penetrated in the anus and vagina – with her 
tampon being removed prior. To all of this the female has no recollection [43].  
The lack of any recollection from the victim would mean that support and case severity 
would be hard to determine. The defence may state that an object was used to penetrate 
the female, that she penetrated herself while masturbating or that no sexual activity 
occurred at all. Due to the victim’s lack of recollection, although examination showed 
penetration occurred a jury would have reasonable doubt that rape didn’t occur. If BFID 
could be utilised on her intimate samples that indicated semen presence, then ideally 
alongside the suspects DNA profile a clear description of the events could be provided to 
the jury.  
In the case of Regina v Weller, self-administer intoxication led to the suspected 
opportunistic sexual assault of a young female.  
Case Study 1-8: R v Weller [2010] EWCA 1085:  Emma was a 16 year old female who 
attended a party with her friend. Emma knew the appellant who lived at the residence of 
the party. She drank steadily through the night and after realising her friend had gone home 
and she was unable to contact anyone to take her safely home, decided to stay the night. 
Emma felt drunk and dizzy and vomited throughout the evening. The appellant was 
tentative and took care of Emma, after a few visits to her bedroom he began stroking her 
body and breasts and then inserted his finger into her vagina in such a way that caused a 
lot of pain. She later managed to leave the house via a friend who took her to be examined 
upon hearing about the events of the evening. The defendant admitted to taking care of 
Emma but denied the charges of sexual assault. Fingernail clippings were taken which 
showed a minor profile contribution matching Emma’s reference profile was found on the 
underside of the fingernail. The defendant, although charged with sexual assault stated 
there was a number of way the DNA evidence could have got there, including, contact with 
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the victims vomit, moving/holding her hair while she was vomiting, transferring her into her 
bed or while placing her in the recovery position and well as picking up her clothes  [62].  
In this case, the likelihood of the defence’s causes for the victims DNA being found was 
accounted for and deemed unlikely, resulting in a conviction for sexual assault by 
penetration. This evidence within this case could however have been improved with BFID. 
If the material under the fingernail was shown to be vaginal material the defence would not 
be able to suggest the possible reasons they did, with the only reason being penetration of 
the vagina. It could have been further implemented on the vaginal swabs of the 
complainant; if a full of partial DNA profile is obtained along with an identification for skin 
it would further support the prosecution that digital penetration occurred.   
 Domestic Sexual Assaults 
When a sexual assault occurs within a marriage or a long term relationship the victim may 
feel they are obligated to have sexual interactions with their partners and therefore not 
determine the experience as rape. This obligation or feeling that they should serve their 
partner regardless of their feelings makes it unlikely they will report the incident to police. 
The home office collected data of all domestic abuse cases that were reported and 
identified the percentage involving sexual assault, observed in Figure 1.8. This data is based 
solely on reported crimes and therefore the value is likely higher due to lack of reporting. 
Domestic violence made up 11% of all recorded cases. Violence against a partner was 
observed to be the most prevalent offence (33%) however 12% of all domestic violence 
cases were reported to include sexual offences [63]. Women may not feel an obligation to 
engage in sexual behaviour with their partner but rather suffer sexual abuse and feel they 
have no way to remove themselves from the situation. In cases such as this the women may 
feel they cannot report their abuse and therefore are subjected to re-victimisation.  
 
 
 
 
58 | P a g e  
 
 
 
 
Figure 1.8: Breakdown of reported domestic abuse cases occurring from April 2015 to March 2016. Data reports that 11% 
of all recorded offenses within that year involved domestic violence (Orange). Of that 11%, 12% involved an aspect of 
sexual assault [63]. 
 Sexual Fantasies of Rape 
The area of sexual fantasies is extremely diverse; however the area that has proven to be 
most intangible is that of ‘rape fantasies’. The idea that women find pleasure in fantasising 
about an experience that would be viewed unpleasant by the majority of public opinion 
has been an interesting topic of research for many psychologists since the 1940s [64, 65]. It 
is understood in some research groups that fantasies operate in terms of wish fulfilment 
and therefore on a certain level, females desire to experience this, this has however been 
disputed in other publications [66-68].  Studies are however deficient due to a multitude of 
factors; if awareness is made that some woman have erotic rape fantasies it might reinforce 
an individual’s notion that women want to be forced into having sexual intercourse. There 
is also a stigma attached in revealing these fantasies within a public setting, such that they 
could be viewed as having something wrong with them [66-68].  
Critelli’s research group suggested that 31-57% of women have fantasies, on some level in 
which they are forced into sex, with 9-17% of those women affirming these are frequent 
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fantasies. Critelli’ et al correlated data from many studies and found that almost all included 
the words ‘’overpowered’’, ‘’forced’’ and ‘’surrender’’ in their description of their fantasies 
[69]. Research by Laumann et al. indicated that over 99% of women specified that they no 
desire to be genuinely raped, saying the idea would repulse and traumatise them [70]. 
However, women who find themselves frequently fantasying about rape or divulging these 
fantasies to others, could unintentionally find themselves in situations where they are at a 
higher risk.   
Case Study 1-9: DPP v Morgan (1976). Morgan was a married man with a senior role in the 
Air Force. He began an evening of drinking with three junior officers, he explained that his 
wife had rape fantasies and that the men should join him at his home and all have sex with 
his wife. She would protest and try to resist but this greatly heightened her sexual pleasure 
and therefore they should go along with the act. The junior officers agreed and all travelled 
to Morgan’s house where they dragged Morgan’s wife into a spare bedroom and all 
proceeded to have sexual intercourse with her. Morgan’s wife resisted and struggled 
throughout the assault and was later admitted to hospital for her injuries [5].  
Under the SOA active in 1976 a husband could not rape his wife and therefore he was only 
charged as an accomplice, the junior officers were however all charged with rape. The junior 
officers argued they lacked mens rea, which at the time was stated as ‘at the time the 
perpetrator is aware that the person does not consent’, due to the their senior officers 
comments on his wife’s rape fantasies and that she was consenting even though she 
displayed physical signs of resistance. The House of Lords accepted that there was a lack of 
mens rea due to their genuine belief however the convictions were maintained on the basis 
that a correctly directed jury would never have accepted that Morgan’s wife had provided 
consent.  
A current case such as this would be addressed differently under the current SOA, a lack of 
mens rea is only acceptable if their mistake is deemed reasonable. In a case such as this the 
SOA states although the junior officers truly believed they had consent they had not taken 
the due care to determine if the victim was providing consent [5]. If in cases such as DPP v 
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Morgan the victim had voiced her excitement over rape fantasies to her husband or her 
friends it could have provided support to the defence even though she may only have 
wished them to be fantasies. BFID and DNA profiling would have identified the individuals 
and the presence of semen but the issue of consent could not be addressed.  
 False and Baseless Sexual Assault Reports 
When a criminal investigation is launched into an accusation of rape the police can label the 
case ‘unfounded’ for either of two reasons, if they believe the claim is false, or if they believe 
it is baseless [71]. The problem with this system is that, although occasionally 
interchangeable they carry significantly different definitions. A deliberate fabrication of 
events by an individual describing themselves as the victim of rape will be reported as false. 
It is defined as baseless when the complainant s account is truthful but surrounding factors 
do not meet the legal definition of rape or other sexual offences [72]. In a case where a 
sexual assault is committed against an unconscious female that results in no forensic 
evidence that the event occurred, the complainant s allegation would be determined 
baseless but not deliberately false. Both these issues need addressing; false reports must be 
assessed correctly to ensure innocent people are not prosecuted and baseless reports must 
have more efficient techniques for identifying factors of sexual assault.  
Case Study 1-10: A woman contacted police about a white van that pulled up beside her 
and asked if she required a lift, after she entered the vehicle the suspect parked under an 
overpass, brandished a knife and threatened her with violence if she was not compliant. 
When the complainant next visited her therapist she spoke of her ordeal and was advised 
to report her claim. Upon visiting the alleged crime scene with an investigating officer, she 
was made aware that a security camera was present and would be able to identify the 
vehicle involved in her complaint. It was at this moment that the complainant admitted to 
fabricating the incident, stating that when depressed she occasionally initiates sexual 
encounters with older men and that all of the stated event was consensual [71].  
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In this case DNA profiling and BFID techniques would have identified semen that matched 
the profile of the suspect, providing substantial support to the prosecution. The prosecution 
of this case may have led to an innocent man facing a custodial sentence. 
Although it is important to increase the conviction rape of sexual assault cases there is also 
a need to protect victims of false accusations. In 2012, a report was conducted by the CPS 
equality and diversity unit, into charges made against false reports of sexual assault and 
domestic violence. The Director of Public Prosecutions understood the controversies and 
sensitivities that surround false allegation charges and wished to assess all charging 
decisions. The Director analysed 159 cases throughout January 2011 to May 2012, 121 of 
which included an allegedly false rape or sexual assault claim. Of these 121 cases, 105 
claimed rape, ten claimed sexual assault and five claimed other sexual offences. The results 
of these allegations resulted in twenty five charges for perverting the course of justice and 
ten for wasting police time. 75 cases received no further actions with the remaining cases 
being dealt with using out of court disposal methods [73].  
The reported also analysed the age and sex of the suspects, stating that 92% of all the 
alleged rape and domestic violence cases were female. The report showed that 51% of the 
121 rape cases were made by individuals under the age of 21, 8% of those being below the 
age of 16. In these alleged rape and domestic abuse claims 98% of the victim’s attackers 
were male, with the majority of victims being above the age of 21 [73].  
The final factor the report analysed was the relationship between suspects and the 
individuals they had accused. From the 121 rape allegations 96 suspects had identified a 
specific individual as the alleged attacker, of these cases, 25 were currently or previously 
within an intimate relationship, 11 were a family member and 32 were a simple 
acquaintance. The report’s conclusions showed that over half the suspects, who at the time 
were under 18 did not make the initial allegations, but through a third party. It also states 
that in the majority of these cases the suspect felt like the investigation had spiralled out of 
control and they were unable to cease the investigation [73].  
 
 
 
62 | P a g e  
 
 
 
The report highlighted many reasons that may cause an individual to feel like they should 
make an allegation of rape, these include family pressure, mental disability, and 
embarrassment and/or resentment against another individual, selected case studies from 
this report are displayed below [73]. 
Case Study 1-11: A 14-year-old female was in an intimate relationship with a 17-year-old 
male, the father became aware of this relationship and forbade them from continuing. The 
male and female had penetrative intercourse, when questioned by her father she stated she 
did not want to have sex and that he forced himself on her. Her father contacted police to 
which the female proceeded to give a statement, the young male was arrested and 
prosecuted for sexual offences against a child. Throughout the investigation police found 
evidence supporting the defence and therefore re-questioned the young female.  She 
admitted to making a false allegation as to not upset her father however felt powerless to 
stop the investigation once police were involved [73].  
Case Study 1-12: A 20-year-old male, known as Mr W was in a sexual relationship with a 
female, during a conversation with his mother he claimed he had been raped by another 
man. A report was made with police through the mother and the individual was arrested 
and interviewed. He claimed sexual intercourse had occurred however it was consensual. 
As the investigation continued evidence supporting the defence was found and Mr W was 
re-interviewed. Mr W then admitted he had been struggling to reconcile with his 
homosexuality and made the allegations out of depression and guilt over his sexuality. 
Within this case, Mr W was prosecuted with perverting the course of justice [73]. 
The cases and data from this report seems to suggest that younger women are more likely 
than men to make a false accusation, especially against an older male, however in context 
only 29% were prosecuted for false allegations. The report also compared their data with 
CPS data for rape prosecutions, during the same time period 5,651 claims of rape were 
prosecuted in a court of law throughout England and Wales whereas only 35 individuals 
were prosecuted for making a false accusation of rape. This data therefore suggests that 
over this time period approximately 0.6% of prosecuted sexual assault cases were false, 
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highlighting that although false allegations are a serious and sensitive issue, they are 
minimal in number compared to genuine sexual assaults [73].  
The issues surrounding the investigation and prosecution of false reports of sexual assault 
become even more convoluted when placed in common circumstances such as marriage 
or family settings 
Case Study 1-13: R v Ashley [2010] EWCA Crim 2913: In 2010, the Court of Appeal addressed 
a difficult case. Mrs Ashley contacted the police and reported she was regularly abused and 
had been raped by her husband on multiple occasions. Mr Ashley was subsequently 
arrested and charged with sexual offences. A short period after Mrs Ashley states that 
although her statement was true, she and her husband had resolved their problems and 
she no longer wished for him to be prosecuted. The CPS determined that cases of rape were 
not considered a private matter between domestic partners and therefore continued 
prosecution. This prompted Mrs Ashley to declare that her initial statement had been 
fabricated and therefore removed any evidence from the case.  Due to Mr Ashley spending 
time in custody over these false allegations the CPS prosecuted Mrs Ashley for perverting 
the course of justice, after being charged Mrs Ashley retracted her previous statement and 
stated the initial allegations of rape were true. The result of her case was a sentence of 
8months imprisonment for dishonestly withdrawing a real allegation, known as a double 
retraction [74]. 
In cases such as this the victims of sexual assault are further punished for trying to speak out 
about their experiences. In domestic situations victims can feel loyalty or obligations to their 
family / partner or face pressure or stigma from others and therefore refuse to report their 
ordeal or refuse to acknowledge the severity of what happened. Mrs A describes her 
husband and father of her children as a man who felt he must exert dominance and control 
over his family, women in these situations become particularly vulnerable and need to be 
protected by a court of law. The appeal for this case saw Mrs Ashely’s custodial sentence 
replaced with a community sentence.  
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The cases described above highlight the need for improved techniques in forensic 
examination and the CPS’s processing of false allegation. Ensuring cases that are reported 
false or are retracted out of fear or pressure can be accurately assessed and victims of rape 
or false accusations are fully protected. BFID techniques may provide substantial support in 
correctly identifying false allegation: If an individual states they were sexually assaulted by 
a male and supporting evidence causes suspicion on the truthfulness of the events, the lack 
of DNA profile and absence of markers used for identification of body fluids would increase 
the support of the defence hypothesis that sexual interaction did not occur.  
 Summary of Sexual Assault 
Sexual assault is a highly prevalent act with seriously damaging effects on the victims. 
Despite the associated trauma, victims frequently do not report their experiences to the 
police and justice is not provided. Although reporting rates have dramatically increased 
there is still a high proportion of victims that are not supported. Sexual assault cases are 
seen across a widespread population, however the most at risk groups are young females, 
the mentally and physical disabled and the elderly.  
Overall sexual assault can be very difficult to prosecute in a court of law, there are many 
contributing factors that affect whether a case will even be heard in a court room. In many 
cases additional information would provide essential support to a victim, be it eye witness 
accounts or the identification of body fluids present, to fully understand what events 
occurred without the need to rely on the statements of those involved.  The research and 
development of BFID techniques could provide this additional evidence, resulting in an 
improvement in conviction rate. An increase in conviction rates may lead to an increase in 
reporting rates as victims can physically observe this trend and could think they will be 
successful as well. As previously described, a tenable link was suggested from the 
investigations into high profile cases and an increase in reporting rates, therefore this would 
likely be seen again if conviction rates were to also increase [12,14].  
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DNA evidence has been available for use in the courts since 1986. Its first implementation 
was to exonerate a 17 year old male accused of a double rape-murder charge. The first 
conviction using DNA evidence was in America, following a DNA match from a semen 
sample and the suspect’s blood sample in a rape case [75, 76]. Although the technique has 
improved it is still the same evidence and even though a suspect can be identified, it only 
places them at the scene. A simple defence argument can transform the weight of DNA 
evidence, for example, the suspects DNA found in the vaginal canal is from epithelial cells 
from digital penetration not from semen. This would be hard to prove without BFID. If 
offenders as well as the prosecution and defence were aware of the existence of BFID it may 
limit the variability of the defence hypothesis but ideally make potential perpetrators aware 
of the increased capabilities for building evidence and thus not commit the offence.  
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 Forensic Scientists  
It is the obligation of the forensic scientist to interpret data objectively and to form and 
state a hypothesis based on the results obtained from crime scene stains. Many forensic 
scientists may analyse samples for a case and it is important they remain unbiased and 
impartial. It is their role to provide evidence that can support either the defence or 
prosecution; they cannot however address consent and therefore stating whether charges 
of rape or sexual assault should be applied is impossible. Any information such as DNA 
profiling or BFID obtained from samples can only be presented to support a hypothesis, be 
it defence or prosecution [77]. Forensic evidence is therefore essential in determining the 
actus reus but not the mens rea. 
 Components of Body Fluids Often Located at Crime 
Scenes 
2.2.1. Whole blood 
Analysis of bloodstains is a key component to many crime scenes, utilising techniques 
including DNA profiling and blood pattern analysis (BPA). These techniques are constantly 
evolving with continuous research into age estimation, degradation or obtaining valuable 
information about the idividual who deposited the stain [78, 79]. Human whole blood is 
composed of four major components, red blood cells (RBCs), platelets, plasma and white 
blood cells (WBC). The normal presence of these components in 1 microlitre of blood is 
appxoimately, 5,000,000 RBCs, 150,000 -350,000 platlets and 5,000 - 10,000 WBCs [80, 81]. 
2.2.1.1. Plasma 
Plasma is the largest component of whole blood, making up approximately 55%, it’s major 
component is water (92%) with the remaining 8% composing of dissolved proteins and <1% 
solutes. The plasma has many roles including maintainence of blood pressure and body 
temperature as well as transport of RBCs, WBCs, platlets and dissolved resources such as 
glucose, minerals, salts, vitamins, CO2 and hormones around the body. The dissolved 
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proteins consist of albumin – involved in blood cleansing and maintaining fluid levels, 
coagulation factors – proteins involved in the immediate clotting and immunoglobins – 
antibodies to target infectious foreign material [81, 82].  
2.2.1.2. Red blood cells and platelets  
RBCs known as erythrocytes comprise approximately 45% of whole blood, they are 
distinguishable by their biconcave disc shape and their absence of nucleus and 
mitochondria. This absence means that processes involved with DNA replication do not 
occur within these cells and therefore different maintenance mechanisms are employed 
[81]. Platelets known as thrombocytes are small fragments of bone marrow cells responsible 
for the transportation of specific clotting chemicals. They compose <4% of total whole 
blood volume and due to their fragmented nature do not contain a nucleus or genetic 
material [81, 82]. 
2.2.1.3. White blood cells  
WBCs known as leukocytes are the smallest contribution within whole blood, making up 
<1% of total volume [82,83]. WBCs are large cells that house a nucleus but no haemoglobin.  
Despite their limited presence their role within blood is essential for healthy biological 
processes. Three classes of WBC exist all responsible for defending the human body from 
pathogens through various immune responses.  
Granulocytes are the most abundant WBCs composing 50-80% of all WBCs, and are the 
primary cells to arrive at an infected site, the defence mechanism involves phagocytosis, in 
which the pathogen is engulfed by the WBC and destroyed. The second immune response 
is controlled by Lymphocytes which secrete antibodies to defend against foreign material 
and contribute 25-33% of all WBC with the final class of WBCs, composing 4-8% of total 
WBCS being monocytes. Despite their low abundance they are the largest of the WBCs and 
can identify antigens that need to be destroyed by lymphocytes or perform phagocytosis 
on foreign material [81, 83].  
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2.2.2. Vaginal material 
The human vagina has a beneficial relationship with many microbes such as Lactobacillus 
however it is continually prepared for processes involved in reproduction and the defence 
from a large range of microbial pathogens. Invading pathogens can lead to infections such 
as bacterial vaginosis or thrush, heightened susceptibility to STI’s, various cancers and even 
fertility problems [84, 85]. Regardless of this continual battle with microbial pathogens the 
occurrences of these symptoms is reasonably infrequent due to the efficiency of the vaginal 
tract’s defence mechanisms. The most efficient mechanism to deter colonisation by 
external microbes is a mixture of intense sloughing of squamous epithelial cells that may 
have adhering bacteria, the competition for nutrients and reduction in pH provided by the 
already colonised commensal microbes and the hydration and cleansing of the cervix and 
vaginal areas by cervical-vaginal fluid (CVF) secreted from the glands within the cervix and 
vagina. The volume of CVF present within a sexually un-stimulated vagina is reported at 
around 4mL [84, 85]. 
Submucosal glands neighbouring the cervico-vaginal mucosa and plasma cells control the 
immune response within the vagina, secreting antimicrobial proteins/peptides (AMPs) such 
as defensins and lysozymes, immunoglobin A and G (IgA, IgG) as well as neutrophils and 
eosinophils. All of which are essential in the immunological defences that protect the 
human body. Antimicrobial proteins derived from epithelial cells also provide additional 
defence to destroying foreign pathogens [84, 85]. Forensic vaginal swabs will therefore 
have a high abundance of epithelial cells and proteins involved in the immunological 
response. The issue that saliva is very similar in appearance to vaginal material is also 
apparent on a cellular level due to both body fluids requiring immunological defence of 
foreign microbes.  
2.2.3. Menstrual blood 
The human female undergoes a continuous 28 day reproductive cycle in which an ovum is 
prepared for fertilisation. Following ovulation at day 14 the uterus forms a protective lining 
known as the endometrium in which a fertilised ovum can be implanted. The endometrium 
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consists of a collection of compact epithelial cells, connective stroma and various glands, 
these align to form a basal layer, a transitional spongiosa layer and a dense epithelial layer. 
The spongiosa and epithelial layer are connected via fibrous tissue and small blood vessels 
that would provide a supportive environment for fertilised ovum growth [86, 87].  
When an ovum is released and not fertilised there is a decline is progesterone production, 
this causes vasoconstriction of the blood vessel which results in apoptosis. The destruction 
of the blood vessels causes blood to enter under the compact epithelial top layer causing 
inflammation and further rupturing of the endometrium. Anticoagulant factors such as 
plasmin are activated by protease prevent clotting while matrix metalloproteases (MMP) 
breakdown the stroma for release during menstruation. This is followed by immediate 
construction of extracellular material and stroma for building the endometrium for the next 
cycle. Menstrual blood therefore originates in the uterus and consist of three main 
components; the single celled unfertilised ovum, the endometrium and blood. The 
endometrium is reasonably fibrous and therefore is the bulkiest component however is in 
the minor component when compared to blood. As the endometrium sheds from the 
uterus wall the small blood vessels travelling across the endometrium are broken and 
release the contained blood into the uterus. Menstrual blood then travels through the 
vaginal canal and combines with all the components of CVF [86, 87].    
The proteins involved in menstruation have protective and destructive roles and are 
therefore possess the most dynamic mechanisms compared to other body fluids. A 
proportion of proteins are responsible for the preparation of implantation by a fertilised 
ovum followed by supporting its development. If implantation does not occur enzymes 
responsible for apoptosis and immunological responses are activated to ensure the 
destruction of all material so that fresh material can be prepared for the following cycle [86, 
87]. The expression of protein in all tissues and organs is a result of the current environment 
and functional needs, since the menstrual cycle involves structural and hormonal changes 
almost daily, the regulation of gene expression must be tightly regulated.  
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2.2.3.1. Comparison of venous and menstrual blood 
Venous blood is comprised of RBCs, WBCs, platelets, haemoglobin as well proteins such as 
fibrin and molecules such as glucose. Since blood fills the endometrium these same 
components will be present in menstrual blood, however menstrual blood will have the 
addition of a large volume of epithelial cells, the stromal basal lamina biomaterial and 
various glands. The primary function of venous blood when outside the blood vessel is to 
form a protective clot, whereas as high number of anti- coagulation factors are present 
within menstrual blood to ensure removal from the uterus. Overall although similar in 
appearance the genetic material content within menstrual blood is significantly higher than 
in venous blood with an abundance of protein regulated processes [81, 82, 86, 87] 
2.2.3.2. Factors that affect the menstrual cycle 
A regular menstrual cycle is a dynamic and continuous change within a female’s body 
controlled by multiple hormones. It involves dynamic changes in the immune cell 
population to ensure simultaneous destruction and remodelling of cells and blood vessels.  
There are however many internal and external factors that can cause physiological changes 
to the frequency, composition and flow rate. The main processes of the menstrual cycle can 
be seen in Figure 2.1. The cycle is controlled by 4 main hormones; luteinising hormone, 
follicle-stimulating hormone, oestrogen and progesterone [88].  
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Figure 2.1: Mechanisms and hormonal fluctuations over a standard menstrual cycle in a healthy female [88]. 
2.2.3.2.1. Age, weight, ethnicity and lifestyle 
The menstrual cycle is not a synchronised event that occurs with all females, variations in 
regularity, flow rate and duration occur across all individuals. It can therefore be suggested 
that internal and external factors have a strong role in the regulation of the menstrual cycle. 
Liu et al. performed a study analysing the menstrual cycles of 309 women in the age range 
of 20-44. On average the females provided data for five menstrual cycles, with mean cycle 
length (MCL) analysis being performed on the metabolites of menstrual hormones present 
in urine. The results discovered that on average the MCL of women over 35 was reduced by 
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approximately 1 day (usually observed in the follicular phase). They also discovered that 
Asian females had a MCL that was approximately two days longer than those observed in 
Caucasian females. The data also indicated that alcohol (a minimum of 1 drink per week) 
had a reducing effect on MCL in younger women while physical exercise minimally 
increased follicular phase and therefore mean cycle length in the majority of women. The 
only factors where no observable difference in MCL occurred were BMI and smoking habits 
[89]. 
2.2.3.2.2. Current available contraception 
Research states that in 2012, approximately 645 million females in developing countries 
were utilising some form of contraception [90]. There are many reasons females may wish 
to take contraception such as pregnancy prevention, aiding skin issues such as ache, 
reduce/regulate heavy or painful menstruation and manage conditions such as iron 
deficiency anaemia by reducing menstrual flow. Various contraceptive methods have also 
been linked with considerable decreases in likelihood of ovarian and endometrial cancer 
[91, 92]. The type of contraception available are dependent on a female’s health and family 
history as well as her personal preference.  
2.2.3.2.3. Hormonal contraception 
The most popular form of current contraception is the combined oral contraceptive pill (the 
pill), with current use estimated at above 60 million females worldwide [92]. Ingested daily 
it releases artificial forms of oestrogen and progesterone into the body [93, 94]. Oestrogen 
inhibits FSH, which is responsible for releasing of an ovum, the increase of this hormone 
therefore inhibits the body from releasing an ovum that has the potential to become 
fertilised. Progesterone is responsible for the thickening of the endometrium however an 
increased presence will not trigger this regulation and a thinner endometrium will be 
produced thus reducing menstrual volume, progesterone also causes thickening of the 
mucus within the cervix and therefore create a barrier in which spermatozoa cannot pass.  
The full advantages and disadvantages of hormonal contraceptive are not comprehensively 
understood with contradicting research on the increased risk of cancers, largely focused on 
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oestrogen and the link to breast cancer [92, 95, 96]. For women categorised as high risks for 
breast cancer a progesterone only pill or non-hormonal contraceptive is available. The two 
other widely used contraceptive methods are the contraceptive implant, a thin tube 
inserted into the arm to release hormones and the contraceptive injection (Depot) a large 
dose of hormones that circulate the body for approximately 12 weeks. Both forms releases 
progesterone and therefore manage the menstrual cycle as the progesterone only pill 
would [93, 94].  
The menstrual flow and heaviness will vary between individuals and different 
contraception. From a survey of 50 females on various forms of hormonal contraceptive the 
menstrual cycle can completely cease, become continuous but light, reduce from heavy 
flow to light bleeding, become extremely irregular (bleeding once every 2 or 3 months 
compared to every 28 days) or become regular but very heavy. Since these contraceptives 
contain the same hormones it is the individuals body that causes these varied changes and 
therefore expression of regulatory mechanism may change. Fluctuations in expression 
would also be expected due to introduction of artificial hormones which may cause 
suppression of the regulatory mechanisms employed by the body for a ‘normal’ menstrual 
cycle. Overall menstrual blood from females using hormonal contraception will likely not 
contain an ovum and have a more fluid viscosity due to a reduction in endometrium.  
2.2.3.2.4. Non-hormonal contraception 
Females who do not wish to use methods involving artificial hormones are offered 
hormonal free alternatives. An intrauterine device (IUD) can be inserted into the female’s 
uterus, IUDs utilise the spermicidal effects of copper and is manufactured as a copper coil 
or wrapped around T-shaped plastic object. The IUD contains copper which increases 
abundance of copper ions, prostaglandins and WBCs within the uterus and fallopian tube 
fluid, this causes an immunological response that destroys any semen that are present. The 
uterus also detects the IUD as a foreign body and therefore increased phagocytic WBC 
activity is present within the stroma and epithelium of the endometrium. This continual 
destruction of the endometrium ensures if a fertilised ovum is created it cannot be 
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implanted. Menstrual blood within females using IUDs tend to be heavier and darker in 
colour, this is likely caused by the high abundance of WBC but also the increased RBC and 
cellular debris causes by apoptosis of the cells within the endometrium [97].   
2.2.3.2.5. Diseases 
Endometriosis is a reasonably common benign gynaecological condition affecting around 
1 in 5 women. It is present during the reproductive periods of the female’s life and involve 
endometrium like tissue forming on the outside of the uterus and fallopian tubes [98]. The 
disease is recorded to increase the ‘heaviness’ of menstrual flow and bleeding in between 
normal menstruation. Blood obtained from the vaginal canal when menstruation is not 
actually occurring would need to be analysed to assess whether the additional components 
of menstrual blood are present. Research suggest that immunological response cells 
present within regular endometrium is highly dysregulated in individuals suffering from 
endometriosis [98].  
2.2.3.2.6. Cessation of menstrual cycle 
Many factors cause a cessation of the menstrual cycle, as described some hormonal 
contraceptives are responsible however the process of human pregnancy also removes the 
requirement for preparation as the uterus adapts to protecting and providing nutrition to 
the developing baby. The menstrual cycle can also be affected by mental and physical 
conditions, eating disorders are highly prevalent in adolescent females, with approximately 
40% of cases consisting of females aged 15-19 [99]. Eating disorders can have very harmful 
effects not only on mental health but regularly cause severe problems with physical health. 
Vale et al. analysed 62 adolescent females with diagnosed eating disorders. Their results 
showed 21 females (34%), the majority comprising of bulimia and anorexia disorders 
displayed irregularities or disruption of the menstrual cycle; seven participants experienced 
irregularity where menstruation was still present but unpredictable and varying flow rate 
while secondary amenorrhea, the complete lack of menstruation for a period longer than 
three months was observed in the other 14 females. 22% of the females diagnosed with 
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eating disorders experienced complete cessation of their menstrual cycle with uncertainty 
that a regular cycle would return [100].  
In summary, a ‘normal’ menstrual cycle is dynamic and involves many processes that require 
strict regulation. Flow rates and frequency vary between individuals however the 
introductions of factors such as disease, contraception and pregnancy can have massive 
effects on the composition, duration and flow rate of menstrual blood and therefore 
expression of regulatory factors must be taken into account when validating a BFID marker 
for menstrual blood.  
2.2.4. Saliva 
Salivary fluid is secreted from the salivary or oral mucous glands with the objective of 
lubricating the mouth and ingested food for swallowing. Saliva is composed of around 99% 
water, within this solution are many enzymes, immunoglobulins, antimicrobial factors, 
glycoproteins and traces of albumin there is also an abundance of minerals such as 
potassium, sodium, calcium, magnesium and phosphates. All the proteins and minerals 
present ensure a healthy oral cavity, capable of defending against infection and foreign 
antigens [101]. There are many salivary glands within the oral cavity, all with various roles 
and differing enzyme abundance and activity. Some salivary glands such as the patroid and 
submandibular glands secrete a higher volume of saliva when stimulated by food ingestion 
and mastication therefore their role is not focused on lubrication or oral health but the initial 
digestion of food. This is performed by the secretion of α-amylase, an enzyme responsible 
for breaking down starch within food products. α-amylase makes up around 50% of all 
proteins synthesised by the salivary glands, enzyme activity is inhibited by the acidic 
conditions throughout the gastrointestinal tract and therefore it’s presence is only located 
within the mouth making it an ideal protein in salivary identification techniques [101, 102].  
Whole saliva is a mix of all fluids secreted by the various salivary glands, mucous, food 
debris, epithelial cells and oral bacteria. Buccal swabs obtained from individuals will contain 
a combination of all these fluids and factors however the proteins being secreted at the 
time of collection will fluctuate dependant on if the participant has a healthy mouth, an 
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infection or has been eating. If eating has recently occurred there will be a higher volume 
of α-amylase in the sample however if the participant has a mouth infection a range of 
immunologic proteins may be present. Immunoglobulin A (IgA) is the most abundant 
immunologic protein secreted by the gingival fold salivary gland, this protein along with 
the less abundant IgG and IgM destroy harmful bacteria and viruses to preserve oral health. 
Medication such as antidepressants and antihistamines have also been shown to alter the 
composition of salivary fluid [101, 102].  
2.2.5. Semen and seminal fluid 
Post pubertal males create sperm cells within the testes which are then matured in the 
epididymis. The epididymis secretes potassium and sodium to supply energy to the 
spermatozoa. Once matured they travel through the vas deferens where they are mixed 
with components to form semen. Human semen is a combination of components that have 
been synthesised by various glands such as the vas deferens, seminal vesicle, the prostate 
and the epididymis, the major components are proteins, lipids, carbohydrates and peptides. 
During ejaculation the components in the initial ejaculate are not thoroughly mixed and are 
therefore not a completely homogenous mixture [103, 104]. 
Up to 75% of semen is secreted by the seminal vesicles, which incorporates a large volume 
of fructose and antioxidants. Fructose ensures the spermatozoa have a sufficient energy 
supply while the antioxidants provide protection from oxidative substrates. Approximately 
20% is secreted by the prostate gland, consisting of the protein acid phosphatase, calcium, 
magnesium and coagulation/liquefaction enzymes. The remaining components consist of 
spermatozoa and proteins secreted from the bulbourethral gland when sexually stimulated 
[103, 105].  
Research by Fung et al. aimed to identify the peptide and proteins that made up seminal 
fluid, they analysed 5 human semen samples using two-dimensional electrophoresis (2DE). 
Their conclusions stated identification of over 100 different proteins and peptides in a 
healthy human semen sample [104]. Research by Oliva et al. attempted to characterise the 
proteins involved with in the spermatozoa and seminal fluid, their research observed that 
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approximately 50% of the proteins identified were responsible for providing the 
spermatozoa with energy. This is expected as the spermatozoa is required to travel a large 
distance through hostile environments to reach the ovum, if the energy source is depleted 
reproduction cannot occur. Oliva et al. research also observed there was very little proteome 
variation between participants that were noted as highly fertile, whereas in participants 
known to have low spermatozoa count, many of the proteins were either increased or 
completely absent [106].  
2.2.5.1. Semen persistency 
The survival on semen within the vaginal canal following sexual intercourse is dependent 
on many factors. These include the stage of the menstrual cycle, the fertility of the 
spermatozoa, and the health of the environment within the vagina [107]. 
Following sexual intercourse the spermatozoa quickly move throughout the vaginal canal 
with some of the spermatozoa reaching the site of fertilisation in approximately 5 minutes. 
A female’s cervix contains a dense mucous plug which the spermatozoa must pass, this plug 
varies in composition throughout the menstrual cycle. Spermatozoa will pass through the 
mucous plug with least resistance when the female is ovulating. Cervical mucus is 
comprised of a long chain of mucoproteins that have a highly variable level of cross-linkage 
between the chains. The thickness of the mucus is altered by the number of cross links 
which in turn is controlled by hormonal presence. Mucus in the follicular phase is sparse but 
very thick, the increase in Oestrogen then reduce the cross-linkage and reduces the 
viscosity [107].  
Secreted by glands on the cervical canal wall, the cervical mucus forms strands which direct 
the majority of spermatozoa towards the canal wall. Once incapacitated on the wall the flow 
of CVS ejects the spermatozoa from the vagina. Regardless of the capability of the vaginal 
canal to eject spermatozoa, fertility and viability spermatozoa can persist in the vagina with 
some research suggest motile spermatozoa can be identified up to 8 days after ejaculation 
[107]. The degradation of spermatozoa in the female reproductive tract is also due to 
phagocytic activity from neutrophilic leucocytes and mononuclear cells. Phagocytosis of 
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spermatozoa occurs in both the vaginal and cervical fluids, with components such as the 
sperm head and tail being observed within the cytoplasm of these cells [110]. 
Wilson et al. studied the forensic benefit to ascertaining the persistency of spermatozoa 
within the vagina. The results showed every vaginal swab obtained prior to 9 hours 
following UPSI were positive for spermatozoa. A steady decrease in positive results as well 
as number of spermatozoa present was then observed as the time interval increased. Their 
results did indicate that the location of sampling could have an effect on positive 
identification [108].  
The quantity of spermatozoa identified on vaginal swabs was much higher than those 
identified on cervical swabs on fresh swabs. The quantities did not become equal until 
approximately 24 hours had passed.  When 48 hours had passed their results showed an 
increased chance of identifying spermatozoa on the cervical swab compared to vaginal 
swabs. They concluded their study by showing positive identification in the cervix and the 
vagina up to a period of 10 days following UPSI, with a more complete spermatozoa usually 
being found on the cervical swabs [108].  
A study performed by Davies et al. obtained samples from female donors within their 
laboratory. Cotton-wool swabs were inserted as high as possible at pre-determined 
intervals following unprotected sexual intercourse (UPSI). Their sample number was limited 
and obtaining samples passed 96 hours proved difficult however their results showed a 
positive identification of spermatozoa on all samples prior to 30 hours, limited negative 
results prior to 48 hours and a frequent trend in negative results up to 96 hours. They noted 
their last positive results was at 144 hours. From time points 90 to 156 hours, only 34% of 
swabs gave a positive identification for spermatozoa. Motile spermatozoa were commonly 
found in samples up to 16 hours but decreased rapidly after this time point [109]. 
One of the more comprehensive semen persistency studies was performed by Willott et al. 
They assessed the presence of semen on 2410 casework swabs, of which 1332 were internal 
vaginal swab. Murder victims were not included in the study therefore all samples were 
from living victims. The method for identification was visual, utilising haematoxylin and 
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eosin staining on microscope slides. The classified the quantity of spermatozoa present into 
many in every field (++++), many in most fields (+++), some in some fields (++) hard to find 
(+) few and zero. The presence of tails was also noted.  6% of swabs came back ++++, 29% 
between +++ and ++, 22% between few and + and 43% with zero.  The longest duration a 
spermatozoa was identified was 120 hours, this fell to 26 hours when recording presence of 
tails [110].  
Willott et al. found discrepancies in results when comparing to studies by Davies and Wilson. 
The results obtained from this study showed a large proportion of case work swabs did not 
show any spermatozoa when taken three hours after the alleged UPSI compared to the 
100% of positive samples identified in Davies and Wilson’s studies. Willott was however 
studies case work samples, some of which may not always contain semen. Despite the 
variation to other literature positive identifications were made on a number of swabs from 
different areas, the longest time duration after UPSI for positive identification can be seen 
below in table 2.1 [110]. 
Location         Persistence 
Internal vaginal swabs 120 hours
External vaginal swabs 120 hours
Rectal swabs 65 hours
Anal swabs 46 hours
Oral swabs 6 hours
 
Table 2.1: Persistency of semen found from various intimate swabs [110]. 
Overall the literature shows various time durations following UPSI for positive semen 
identification, with no research showing 100% positive identification passed the initial 48 
hours. Positive identification was however seen following 120-156 hours suggesting that 
likelihood of spermatozoa survival will vary in each sexual assault case. An improved 
technique for the identification of spermatozoa may improve the number of positive 
identifications made as well as the length of time they can be detected. 
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2.2.5.2. Azoospermia 
Azoospermia is a condition in which spermatozoa are not present in ejaculate [111]. It can 
be caused by an obstruction in the vas deferens, such as inflammation or a failure of 
spermatogenesis. Spermatogenesis is strictly regulated by a large number of genes which 
control spermatozoa development and transport, with research showing that around 29% 
of cases of azoospermia involve genetic abnormalities such as chromosomal/ gene 
deficiencies or epigenetic modifications [111]. 
 Current Body Fluid Identification Techniques  
Biological samples of various body fluids collected and then analysed from crime scenes are 
the foundation for forensic investigations. The samples provide vital evidence through the 
technique of DNA profiling. Profiling analyses the number of short tandem repeats (STRs) 
are specific loci to provide a DNA fingerprint that, if excluding monozygotic twins has an 
extremely low likelihood of completely matching another individual. Close genetic relatives 
such as siblings and parents will share many common allelles however the large number of 
loci analysed in current DNA profiling techniques ensures the differences between closely 
shared profiles can be identified [112]. The profiling of the biological samples can identify 
individuals that participated in a crime but can also be used to exonerate and thus is often 
key evidence in a court of law. DNA profiling cannot however provide information as to the 
events that occurred during a crime and thus a robust technique is needed that could 
provide this data [113, 114].  
The determination of the type and source of body fluids located at crime scenes allows for 
forensic scientists to reconstruct the actions that took place by providing a connection 
between the body fluids identified and the statements of the complainant and alleged 
perpetrator. The presence of certain body fluids can be used as indicators of the sequence 
of events which occurred. For example, venous blood stains can indicate a violent or forceful 
altercation that could be supportive of a prosecution hypothesis in a murder case; just as 
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the identification of semen or vaginal material would be suggestive of a sexual act occurring 
[115].  
The most frequent body fluids identified by scene of crime officers (SOCO) are venous 
blood, semen, saliva, vaginal material, urine, and sweat [116]. In cases involving sexual 
assaults the likelihood of vaginal material and semen presence is very high.  When a SOCO 
locates a possible body fluid stain, chemical or visual methods are utilised to determine 
which body fluids are present. Presumptive tests are performed to provide a preliminary 
identification of the source of the body fluid stain with further confirmatory tests, if 
available, conducted by scene of crime DNA analysts in a forensic laboratory [114].  
Certain BFID techniques have been utilised since the beginning of the 1900’s with many of 
the same presumptive techniques and protocols still being used in current forensic 
laboratories [114]. Development of techniques for BFID include catalytic activity of specific 
enzymes, visual and chemical test, immunological testing and spectroscopy. The problem 
with the majority of these techniques are they are only presumptive and therefore only 
provide an indication of the body fluid source, confirmation of BFID can only be achieved in 
tests such as the physical observation of spermatozoa under a microscope [114]. 
Presumptive techniques tend to become unreliable in degraded or low volume samples 
suggesting low specificity and sensitivity. Samples obtained from crime scenes are valuable 
and in most cases cannot be obtained again if needed, it is therefore imperative that 
identification techniques do not waste value sample during analysis, this is however the 
case in many presumptive BFID techniques.  
2.3.1. Catalytic presumptive tests for body fluid 
identification 
2.3.1.1. Identification of blood: Leucomalachite Green and Kastle-Meyer 
Catalytic methods are founded on enzymatic activity which catalyse reactions of numerous 
substrates which create observable changes in colour. A variety of catalytic tests are 
frequently utilised to screen blood samples providing a presumptive identification. This is 
achieved by analysing the peroxidase-like activity of the haem group [113, 114].  Red blood 
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cells are saturated with iron rich haemoglobin which binds to oxygen and transports it 
around the body. The haem group present on the haemoglobin molecule catalyses the 
degradation of hydrogen peroxide (H2O2). This process produces an oxidising molecule that 
causes a colour altering reaction when interactions occur with other substrates. Two 
common substrates uses are leucomalachite green (LMG) and phenolphthalein (Kastle-
Meyer) which produce a green and pink colour change respectively. If the sample contained 
haemoglobin the addition of the leucomalachite or phenolphthalin reagent and H2O2 will 
result in a colour change and a positive identification for blood. Although very popular it 
only provides a presumptive identification and is known for displaying false positives when 
substances such as rust, grass or vegetable peroxidases are also present within a sample. 
The advantages of LMG and Kastle-Meyer is that analysis is instantaneous, LOD is 1: 10,000 
and although requiring part of the sample to test it does not damage the remaining sample 
so DNA profiling can be performed. This technique cannot however differentiate between 
venous and menstrual blood [113, 114].  
2.3.1.2. Identification of semen: Acid phosphatase 
The most frequently used identification technique for semen is the acid phosphatase (AP) 
test. This test focuses on the activity of enzyme AP due to its high abundance within semen. 
Secreted by the prostate gland the activity of AP is approximately 1,000 greater in semen 
compared to other body fluids. The catalytic activity of AP results in colour changes by the 
hydrolysis of phosphates which react with reagents such as Brentamine Fast Blue to 
produce a violet colour. The limitations to this method include cross reactivity due to 
presence of AP within body fluids including vaginal material, low sensitivity and sample 
usage [114].  
2.3.1.3. Identification of saliva: alpha-amylase and PhadebasⓇ test  
Identification of saliva focuses on alpha amylase, an enzyme that is highly abundant within 
saliva. This test involves the addition of iodine which reacts with any starch present in the 
saliva to create an intense violet colour, the enzyme hydrolyses polysaccharides such as 
starch into many sugar molecules. The result is the reduction of intensity of any colour 
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observed due to the hydrolysis of the starch. Another catalytic method for identification of 
alpha amylase is the PhadebasⓇ test, instead of iodine this test incorporates amylopectin-
procion red to cause a colour change due to starch hydrolysis. The advantages to these 
methods are a relative high sensitivity, low cost and quick analysis time. There are 
limitations in that as with most catalytic tests, cross-reactivity to substances such as urea, 
faecal matter or moisturisers create false positive [114, 117]. 
2.3.2. Protein analysis/ Immunological techniques for 
confirmatory body fluid identification  
2.3.2.1. Identification of blood:  HemaTrace test strip 
The specific reaction between antibody and antigen is the foundation for the majority of 
immunological testing. The detection of blood using the HemaTrace test strip is based on 
the same haemoglobin molecule used in LMG and KM. If present within a sample, the 
haemoglobin will react and combine with anti-human haemoglobin antibody that resides 
within the HemaTrace test strip. The test strip contains a membrane which is permeable to 
the antibody-antigen complex, once permeated it is collected. The more antibody-antigen 
complex that travel through the membrane and accumulate the more intense the colour 
change will become resulting in an intense pink colour observable within the test site. The 
HemaTrace test strip has shown popular due to its lack of cross reactivity, almost immediate 
analysis, its portability for use by SOCO or DNA analysts and its high sensitivity [114]. 
2.3.2.2. Identification of semen:  prostate specific antigen testing 
Identification of semen can be performed through staining and visualisation through a 
microscope, a more frequently utilised confirmatory protocol focuses on the identification 
of prostate specific antigen (PSA) [118, 119]. As with AP it is abundantly produced and 
secreted by the prostate gland. The detection is shown by an observable line along the test 
strip in which the anti-human PSA antibody has adhered to the PSA within the sample and 
travelled the length of the test stripe. It has the same advantages as the HemaTrace test 
strip however it has the added advantage of semen identification that does not rely on the 
presence of spermatozoa [11, 119].  
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2.3.2.3. Spectroscopy techniques for body fluid identification  
Current research into the use of attenuated total reflectance Fourier transform infrared (ATR 
FT-IR) spectroscopy has shown promising data into the identification of number of body 
fluids. The technique produces a spectrum for each sample, within this spectra are peaks 
which are characteristic of vibrations within structural bond of biological samples. 
Comparing the spectra to reference body fluids allow for confirmatory identifications to be 
made [116]. 
Orphanou et al. analysed samples of venous blood, semen, saliva and vaginal material using 
ATR FT-IR. Five samples per body fluid were analysed with a reference spectra being 
obtained for all four body fluids. Each spectra displayed dominant peaks that could be 
correlated to known proteins within that fluid, these peaks were significantly different 
enough to distinguish from the other three body fluids. Although body fluids such as 
menstrual blood, azoospermic semen and skin were not analysed this method proposes a 
very promising non-molecular technique for the identification of body fluid. Its application 
into a forensic lab would require new equipment and lab space, training of new technicians 
and analysts and a completely separate protocol to DNA profiling however if validated on a 
full panel of body fluids could be a useful technique to forensic scientists [116]. 
 Limitations of Current Body Fluid Identification 
Techniques  
2.4.1. Absence of semen 
The inability to determine the presence of spermatozoa in samples taken from victims of 
sexual assault can be explained by a number of factors; a prolonged post coital interval, use 
of spermicidal solutions, digital penetration or use of a condom. In these cases semen is 
destroyed or was never present. In cases where the male is azoospermic or has been 
vasectomised and in some instances where penetration but not ejaculation occurred, 
semen will be present but the spermatozoa will be absent [111]. In these instances DNA 
profiling is highly unlikely to provide a useable profile and testing for spermatozoa will 
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come back negative thus providing support to the defence. In cases such as these the 
identification of seminal fluid would support the statements that declare sexual intercourse 
occurred and provide the courts with clearer evidence on the event that occurred. It is 
important that a technique is available that can identify the presence of seminal fluid 
without the need for spermatozoa being present.  
2.4.2. Menstrual blood vs. venous blood 
Sexual assaults can often be violent in nature, such that bleeding injuries occur. In cases 
where penile swabs from a suspect show the victim’s blood, the origin is very important to 
assigning case level. The aforementioned sections show just how easily sexual assaults can 
occur and how important it is to obtain correct evidence. In cases where a female victim 
states sexual assault has occurred, an intimate exam will be performed on her as well as any 
possible suspects. If blood is found it may show support that a violent assault occurred and 
thus support the prosecution, however the suspect may state that consensual intercourse 
occurred while the female was menstruating. These contradicting reports would not be 
useful in a court of law. The utilisation of a technique that could differentiate these two 
fluids within the sample would show an increase in support to either the defence or 
prosecution hypothesis. Alternatively, if a female is assaulted while menstruating, 
identifying venous blood within a mixture of menstrual blood would support the 
prosecution hypothesis. 
Case study 2-1: LGC reporting officer 2015: An individual was arrested on suspicion of 
murder. Analysis of his car showed a blood stain in the front seat that matched the victims 
DNA profile. The defendant claimed the victim had been sat in his front seat and started 
menstruating, thus leaving the blood stain when she left the defendant to go home 
In this case the differentiation of venous blood from menstrual blood would provide vital 
evidence into the validity of the suspect’s statement. A BFID technique that confirmed an 
absence of menstrual blood would show the blood within the car came from an open 
wound on the victim,  
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2.4.3. Differentiating vaginal material from saliva 
As stated, sexual assault is not solely defined as vaginal penetration from a penis. It is 
important to determine body fluid origin to assign correct case level.  In cases where the 
complainants DNA is found on a suspect’s penile swab, the DNA evidence from that would 
indicate that the suspect’s penis came into contact with the victim. Identification of body 
fluids would allow for a greater description of the events to be determined. The 
complainant in this case may suggest she was vaginally sexually assaulted, while the 
suspect may claim he only received consensual oral intercourse. Both hypotheses would 
result in the victims DNA being found on a penile swab. If a technique could be used to 
differentiate vaginal material and saliva the origin of the body fluid present on the penile 
swab could be identified and thus show strong support to either the complainant’s or the 
suspects version of events. 
Alternatively, in a case where non-consensual oral intercourse occurred, the defence may 
state it never occurred or if the complainants DNA profile from a buccal swab is identified 
suggest it was consensual or from her saliva while kissing. The use of a BFID technique that 
could identify vaginal material from a buccal swab would confirm the suspect gave false 
information and provide support to the prosecution.  
 Current and Emerging Molecular Based Techniques 
for Body Fluid Identification  
The human body is compiled of approximately 210 different cell types, each with a 
specialised function that is varied from other cell types [120, 121]. Despite their differing 
regulatory roles, nucleus containing cells all contain an identical genome within an 
individual. The identical genome within cells is the foundation for DNA profiling, enabling 
vaginal material samples obtained from penile swabs to be profiled against a reference 
buccal swab obtained from a potential victim. Current molecular based techniques 
however focus on the factors that cause regulatory changes within cells which when 
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identified could be used to determine the same molecular changes within cells found at 
crimes scenes [120].   
Throughout embryonic growth the determination of the type of cell is tightly regulated by 
gene expression. Gene expression is controlled through the process of transcription of DNA 
into single stranded complimentary RNA followed by the translation of messenger RNA 
(mRNA) to produce proteins. The human genome consists of over 22,000 coding genes, of 
which only a small proportion are expressed per cell type [120]. The identification of the 
regulating factors over expression could therefore be essential to forensic BFID. RNA 
molecule analysis is continually being researched and is becoming an encouraging novel 
technique for many forensic applications. They are currently used in post-mortem interval 
(PMI) and wound age estimation [122], blood stain age estimation [123] and human body 
fluid identification [124-127].   
The majority of the presumptive and confirmatory techniques described include many 
limiting factors, however they are also performed as a precursor for DNA analysis and are 
not run in parallel to it. The development of molecular techniques have identified a number 
of methods that can analyse BFID alongside DNA profiling. These techniques focus on tissue 
specific mRNA and miRNA and the patterns within DNA methylation. These methods are 
more suitable for BFID due to high sensitivity and specificity [120, 126].  
2.5.1. Analysis of DNA methylation patterns 
Since recent whole-epigenome analyses indicated that DNA carries tissue-specific 
methylation patterns, the potential of tissue-specific differential DNA methylation for BFID 
has been examined within the forensic field [115, 120, 128-131]. DNA methylation is an 
epigenetic mechanism that controls the precise expression or silencing of genes. Unique 
sequences throughout the human genome encode for exclusive patterns of DNA 
methylation and are referred to as tissue-specific differentially methylated regions (tDMRs) 
[132]. Methylation alters as human develop due to ageing as well as environmental factors 
such as smoking and therefore may provide a solution to the problem of identical twins 
with matching genomes [129], Stewart et al.  performed a study on a selection of identical 
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twins, samples were obtained from both blood and saliva and underwent bisulfite 
treatments followed by qPCR and high resolution melt curve (HRM) analysis. Results 
showed a difference in methylation in one set of 53-year-old twins, with no significant 
success in twins aged around 20. If patterns change with age it would be expected that a 
more observable difference could be made in older adults [131].    
DNA methylation occurs at the 5'-position of the pyrimidine ring of cytosine in large clusters 
of repetitive CpG dinucleotide sequences known as CpG islands. Methyl groups are adhered 
to alter the activity of the DNA sequence without modifying its nucleotide sequence. These 
are heavily found in the promoter regions so repression of transcription can occur. Within 
the human genome up to 80% of CpG sites are methylated, with the remaining un-
methylated CpG sites being responsible for housekeeping genes [132, 133]. Current 
research has therefore analysed DNA methylation at certain CpG site of tDMRs to identify a 
new BFID technique. 
Frumkin et al. identified 15 genomic loci which display different methylated patterns among 
blood (venous/menstrual), vaginal material, semen, saliva, skin epidermis and urine. In this 
research, they applied an assay for certain markers using methylation-sensitive restriction 
enzyme-PCR (MSRE-PCR) made up of methylation-sensitive restriction enzyme digestion of 
sample DNA followed by multiplex PCR of specific genomic loci with fluorescence-labelled 
primers, capillary electrophoresis of amplification products and automatic signal detection. 
The assay could easily be assimilated into standardised procedures of forensic laboratories 
like short tandem repeat (STR) analysis, and could successfully identify source tissues in 50 
DNA samples from blood, semen, saliva, and skin epidermis [134].  
Later, Wasserstrom et al. advanced Frumkin’s approach by developing the kit, DNA source 
identifier (DSI)-SemenTM, which aimed to replace microscopic examination of sperm cells for 
forensic semen identification in casework samples. This assay is based on the recognition of 
semen-specific DNA methylation patterns in five genomic loci using MSRE-PCR. The kit was 
validated with 135 samples of various body fluids and 33 samples from casework from the 
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forensic biological laboratory. It suggested it was robust and reliable by showing a positive 
result for semen given as little as 31pg of template DNA input [135].  
Lee et al. examined the potential of tDMRs for forensic body fluid identification using a 
bisulfite sequencing method. Bisulfite sequencing determines the DNA methylation status 
by detection of nucleotide base change due to sodium bisulfite treatment. Bisulfite 
treatment has no influence on methylated cytosine, but converts free or un-methylated 
cytosine of CpG to uracil, which becomes thymine during subsequent PCR. Using this 
method, they produced methylation profiles for five tDMRs in pooled DNA samples from 
blood, saliva, semen, menstrual blood, and vaginal fluid. The tDMRs for DACT1 and USP49 
were chosen as a semen-specific marker by showing semen-specific hypomethylation, and 
the PFN3 tDMR was suggested to be used for vaginal fluid identification [115]. 
An et al. further investigated age-related methylation changes in semen-specific tDMRs 
using body fluids from young and elderly men, since DNA methylation patterns are known 
to be susceptible to change by aging. After confirming the stability of the body fluid specific 
DNA methylation profile, they suggested two multiplex systems to analyse the methylation 
status of the USP49, DACT1, PRMT2 and PFN3 tDMRs. The two multiplex systems were 
created using MSRE-PCR and methylation SNaPshot, and both successfully identified semen 
with sperm cells and could distinguish menstrual blood and vaginal fluids from other body 
fluids in a test with 144 DNA samples. Unlike MSRE PCR, which shows only the quantity of 
methylated CpGs, methylation SNaPshot has the advantage that it can measure the 
proportion of the methylated and/or un-methylated cytosine of the target CpG site 
simultaneously, because this assay is carried out by the amplification of bisulfite-converted 
DNA and subsequent single base extension reaction [136].  
Alternatively, since genomic DNA can be degraded during bisulfite treatment, a bisulfite-
based methylation SNaPshot assay may consume more samples than MSRE-PCR. Therefore, 
a sensitivity test was performed for the multiplex methylation SNaPshot. The result showed 
that a minimum of 500pg of starting genomic DNA, or 125pg of bisulfite-converted DNA, 
was sufficient for successful DNA methylation profiling of the selected tDMRs, which 
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demonstrates the possible practical application of the multiplex system to forensic 
casework [136].  
A recent paper by Madi et al. also described tissue-specific DNA methylation in forensically 
relevant biological samples including blood, saliva, semen and epithelial cells. They 
examined various genomic loci using bisulfite modification and pyrosequencing to find that 
the methylation patterns at the ZC3H12D and FGF7 loci can differentiate sperm from other 
biological samples while the C20orf117 locus and the BCAS4 locus can differentiate blood 
and saliva from other samples, respectively. These results also suggest that the DNA 
methylation-based methods could be a valuable analysis tools for the characterisation of 
forensically relevant biological fluids, but further validation studies including more markers 
will be required for actual casework applications [130].  
2.5.2. Messenger RNA  
Messenger RNA (mRNA) are single stranded RNA molecules that convert the sequences of 
triplicate nucleotides into amino acids for proteins synthesis during translation. When DNA 
is transcribed into RNA by RNA polymerase it contains vital coding information as well as 
non-coding regions [120, 137]. The RNA molecules are spliced, with approximately 9 exon 
sequences retained and 8 intron sequences being cut out to produce an informative mRNA 
molecule that will code for a particular protein synthesis for gene regulation. mRNA in 
humans have an approximate half-life of 10 hours, ensuring the cell can immediately 
change its protein synthesis based on the cells current requirements [120, 137, 138]. 
RNA is well known for its instability due to universally present ribonucleases that degrade 
these nucleotide chains [114, 125]. However, research has reported that RNA isolated from 
some forensic stains showed unexpectedly high stability. Using whole-genome gene 
expression analysis on aged blood and saliva stains, Zubakov et al. identified blood and 
saliva specific mRNA markers which showed stable expression patterns in stains following 
180 days of storage. Some of these markers showed successful and consistent amplification 
in much older stains, such as 16 year-old blood stains [139].  Setzer et al. lead a more 
comprehensive study on mRNA stability in forensic samples. They exposed various 
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biological stains to a collection of environmental conditions and performed mRNA profiling 
analysis using eight different mRNA transcripts of selected housekeeping and tissue-
specific genes. The results established that RNA is detectable in some samples stored at 
room temperature, even after 547 days, with heat and humidity appearing to be most 
detrimental to RNA stability [140].  
2.5.2.1. Advantages to mRNA analysis 
One of the key advantages of body fluid identification by mRNA profiling is the possibility 
of simultaneous extraction of mRNA and DNA from the same body fluid stain. In forensic 
investigations, where sample material is often limited and highly valuable this offers a major 
advantage. Multiple optimised methods have been developed for simultaneously isolating 
mRNA and DNA from the same crime scene stain, this then allowed identification of the 
stain as well as confirming the assailant’s identity through DNA profiling [125, 141, 142]. 
Although this has the advantage of allowing parallel analyses currently used protocols 
require modification to the standard DNA extraction protocol (Figure 2.2) [141]. RNAs are 
eluted in the lysis buffer fraction and require its recovery and storage (-80oC) for RNA 
analysis. Not only does this require a separate storage space to archived DNA extracts, it also 
means there is no cold case capability on samples that have already been extracted.  
 
Figure 2.2: mRNA work flow protocol for mRNA expression analysis and DNA profiling. Adapted from [143] 
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Another important advantage of mRNA profiling is the possibility of detecting several body 
fluids in one multiplex reaction, providing data on the expression of multiple genes 
simultaneously. Various multiplexes have been reported, using reverse transcription 
endpoint polymerase chain reaction (RT-PCR) methods and real-time quantitative reverse 
transcriptase-PCR (RT-qPCR) assays [126, 142, 144]. Many transcripts are not completely 
tissue specific, exhibiting differences in expression level. This allows for RT-qPCR to be more 
appropriate for the detection of relative gene expression levels in different samples, 
meaning endpoint PCR might be suitable for the detection of certain transcripts with highly 
tissue-specific expression. Xu et al. proposed a multiplex RT-PCR method for the 
identification of body fluids that are commonly encountered in forensic casework. They 
evaluated using 16 selected body fluid-specific genes, i.e., Glycophorin A (GLY) and 
porphobilinogen deaminase (PBGD) for blood, histatin 3 (HTN3) for saliva, transglutaminase 
4 (TGM4) and protamine 2 (PRM2) for semen, and human beta-defensin 1 (HBD-1) and 
mucin 4 (MUC4) for vaginal secretions for BFID in a multiplex reaction. Their results 
demonstrated a highly sensitive and specific multiplex assay capable of differentiating a 
number of body fluids which would not only bring down the cost of analysis but reduce the 
workload of the analyst [145].  
To validate mRNAs incorporation into forensic casework the European Forensic Genetics 
Network of Excellence (EUROFORGEN-NoE) performed a collaborative research study in 
which a multiplex mRNA technique regularly implemented at the Netherlands Forensic 
Institute (NFI) was provided to a variety of laboratories with the aim of analysing the 
reproducibility of the results. With the exception of a skin and a vaginal material marker the 
multiplex consistently performed well in all laboratories and successfully identified 
challenging crime scene stains such as seminal fluid from a vasectomised or azoospermic 
male. Overall the collaborative exercise demonstrated the importance of providing both 
DNA and RNA analysis to ensure robust evidence is delivered in a court of law [146]. 
 
 
 
 
 
94 | P a g e  
 
 
 
2.5.3. MicroRNA: 
Multiple classes of small RNA molecules exist, each with various and essential roles in the 
regulation of genes:  
 Small nucleolar RNA (snordRNA) – non-coding RNA which manage and control 
ribosomal RNA assembly and function  
 Small interfering RNA (siRNA) – Around 25nt in length, siRNA bind to complementary 
sequences within mRNA and initiate cleavage. 
 Transfer RNA (tRNA) – Aides at specific sites in the ribosome when decoding mRNA 
sequences into proteins. 
 Ribosomal RNA (rRNA) – RNA component within ribosomes. 
  microRNA – non-coding RNA which regulate gene expression through translation 
repression of mRNA [147-149]. 
MicroRNA (miRNA) were first discovered in the nematode Caenorhabditis elegans by Victor 
Ambros et al. in 1993 [150]. Further research showed miRNA presence in the majority of 
eukaryotes and their high abundance in human cells [151]. Since their discovery, the study 
of miRNA has progressively increased with research into its many applications being 
performed. The vast interest in miRNA revolves around their central role in gene-expression 
regulation which controls various metabolic and cellular pathways and the implication of 
miRNA-specific expression in the pathogenesis of cancer, cardiac, immune-related and 
other diseases [152-156]. If regulation is controlled by the varied processes within the cell 
then the likelihood of cells within different body fluids containing different miRNA is high.   
MicroRNAs are naturally occurring, non-coding, single stranded RNA molecules with an 
approximate length of 18-22 nucleotides (nt) [157-159]. MicroRNA control gene regulation 
by silencing mRNA molecules; miRNA bind to target specific mRNA sequences to negatively 
control expression and thus inhibit protein production. Silencing of mRNA and therefore 
regulation of vital cellular process occurs through two processes, translational repression or 
cleavage of a specific mRNA [151, 158, 159]. The guide miRNA strand interacts and is 
integrated into the RNA-induced silencing complex (RISC), the complimentary sequence of 
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miRNA then binds to the target complimentary sequence of the mRNA that the cell wishes 
to silence. Proteins within the RISC complex will either cleave the mRNA molecule and thus 
inhibit translation or ensure that the ribosomal sub-unit responsible for translation cannot 
bind and cause translational repression.  The choice of repression is presumed to be caused 
by the level of complementarity between the miRNA and target mRNA [147, 15]. 
Research estimates that miRNA contribute up to 5% of the entire human genome, which 
control over approximately 30% of protein-coding genes suggesting that abundance of 
various miRNA within a cell is very high [147]. Currently miRBase states that 2588 mature 
Homo sapiens miRNA sequences have been identified2 [160] many of which have been used 
in clinical, medicinal and forensic research. With only around 30% of gene not being 
silenced due to miRNA and the distinct variation in cell types over different body fluids it is 
highly likely that tissue-specific miRNA are present within all cells.  
2.5.3.1. Biogenesis  
Within the human genome, miRNA genes are present. They contain the genomic 
information of a number of miRNAs and exist as distinct transcriptional units. Research 
groups have proposed that roughly 50% of determined mammalian miRNA are located in 
non-protein coding RNA or the intron of protein coding genes, as opposed to them being 
present in their own unique transcriptional unit [151, 159]. Intronic miRNA are usually 
located in the equivalent orientation and thus are co-ordinately processed with the 
precursor mRNA where they reside, thus sharing a single primary transcript. The miRNA 
genes are transcribed by RNA polymerase II, a eukaryotic enzyme that targets the promoters 
of protein-coding genes in living cells and a double stranded RNA-binding domain (dsRBD) 
protein partner, as seen in Figure 2.3. The transcription produces long ‘hair-pin’ primary 
transcripts knows as pri-miRNA. A nuclear RNase III type enzyme known as Drosha then 
processes the pri-miRNA, by cleaving the RNA approximately 11nt from the hair pin base to 
produce a stem loop, ∼ 70nt in length known as precursor miRNA (pre-miRNA). Drosha 
leaves an overhang of two or three nucleotides on the 3’ end of the pre-miRNA, this 
                                                          
2 Correct as of 04/12/2016 
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overhang is recognised by Exportin 5, a RanGTP-dependent dsRNA-binding protein that 
causes the pre-miRNA to be exported from the nucleus into the cytoplasm. Once outside 
the nucleus an RNase III protein called Dicer severs the hair pin to create an unstable 19-
25nt mature miRNA duplex structure. The less stable mature miRNA strand of the duplex is 
integrated into a multiple-protein nuclease complex known as the RISC. This combination 
allows for mature miRNA to target certain genes and regulate their activity by causing 
cleavage or translational repression of the mRNA, thus ceasing protein synthesis [159, 161-
164]. 
 
Figure 2.3: The pathways of miRNA within the cell created from [159, 161-164].  
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2.5.4. Advantages of miRNA analysis 
The small size of miRNA makes them highly stable with strong research supporting them as 
a more efficient and suitable identification tool compared to their longer mRNA 
counterparts. Court’s research group presented data that show approximately 200 miRNAs 
performed better than several thousand mRNAs when being used to classify highly similar 
tumours [165]. Their stability also means that they should be more robust and reliable in 
their performance as the likelihood of the small strands being damaged or denatured is 
considerably less. Another promising quality is that they are vastly abundant within a cell 
Batel et al. assessed that within an adult worm cell, certain miRNA contained approximately 
50,000 strands of distinct miRNA [151]. Human cells have much more complex regulatory 
mechanism and therefore the abundance of miRNA is likely to be higher. This would be of 
great importance as samples found at crime scene can be degraded or have low volumes 
of sample. This huge presence in a cell would mean that analysis could still be performed 
even with small volume samples.  
Due to the important role miRNA play in gene regulation it can be suggested that certain 
miRNA only target an individual gene, therefore their expression would only be identified 
in the body fluid related to the process that gene controlled. Since menstruation only occurs 
at the end of the menstruation cycle, the miRNA that regulates that pathway should only 
be present during that time, therefore if a menstrual blood specific miRNA can be identified 
it would be extremely valuable in determining menstrual blood and thus solve a current 
problem facing forensic scientists.  
Wang et al. researched miRNA application into BFID. qPCR was utilised to analyse 7 
proposed miRNAs against forensically related body fluids. Their results indicate 5 of their 7 
miRNA markers could determine with statistical significance the presence of venous blood, 
semen and menstrual blood [166]. Sauer et al. also researched the effectiveness of miRNA 
for forensic BFID, in this study qPCR was also utilised on 36 proposed miRNAs. Their results 
determined that only four of their miRNAs were required to identify saliva, blood, vaginal 
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material, menstrual blood and semen. The study also utilised 36-year-old blood stains that 
were correctly identified as displaying the stability and robustness of miRNA in BFID [157].  
The ideal BFID technique would run in parallel to DNA profiling, although this was 
achievable in mRNA techniques it required waste elute being kept and analysed. Van der 
Meer et al. analysed the capability of DNA/ miRNA co-extraction using Qiagen’s total DNA 
extraction kit. Blood and saliva samples were extracted and underwent DNA profiling and 
RT-qPCR for BFID. Results showed all samples were correctly identified by body fluid as well 
as producing a full DNA profile [167]. This technique removes all additional steps within 
DNA extraction with no destruction of sample, it also provides the opportunity for 
previously analysed samples where BFID would have been useful to be reanalysed 
signifying miRNA analysis has a vast cold case capability.  
2.5.5. Comparison of current mRNA and miRNA techniques 
There is limited literature comparing the techniques or mRNA against miRNA. Both show 
very promising results for BFID and both have components that make them suitable for 
forensic application. The majority of comparative research has been performed on formalin-
fixed paraffin-embedded (FFPE) samples. This an important technique in many laboratory’s 
for storing and archiving tissue samples [168]. It is important to note that crime scene 
samples would not undergo FFPE treatment and therefore may differ to current literature. 
Crime scene samples are often degraded so it is useful to note the stability of miRNA and 
mRNA over various condition.  
Liu et al. performed a study to identify which provided the best molecular expression data 
and if the need for a fresh tissue sample was an absolute requirement. Total RNA was 
prepared from paired samples of FFPE and fresh frozen malignant melanoma. A microarray 
was then utilised to compare the expression profiles obtained from miRNA in the FFPE and 
fresh tissue with the mRNA expression profiles obtained from the same sample. The 
expression profile obtained using miRNA from the FFPE sample closely mimicked that 
obtained of the fresh sample. This relationship was distinctly more observable than that 
 
 
 
99 | P a g e  
 
 
 
obtained from the mRNA expression profiles. They concluded that a fresh sample was not 
necessary for successful molecular expression analysis and that miRNA displayed a most 
vigorous analysis tool for gene expression analysis than mRNA [169].  
Klopfleisch et al. performed a more extensive review of the potential of identification and 
quantification in FFPE tissue obtained from DNA, miRNA, mRNA and proteome techniques. 
Their results showed that the chemical reactions involved in creating FFPE samples highly 
degraded mRNA and proteome samples. The poly A tail of the mRNA was almost always 
completely degraded meaning reverse transcription would only be suitable with random 
primers. Fragmentation was also observed in DNA samples, with fragments longer than 
200bp becoming split and unable to amplify in PCR. The only technique that seemed 
relatively unaffected by the formalin fixation was miRNA [168].   
A small selection of studies have been performed on mRNA stability over various conditions. 
Leonard et al. Isolated mRNA from brain tissue that had been frozen following post-mortem 
examinations. The samples varied in factors such as time since death, length of time before 
freezing and the duration the samples were in cold storage. The results discovered that 
when kept at a temperature of -70°C the majority of RNA had lost their Poly A tails meaning 
oligo-dT primers could not be used for reverse transcription. It was noted however that in 
some of the cases there were enough partial sequences present to perform amplification 
by PCR if random primers were used. They concluded that although not as successful when 
compared to fresh tissue, gene expression analysis may still be successful following long-
term storage [170].   
The most comparative study of miRNA and mRNA was performed by Ge et al. The study 
assessed the effect on stability caused by various storage lengths and temperature on 
mRNA and miRNA stability. Healthy volunteers provide plasma samples, these were then 
stored at temperatures of 4 °C, −20 °C and −80 °C and underwent no freeze-thaw cycles. 
Exosomes (minute membrane-bound vesicles secreted by the majority of cell types) were 
then taken from the plasma at time points of two weeks, two months, three years and five 
years. RNA and miRNA were isolated for the various exosome and equivalent plasma 
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samples. When studying RNA derived from the exosomes, no significant difference was 
observed across the various storage conditions. The results were very difference when 
looking at the RNA derived from plasma, significant degradation was observed in samples 
stored at 4 °C for two weeks as well as sever degradation in samples stored at −20 °C up to 
a period of five years [171].   
When results of miRNA were compared to that of RNA a distinct increased in stability was 
observed. A decrease in expression was seen in samples stored at 4 °C for two weeks for 
some of the miRNA, however all miRNA tested were still detectable at this time point. No 
decrease in expression was observed across any other storage condition suggesting there 
is a superior stability of miRNA in plasma and exosomes than in mRNA [171].     
The study went on to examine mRNA and miRNA stability when undergoing freeze-thaw 
cycles. Plasma and exosome samples which had been kept at −20 °C with one and two 
freeze-thaw cycles were analysed against the same storage conditions with no freeze-
thaws. RNA from plasma samples saw a vast decrease in concentration following one cycle, 
which was even greatly decreased when analysing a second cycle. RNA from exosomes only 
displayed a vast decrease following the second cycle. When looking at miRNA a decrease 
was observe following one and two cycles in plasma however not to the extent observed in 
RNA, with no significant difference being observed in exosomes [171].   
The presence of miRNA within the components of blood was discover in 2008. The miRNA 
isolated from plasma showed high stability under extreme conditions such as boiling, 
extreme pH values, long durations stored at room temperature and a multitude of freeze-
thaws. When tested against synthetic mimics a quick degradation was observed, 
suggesting that cell miRNA’s have a protection mechanism that allows them to avoid being 
degraded. Although this mechanism is unknown it has been theorised that they could be 
packaged into micro-particles such as micro-vesicles, be linked with RNA-binding proteins 
or complexes such as high-density lipoproteins [172].   
Current research into miRNA stability is still being performed however various studies have 
been performed. Balzano et al. became aware of the increased levels of research into miRNA 
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and BFID but not the stability of miRNA over time in storage. His study involved samples 
from clinically healthy donors which were then tested for abundance and stability following 
long durations in cold storage [173]. qPCR was performed on eight markers on samples that 
were freshly isolated from plasma and from those that had been stored at −80 °C for a period 
of between six and 12 months. They noted that no significant degradation could be 
observed therefore showing the miRNA markers were stable during this length of storage. 
They increased their experiment to include samples stored over a period of up to 14 years. 
The results showed miRNA remained stable up to a period of four years, following which 
although still detectable they became less stable [173]. The samples used in forensic work 
flow would either be fresh or archived in a -80°C freezer therefore suggesting the prospect 
that miRNA could be used on cold case samples.   
Mittchell et al. was aware of the high levels of miRNA stability observed in FFPE tissues which 
led him to further test the stability of miRNA in plasma and serum. RT-qPCR was performed 
using hydrolysis probes. Several miRNA were assessed on plasma samples that had been 
incubated at room temperature for a period of 24 hours and plasma samples that had been 
through eight freeze-thaw cycles. The RNase activity within blood plasma is very high thus 
it could be suggested that the highest rate of instability would be observed. The results for 
both freeze-thaw and room temperature incubation samples showed no significant change 
in expression was observed. Synthetic mimics were included as measured in the same way, 
these mimics quickly became degraded when added to the plasma which indicated that 
endogenous miRNA have developed a technique that provides protection from RNase 
activity. This study was repeated on samples obtained from serum with miRNA again 
showing not significant difference in stability [174].   
Overall, this research currently available suggests that miRNA offer a higher level of stability 
over a wide range of factors, there is however some discrepancies in that Mittchell et al. 
[173] states miRNA are highly stable at room temperature while Ge et al [171] showed a 
decrease in miRNA expression when stored at length at room temperature. Degradation 
rates of miRNA and mRNA are clearly linked to the protective property of the nucleic acid, 
with exosomal RNA continually showing high stability in both mRNA and miRNA compared 
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to samples obtained from pure serum. Current literature does show that although both 
mRNA and miRNA gene expression analysis can be performed after long term storage it is 
more successful and higher expression is observed when utilising miRNA.   
2.5.6. miRNA Suitability for Identifying Body Fluid 
Components 
2.5.6.1. Venous blood  
As RBCs and platelets are the only cells within any body fluid without genetic material it 
would suggest that it is miRNA that regulate homeostasis and replication. These miRNA are 
likely to be specific to that regulation and would not be found in the cells containing genetic 
material. The cytoplasm of all RBCs is saturated in haemoglobin, an iron rich protein that 
binds with oxygen in oxygen rich regions such as the lungs, transports it around the 
circulatory system and releases oxygen in poorly oxygenated regions such as muscles. Due 
to the continual alteration in shape to travel through narrow blood vessels, the RBC can only 
survive for approximately four months with the haemoglobin from old cells utilised to 
recreate new RBCs within bone marrow [76]. This constant change in structure to fit through 
narrow vessels and the destruction and regeneration of new RBC is a highly regulated 
process and due to the specific requirements and lack of similar processes to other human 
cells the regulation is likely to be specific and thus require specific miRNA.  
The plasma and WBC within whole blood contain a large number of proteins and regulate 
immunological responses as well as maintaining body temperature and blood pressure [76]. 
These factors can fluctuate rapidly and therefore would require strict regulation from 
miRNA. Due to no other body fluid having homeostatic responsibilities it could be 
suggested the miRNA responsible are highly specific.  
There are many conditions that may cause fluctuation in the regulation of miRNA. Blood 
conditions such as anaemia involve the deficiency of haemoglobin or RBCs, while cancers, 
not limited to those of the blood, will cause drastic changes in the homeostatic 
environment of cells. Schultz et al. analysed the regulation of biomarkers in whole blood in 
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patients with and without pancreatic cancer. The study included 312 healthy participants 
and 434 patients with pancreatic cancer or chronic pancreatitis, their analysis resulted in the 
observation that 38 miRNA were down-regulated in patients with pancreatic cancer when 
compared to the healthy patient control group [175]. This is a large proportion of miRNA 
and if specific to regulation within blood, would impact on the suitability for BFID. In cases 
where blood residue is located the medical history and health of the source will be unknown 
therefore down-regulation due to diseases may cause a false identification. Bio-markers 
must therefore be consistently expressed regardless of factors such immunological 
responses to diseases. 
2.5.6.1.1. Blood response to injury 
If venous blood is located at a crime scene it is likely from trauma to the body, such as 
tearing of the labia during a sexual assault. The instant biological response is for the body 
to instigate physiological reactions to prevent severe blood loss. This is performed by 
creating a haemostatic plug around the damaged site. Haemostasis is the essential process 
of halting excess bleeding at a damaged location, while maintaining regulated blood flow 
to the rest of the circulatory system. The endothelium of blood vessels acts as an interface 
between circulating blood and the vessel wall, it has an anticoagulant surface which 
maintains blood fluidity and ensures cells do not adhere to the blood vessel wall. When 
blood vessels are torn or damaged, as may occur in violent and forceful crimes, fibrous 
components within the endothelium are exposed to the blood. Since platelets are the 
lightest of the cells they are pushed to the edges of the blood vessels and are in first contact. 
They adhere to the fibrous tissue to create a haemostatic plug and thus clot the blood. This 
process is under strict regulation with haemostasis occurring within seconds to ensure the 
minimal amount of blood is lost [176-178]. 
Haemostasis is a vital process for survival following traumatic events, it does however 
suggest that blood leaving a wound may be slightly different in composition to circulatory 
blood. With such tight regulation of haemostasis it would be likely that many miRNAs are 
designated to this essential role. Since no other body fluid requires a clotting factor these 
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haemostasis specific miRNA are likely to be only found in blood. The presence of miRNA 
within venous blood from various trauma wound may also differ; a nose bleed may have a 
completely different composition to venous blood from a tear in the vagina.  
2.5.6.1.2. Blood response to foreign material  
Severe cases of blood loss require whole blood transfusions. Blood types must be matched 
and screening of blood is essential. With all blood transfusions there is a risk of rejection of 
the foreign blood by the patient, if the components within the blood determines the foreign 
material is a threat an immunological response will be initiated [179]. These reactions are 
frequently due to plasma proteins, RBC antigens, leucocytes or additional pathogens. With 
such a significant and immediate response to management of foreign material within the 
blood, it is likely that tight regulation of processes are control by a selection of miRNA, which 
although may regulate an immune response may be specific to RBC and plasma control 
[179]. 
2.5.6.1.3. Stability of blood components 
Zou and colleges utilised Mid-infrared spectroscopy and Raman microscopy; versatile 
optical analysis techniques, to determine the components of whole blood [143]. Analysis 
was performed on 16 blood samples, inclusive of all blood types and both genders. The 
peaks identified were attributed to haemoglobin, acetates, haems, lactates and tryptophan. 
Their results showed these components are always found in blood, regardless of different 
ages, genders or blood groups. These findings suggest that whole blood is very stable and 
therefore the regulation of genes and other biological processes should be the same 
between individuals and therefore so should the presence of miRNA.  
2.5.6.2. Similarities between saliva and vaginal material 
Whole saliva is regulated by many enzymatic processes which would suggest a high volume 
of various miRNA are present. These would quickly respond to the increased need of 
immunological proteins or digestive proteins. The specificity of α-amylase within saliva 
would suggest the miRNA responsible for its regulation may also be specific to saliva 
however the issue that saliva is similar in appearance to vaginal material is also apparent on 
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a cellular level due to both requiring immunological defence against foreign microbes. 
MicroRNA responsible for rapid changes in immune responses may be present in both fluids 
which would display dual expression when analysed. The miRNA required for BFID would 
ideally not have a regulatory role in the immune system.  
Research has shown that down-regulation of genes is a key feature in a majority of cancers 
[164]. This would therefore lead to the assumption that miRNA are also down-regulated. 
Wilting et al. analysed the methylation levels of 3 loci encoding the mature sequence of hsa-
mir-124 in patients free of cancer and those know to have cervical cancer. Methylation 
levels, and thus the silencing of hsa-mir-124, showed no methylation in healthy individuals 
but an increase of 93% in cervical carcinoma tissue [164]. Such a significant increase in the 
silencing of hsa-mir-124 and possible other miRNA would make ensuring a BFID technique 
is robust and reliable a difficult challenge.  
2.5.6.3. Menstrual blood  
The higher concentration of genetic material coupled with the high volume of protein 
regulated processes indicate that although similar in appearance, menstrual blood should 
contain a large number of miRNA that would not be required in venous blood. The 
menstrual cycle is largely regulated by oestrogen and progesterone, although these are 
steroid hormones, they interact with protein receptors to catalyse reactions and regulate 
gene expression [93]. It can therefore be suggested that all four hormones are likely 
controlled by miRNA regulation and since the hormone levels change so rapidly and 
abundantly throughout the cycle it is likely miRNA presence will follow this pattern.  
As previously described there are multiple factors that change the frequency and 
consistency of menstrual blood. Both hormonal and non-hormonal contraception change 
the structure and regulation of the endometrium. The IUD causes continual destruction of 
the endometrium suggesting miRNA responsible for regulation of progesterone for 
endometrium building may also be effected as they will likely be in a continuous switched 
on state to repair damage. Pregnancy will initiate strict regulation of new mechanisms to 
prevent damage to the foetus and therefore a whole range of new miRNA may be found in 
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the vaginal material and potential vaginal bleedings of pregnant females. Conditions such 
as endometriosis display a down-regulation of immunological response cells and therefore 
a down-regulation of the miRNA responsible for that response. It could then be suggested 
that women with endometriosis may show no expression pattern of certain miRNA when 
compared to ‘healthy’ menstrual blood samples.  
2.5.6.4. Semen 
The large number and variation of proteins present in fertile males would require strict 
regulation from multiple miRNA. Spermatozoa are only produced in the testes therefore it 
is likely these miRNAs are specific to semen. The remaining are dedicated to providing 
energy to the spermatozoa, since no other body fluid requires an energy source the miRNA 
and their regulation mechanisms are likely to be highly specific to semen. The depletion of 
many proteins when spermatozoa are low or absent would mean that the miRNA 
responsible for regulation of those proteins would also be absent suggesting that a BFID 
technique utilising miRNA must be carefully validated to ensure presence is high regardless 
of spermatozoa presence.   
The current available literature on semen persistency does not provide a definitive time 
frame for positive identification within vaginal material. With no research being performed 
on the persistency of biomarkers such as mRNA or miRNA. It is likely that these would be 
located within the fluid as well as the spermatozoa themselves meaning they may have an 
increase like hood of being identified compared to trying to identify spermatozoa as a 
whole component. Overall each body fluid presents a role within the body that is specific 
to that fluid, although many involve immunological responses they will not all be identical 
and therefore may not share miRNA. The majority of body fluids are susceptible to factors 
that would likely alter the expression pattern of regulatory miRNA, requiring any miRNA 
chosen for BFID to be thoroughly validated before implementation into casework.    
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2.5.7. Marker Selection 
2.5.7.1. Current body fluid specific miRNA from literature 
Markers were selected based on body fluid specificity from current literature. Park et al. 
utilised a genome-wide miRNA micro array comprising more than 1700 miRNAs. Successful 
markers were then screened using RT-qPCR for further analysis of specificity. Their results 
indicated a selection of markers showing specificity, such as hsa-mir-1260b and 654 for 
vaginal material, hsa-mir-223 for saliva and hsa-mir-2392, 891a and 3197 for semen. Park et 
al. research differs from the methods used in this research due to substitution of a hydrolysis 
probe for SYBR green [165]. SYBR is a fluorescent intercalating dye that binds itself into 
double stranded DNA molecules. Binding causes alterations in the dyes composition which 
causes fluorescence. The more DNA produced throughout amplification the higher the 
intensity of fluorescence. The disadvantage of intercalating dyes is the known lack of 
specificity when compared to probe based qPCR, this due to the dye being amplified in all 
double stranded DNA sequences. The likelihood of non-specific amplification is therefore 
high and a melt-curve is required after every analysis. [166]. Park et al. observed that hsa-
mir-16 was highly expressed in venous blood but also displayed high expression in saliva 
and vaginal material. While hsa-mir-203a and 205 which were highly expressed in saliva 
were also highly expressed in semen.  
Sauer et al. also performed a genome-wide miRNA micro array to highlight potential BFID 
miRNA. They analysed a selection of potential markers with TaqMan® based RT-qPCR, they 
concluded that hsa-mir-891a-5p was wholly specific for semen, with hsa-mir-10a-5p, 10b-
5p and 135-5p showing significantly higher expression in semen than other body fluids. 
Sauer’s research found markers specific to both venous blood and menstrual blood, hsa-
mir-144-5p, 144-3p and 451a, however these markers could not differentiate between the 
two. Analysis of hsa-mir-205 and 203a showed high specificity to saliva and vaginal material; 
but again could not differentiate the two body fluids, with only hsa-mir-124 showing 
complete specificity to vaginal material [167].  
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Hanson et al. performed RT-qPCR following SYBR green protocol on 452 human microRNAs. 
Results showed that although true specificity was not identified significant differences 
between body fluids were sufficient for BFID.  The markers chosen for BFID were hsa-mir-16 
and 451a for venous blood, hsa-mir-135a and 10b for seminal samples, hsa-mir-205 and 658 
for saliva, hsa-mir-124a and 372 for vaginal material and utilising differential expression hsa-
mir-451 and 412 for menstrual blood. Of vaginal material markers, hsa-mir-124 was 
observed as highly expressed in vaginal material over all other body fluids, while hsa-mir-
372 showed expression in all body fluids but a higher expression value was observed in 
vaginal material [168].  
Research performed by Zubakov et al. which also utilised microarray screening of 718 
human miRNAs, followed by TaqMan® RT-qPCR displayed body fluid specificity in a number 
of markers, such as hsa-mir-185 and 144 for blood identification, no differentiation from 
menstrual blood and venous blood, and hsa-mir-135a, 10a, 507 and 891a for semen. Their 
research attempted to replicate the work of Hanson et al. using TaqMan® instead of SYBR 
green, with reproducibility only seen in venous blood markers hsa-mir-16 and 451a, and 
semen markers hsa-mir-10b and 135b. Their data did not show reproducibility of hsa-mir-
205 and 658 in saliva, hsa-mir-124a and 372 in vaginal material or hsa-mir-412 in menstrual 
blood. The conclusions of Zubakov et al. work highlight discrepancies between publications 
could be a small sampling size or the differences in methodology in SYBR green analysis 
[185]. The research also showed discrepancies between microarray data and RT-qPCR data 
in which hsa-mir-617 for vaginal material identification and a handful of other markers 
showed high specificity which was only observed in microarray screening and not RT-qPCR 
analysis.  
Research performed by Wang et al. first screened a number of miRNA using the qPCR-array 
(TaqMan® Array Human MicroRNA Cards) which indicated hsa-mir-16 for venous blood, hsa-
mir-888 and 891a for semen, hsa-mir-214 for menstrual blood, hsa-mir-124 for vaginal 
material and hsa-mir-138-2 for saliva. These markers were then validated through TaqMan® 
qPCR normalising with SNORD44. Subsequent TaqMan® qPCR analysis only supported hsa-
mir-16 for venous blood, hsa-mir-888 and 891a for semen and hsa-mir-214 for menstrual 
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blood, with hsa-mir-138-2 not showing specificity [181]. Current research within and 
surrounding BFID also suggest hsa-mir-508 [187], 888-5p [186, 183] as semen specific: High 
expression of hsa-mir-888-5p was observed when performing in-vitro testing on the early 
stages of spermatozoa development indicating it may have semen specific expression [189]. 
Research into endometriosis has also shown a significant down regulation of hsa-mir-199a 
in patients suffering from the disease, indicating that it may have a significant role in the 
normal regulation of the endometrium [190].    
Many researchers have looked at identifying the function of specific miRNA. New miRNA are 
constantly being identified with the majority of functionality unknown. Current literature 
does determine that miRNA’s are responsible for the regulation of specific genes with many 
showing they have a large role in both oncogenic and tumour suppressive functions [191]. 
Martin et al. studied the function of miRNA in seed biology and concluded that miRNA have 
evolved so that their functionality is diverse, they can target multiple different genes which 
have a role in various processes. Therefore miRNA have evolved within each species to 
perform multiple functions. [192]. It would therefore be difficult to determine the exact 
function of the miRNA selected for this screening study. The likelihood of multiple functions 
increases the probability of cross reactivity across body fluids, therefore markers that are 
only expressed within one body fluid would be the ideal BFID candidate. 
2.5.7.2. Comparison of techniques and miRNA selection  
When using micro or qPCR arrays i.e. non-TaqMan® assay, each research group observed at 
least one marker that displayed specificity discrepancies between microarray and RT-qPCR 
data. This was possibly due to the microarray detecting artefacts or that qPCR arrays require 
a higher RNA input and therefore pre-amplification is required [185, 186]  
In current literature, certain miRNA such as hsa-mir-16 for 451 for blood [124, 184, 185, 193, 
194], 205 in saliva [124, 184, 175, 186, 194], hsa-mir-135b and 10b [124, 184, 185] for semen 
are supported by multiple publications as body fluid specific, with other publications 
disagreeing on hsa-mir-205 specificity [186, 193]. Research by Wang et al. also disagreed 
with Courts et al. findings that hsa-mir-203a was specific to saliva in that when tested 
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against other body fluids, it was specific against venous blood but highly expressed in 
vaginal material and menstrual blood [186]. Various endogenous controls were analysed 
throughout these publications such as SNORD 47 [196] and SNORD 44 [186]. Other studies 
were also performed on the reliability of certain markers as endogenous controls; Applied 
Biosystems performed a robust study identifying many endogenous control candidates 
such as RNU38B, 44 and 48 [196] while Sauer et al. analysed the reliability of hsa-miR-93-5p, 
SNORD 7, 38b, 44 and 48, stating the most reliable was SNORD 38b [197].  
The majority of body fluid miRNA markers in current publications have not been 
independently validated by other publications, when this has occurred discrepancies have 
regularly arisen. Further literature from Hanson et al. utilising SYBR qPCR also suggested a 
range of specific markers, hsa-mir-658, 205 and 124* for saliva identification, hsa-mir-892a 
and 891b for semen, hsa-mir-4286 and 124 for vaginal material, hsa-mir-142, 144-5, 144-3 
and 185 for menstrual blood, hsa-mir-455-3p, 3169 for skin cells and hsa-mir-451a and 16 
for blood. The results obtained for this study support other markers found in other SYBR 
studies but also disagrees with other research previously described [193]. The main 
discrepancies observed in literature is the specificity of markers to menstrual blood or 
venous blood, in certain publications hsa-mir-144 is menstrual blood specific [184, 185, 198] 
whereas other report it as venous blood specific [183,185] This has also been observed in 
assigning specificity of hsa-mir-16 with some literature supporting specificity and some 
identifying high expression in other body fluids.  
Overall the current literature surrounding miRNA specificity is not wholly reproducible 
across laboratories. The differences are likely due to various extraction methods, whether 
DNA digestion was utilised, whether SYBR or hydrolysis probe methods were used and if 
pre-amplification occurred. The aim of this research is to run alongside or phase into current 
laboratory processes therefore extraction methods will vary from current research due to 
current forensic laboratory protocol, with steps such as DNA digestion and pre-
amplification being avoided. The variation between studies using SYBR and hydrolysis is 
reasonably large suggesting the selected qPCR technique is important to gaining 
reproducible specific expression values. This would therefore require any miRNA BFID 
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technique implemented into casework to have a set protocol where all laboratories 
performed analysis via hydrolysis probes or SYBR.  
 Summary of Current and Emerging Body Fluid 
Identification Techniques  
Traditional confirmatory and presumptive tests for BFID suffer from a lack of specificity and 
sensitivity as well as being occasionally labour-intensive with high risks of false positives. 
They are also performed before DNA analysis and the majority require destruction of 
valuable sample to provide identification. Among emerging techniques that have been 
discussed, mRNA markers have been most rigorously investigated and the number of 
specific markers is sufficient for the identification of forensically relevant body fluids. Some 
of the other currently used methods have potential for the rapid and non-destructive 
identification of body fluids, but in most cases, tissue specificity is problematic due to cross-
reaction with biological or non-biological material present in samples at crimes scene. 
mRNA markers show high tissue-specificity and adequate sensitivity for forensic analysis 
and can be considered as a valuable new approach to overcome the limitations of 
conventional methods. BFID through mRNA profiling is not yet widely used in forensic 
laboratories owing to the fact that further validation is required and it is not deemed cost-
effective to store waste elute for possible BFID. In addition, heat and humidity remain 
threats to the stability of mRNA markers.  
DNA methylation profiling was proposed as a promising new tool for forensic body fluid 
identification which uses the same DNA samples that are used for DNA profiling. Like mRNA 
profiling methods, DNA methylation profiling showed high specificity and sensitivity, and 
also allowed for the simultaneous analysis of multiple markers, specific for various tissues in 
a single multiplex system. Moreover, DNA methylation profiling methods fit well with 
current forensic applications, and accordingly, can be easily integrated into current forensic 
standardised procedures. Although an extremely promising forensic technique, DNA 
methylation still needs to identify more markers for future practical application to casework. 
BFID is not the only forensic application for methylation analysis with current research 
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showing its potential for age determination and identifying which monozygotic twin a body 
fluid sample originated from [131].    
Overall miRNA, although not currently validated for forensic laboratory work has displayed 
all the benefits of mRNA and methylation analysis. The technique displays the additional 
advantages of having increased stability over mRNA, parallel analysis with DNA profiling 
and with analysis performed on DNA elute the requirement for further storage space is 
removed. This also provides prosecutors of crimes committed years before BFID technology 
emerged to re-analyse already profiled and archived samples for information that could be 
essential to a conviction in a court of law.  
Although miRNA has shown suitability as a BFID technique there are many factors that can 
alter the composition and gene regulation of body fluids. An immunological response to 
pathogens is an ability all body fluids possess, since this involves strict gene expression and 
protein production the regulatory miRNA will also be present in all body fluids. Research 
highlights miRNA as a reliable and tissue specific bio-marker for use in BFID however 
implementation into criminal casework cannot proceed until a number of validation and 
optimisation studies have occurred. This research therefore aims to solve the 
aforementioned limitations of BFID techniques by identifying miRNA that are highly tissue-
specific while robustly analysing them in conditions that could inhibit expression such as 
the menstrual cycle, the absence of spermatozoa or the suppression by higher quantities of 
genetic material from other body fluids. 
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3. Research Aims 
and Objectives 
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 Aims and Objectives 
Sexual assault is an offence which suffers from very low reporting and conviction rates. 
Victims suffer with a wide variation of traumas from the events therefore new techniques 
must be developed to increase the reporting and conviction from the less serious to the 
major offences.   When introduced, the impact of the inclusion of DNA evidence within a 
court room was substantial, with it currently being the most sort out piece of evidence. DNA 
evidence only identifies a person was at or involved in a crime scene, not the events and 
therefore it can be manipulated by the defence and prosecution to show varied versions of 
how the crime occurred. BFID can provide an outline of the events that occurred, making 
evidence clearer for Jury’s to understand but also remove many of the statements that the 
defence and prosecution could use to display their version of events.  
Currently, the Identification of body fluid samples found at crime scenes involve techniques 
that were developed over the past 100 years. These technique are rarely improved upon, 
consume and degrade valuable sample, often require trained experts for testing and are 
mostly only usable as a presumptive identification. It is therefore important that a new 
technique that can run alongside and support DNA profiling evidence is introduced. The 
aim of this research project is to develop a technique that is confirmatory, doesn’t destroy 
valuable samples, can be run in parallel with DNA profile, does not required additional 
extensive training to perform and will not vastly increase the cost or time of analysis. 
Current literature has contradicting opinions on the regulation and expression of miRNA in 
BFID. This appears to be linked to the variety in techniques used with the most 
contradictions being observed with different extraction techniques and when using SYBR 
green based chemistry against probe based chemistry. This research aims to confirm the 
results of current literature using probe base chemistry and to outline a simple protocol that 
can be reproduced by all forensic laboratories. As well as support current literature this 
research aims to identify a panel of markers, ideally multiple for each body fluid that can 
identify the major body fluids found at crimes science with no risk of false identification.  
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The next objective of this research is to provide a definitive identification to problems that 
current forensic scientists face. The differentiation of vaginal material and saliva is currently 
unachievable yet is arguably one of the most important differentiations in a sexual assault 
case. This research aims to provide markers that can not only identify vaginal material and 
saliva as a single body fluid but can differentiate the body fluids when in mixtures of up to 
three body fluids. The lack of DNA evidence in cases where perpetrators have low or absent 
sperm counts will have a large impact on how the case is described in court. This research 
aims to be able to identify ejaculate regardless of whether spermatozoa are present so not 
only can the differentiation between azoospermic/ vasectomised semen and regular semen 
be determined but the presence of either can be identified from a vaginal swab. The final 
identification objective is the differentiation of menstrual blood and trauma blood. The 
identification of trauma blood suggests that an aggressive action occurred which could 
provide greater support to the victim and prosecution hypothesis. It is therefore important 
that this research can isolate multiple markers that can determine which source of blood 
was obtained from the crime scene sample.  
In addition to demonstrating specificity, markers must also demonstrate sensitivity. Crime 
scene samples are rarely found in large volumes with no degradation and in cases of sexual 
assault, the perpetrators contributions may be significantly lower than that from the victim. 
Once a panel of markers have been identified for BFID, their ability for detection at trace 
level will be assessed.  
Once identified, validation of this technique is imperative. Expression of genes within cells 
is a dynamic process, and as such any marker identified as being body fluid specific must 
also be robust enough to deal with these changes. One of the most dynamic processes 
within human physiology is that of the menstrual cycle, and as such the next component of 
this research investigated the specificity and robustness of both target and endogenous 
control markers over a full 31-day screening. The objective of this study was to characterise 
any changes in expression that could occur due to the various stages of the menstrual cycle 
which may ultimate cause a false positive/negative result if analysed on various sexual 
assault samples.  
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The false identification of a body fluid could lead to the exoneration of a guilty suspect or 
the conviction of an innocent. The process for DNA profiling is the same in all forensic 
laboratories, it would therefore be highly beneficial if the technique could utilises some of 
these work flow stages. Although miRNA extraction kits are available all forensic 
laboratories utilise DNA extraction protocols. The introduction of an additional extraction 
method would require double the sample volume, additional personnel to perform the 
analysis and an increase in cost of reagents. This research aims to validate the extraction 
methods currently used in forensic laboratories for their ability to extract miRNA, with a 
comprehensive comparison of DNA and RNA specific extraction methods. The efficiency for 
miRNA extraction as well as the reproducibility and reliability will be fully analysed to ensure 
the implementation of a non-specific miRNA extraction kit would not obstruct BFID.  
The identification of markers that can differentiate body fluids when found in self-collected, 
un-contaminated, single body fluid samples is important however they must provide the 
same infallible identification when utilising on ‘real world’ samples that contain mixtures of 
multiple body fluids. The final research project will analyse the markers ability to detect 
semen within a vaginal material mixture obtained following UPSI as well as the duration 
that efficient and accurate identification can be achieved. To achieve the objective of 
developing a technique that will fit into current forensic work flow, this study will also assess 
the affect DTT has on miRNA. DTT is an essential part of DNA profiling from semen, it is 
destructive to the spermatozoa head therefore the likelihood for damage to miRNA is high. 
This study aims to determine the extent, if any of damage on miRNA through various 
extraction techniques utilising DTT.  
Overall, this research aims to identify a full BFID panel that can solve the current issues 
forensic scientist face as well as providing additional strong weighted evidence for the 
events of a crime scene. Once identified validation will include the most suitable extraction 
method, the identification of body fluids when found in mixtures and the duration certain 
body fluids such as menstrual blood and semen can be detected. 
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4. Methods and 
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 Ethics Statement 
The study was approved by the School of Applied Sciences Ethics Committee on Human 
Research of the University Huddersfield and written informed consent was obtained from 
all participants. Full ethical approval was gained for collecting and processing all body fluid 
samples contained within this research. 
 General Reagents and Consumables 
Unless stated all plastic consumables described in this chapter were purchased from 
Sarstedt (Germany) with all reagents purchased from either Thermo Fisher Scientific, (MA, 
USA), Eurofins Genomics (Ebersberg, Germany), Qiagen (Germany) and Primerdesign 
(Chandler's Ford, UK) 
 Volunteer Selection and Sample Collection 
Individuals were sought out and chosen based on factors that literature and fundamental 
knowledge suggested may cause variation in miRNA expression: Simple factors such as age, 
ethnicity, lifestyle habits (smoking and drinking) and type of contraception were included, 
but also more in-depth factors such as pregnancy history/complications, sterilisations, 
diseases (especially those that target the reproductive systems) and stage of menopause 
(See appendix A and B). A vast range of factors were selected such that if a marker was 
significantly expressed in all the samples it would show its robustness as a biomarker in 
sexual assault cases while also highlighting a possible cause if all but one sample displayed 
expression.  
All samples were self-collected using sterile cotton swabs. After sample collection the swab 
was returned to the sterile tube and dried at room temperature, thus preventing cross 
contamination of samples. Benches were regularly cleaned with MicroSol 3+ to remove any 
DNA/RNA contamination and full PPE was worn while processing the samples. Information 
sheets were provided, followed by completion of a comprehensive questionnaire to ensure 
all intimate female samples with a high likelihood of semen presence were known, proper 
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sampling techniques were followed and to ensure honest answers to intimate questions 
could be anonymously provided. All volunteers were assigned a symbol to ensure 
anonymity throughout processing and analysis. 
4.3.1. Vaginal secretions 
Women self-collected LVS using a standard sterile cotton swab, once sampled the swab was 
returned to its casing, labelled and extracted immediately. If storage before extraction was 
required the swab was kept at -20°C. Volunteers ranged in age from 18 to 65. Individuals 
had extremely varied lifestyles differing in age, smoking, previous pregnancies, all forms of 
contraception, cervical cancers, ethnicity, sterilisation, medication and varying levels of 
sexual activity. Volunteers were requested to provide the approximate day of their last 
menstruation sexual interaction (either oral or penile) on their consent sheet. This ensured 
that any samples that could possibly contain semen or menstrual blood could be identified. 
4.3.2. Menstrual blood 
All women providing vaginal material samples were asked to provide a menstrual blood 
sample, this was achievable in half of the vaginal material volunteers. Factors such as 
cessation due to hormonal contraceptives or time/ distance constraints while menstruating 
meant not all volunteers were able to donate both body fluids. Additional females donated 
menstrual blood as their only body fluid sample. Collection occurred as per vaginal 
secretions. Samples ranged broadly in age of volunteer from woman in variation stages of 
the menopause as well as younger women on different types of contraceptive and with 
varying pregnancy histories. Volunteers were requested to provide their approximate day 
of menstruation on their consent sheet.  
4.3.3. Semen and seminal fluid 
Semen and seminal fluid was obtained from men ranging from 18 to 52. Samples were self- 
collected into a Falcon™ 50mL Conical Centrifuge Tube. The Falcon tubes were stored in a -
20°C freezer and nucleic acids extracted within 24 hours. All samples underwent 
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Haematoxylin and Eosin staining (H&E) to determine presence of spermatozoa (as observed 
in 4.6).  
4.3.4. Blood and saliva 
Samples were collected for each body fluid to allow for comparisons with previous research 
[199]. Saliva was obtained through self-collection using sterile cotton buccal swabs from 
the inside of both cheeks, taken at least 30 minutes after eating. Blood was self-collected 
collected using an Owen Mumford Unistik 3 Extra to pierce the tip of the thumb or index 
finger, a buccal swab was then used to collect the blood until saturated. Antiseptic wipes 
were used to clean the finger before and after to reduce contamination. Visual examinations 
were performed on saliva buccal swabs to reduce the risk of blood being present in the 
sample.  
4.3.5. Skin 
Skins cell samples were self-collected using a scalpel to gently remove the skin cells from 
the back of the hand. Antiseptic wipes were used to clean the hand before and after to 
decrease risk of contamination. Visual inspections of the samples were performed to ensure 
blood wasn’t present within the sample.  
 Nucleotide Extraction  
4.4.1. Standard total DNA extraction 
Total DNA extraction was performed using the QIAamp DNA Mini Kit. DNA was isolated from 
the body fluids using lysis buffer which breaks down the nucleus of the cell to release the 
genomic material while proteinase K degrades proteins that could be damaging to DNA 
[201, 202]. The high chaotropic salt concentrations from the lysis buffer precipitates DNA 
and therefore the DNA binds to the silica-gel membranes within the spin column. The 
addition of ethanol solubilises organic contaminants associated with the cell which then 
pass through the silica membrane. Proteins, divalent cations and other PCR inhibitors are 
removed throughout wash steps: by eliminating cations such as Mg2+ DNA will not be 
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degraded by nucleases. An elution buffer is then used to remove the DNA from the silica 
membrane so they can be eluted to obtain a pure DNA extract.  
Figure 4.1 Stages of DNA extraction following the QIAamp DNA Mini Kit protocol [202]. 
Figure 4.1 shows the process of extraction: 400μl of PBS, 20μl proteinase K and 400μl lysis 
buffer were added to a sample within a sterile 2ml tube. This was then vortexed thoroughly 
and pulse centrifuged to retain the sample at the base of the tube. The samples were then 
incubated for 10m at 56oC.  Absolute ethanol (400μl) was then added to the lysate and 
subjected to a further pulse centrifugation. 700μl of lysate was then transferred into a spin 
column and centrifuged at 8,000 rpm for 1 minute, the flow-through within the tube was 
then discarded and the remaining lysate was transferred to the spin column and the process 
repeated. AW1 wash buffer (500μl) was then added to the top of the spin column and 
centrifuged at 8,000rpm for 1minute, with the flow through discarded. AW2 wash buffer 
(500μl) was then transferred to the spin column and centrifuged at 14,000rpm for three 
minutes. After discarding the flow through, a further centrifugation step at 14,000rpm for 
one minute was carried out to remove any residual wash buffer from the column. The spin 
column was then transferred to a fresh 2ml tube and 150μl of AE elution buffer added and 
left to incubate at room temperature for one minute. The DNA was then eluted from the 
column via centrifugation at 8,000rpm for one minute. The column was then discarded and 
the sample retained at -20 oC prior to downstream analysis. 
4.4.2. Total RNA extraction 
RNA extraction was performed with Qiagen’s RNeasy Mini Kit. The kit has similar principles 
to the DNA extraction kit in that it utilises the selective binding properties of the silica 
membrane. Samples are first lysed and homogenised using a highly denaturing guanidine-
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thiocyanate–containing buffer, inactivating RNases to ensure pure RNA is not degraded. 
70% ethanol is then added to the lysate to create the ideal binding environment. The lysate 
is then transferred to an RNeasy spin column where binding of RNA occurs with 
contaminants being efficiently removed using wash buffers.  RNase free water is then used 
to elute to pure RNA. [203].  
 
Figure 4.2 Processes involved in total RNA extraction following RNeasy Mini Kit protocol [203] 
Figure 4.2 describes the process of extraction: 350μl of RTL buffer was added to a sample 
contained in a 2ml tube, which was then vortexed thoroughly and pulse centrifuged to 
collect the sample at the base of the tube. 350μl of 70% ethanol was then added to lysate. 
The lysate was then transferred to the QIAamp spin column and centrifuged at 10,000rpm 
for 15 seconds. 700μl RW1 buffer was added to the spin column and centrifuged at 
10,000rpm for a further 15 seconds. The flow through was discarded and 500μl of RPE buffer 
added followed by centrifugation at 10,000rpm for 15 seconds. The flow through was 
discarded and 500μl of RPE buffer added and centrifuged at 14,000rpm for three minutes. 
Spin columns were then placed in a new 2ml tube and centrifuged at 14, 000rpm for one 
minute. RNase free water (50μl) was then added and centrifuged at 8,000rpm for one 
minute to elute RNA.  
4.4.3.  Differential extraction 
Differential extraction is the preferred extraction technique when dealing with samples 
from a sexual assault case. The process involves splitting the epithelial portion, the majority 
of which will obtain DNA from vaginal material from the possible spermatozoa. Both 
samples are then DNA profiled with the aim of obtaining two distinct profiles. DTT is added 
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to the seminal fraction to degrade the protein disulphide bridges that make up sperm 
nuclear membranes [204].  
Samples were placed into a 2ml tube containing 1ml of PBS buffer. The swab head 
underwent agitation with a sterile stick for 60 seconds to ensure the maximum yield of 
spermatozoa was removed from the swab followed by vortexing at 12,000rpm for 60 
seconds, this stage was then repeated. Samples were then centrifuged at 14,000rpm for five 
minutes to form a pellet. The swab head and supernatant were then carefully removed so 
the pellet was not disturbed, leaving ~50μl of supernatant surrounding the pellet. 
4.4.3.1. Epithelial fraction 
125μl of 1% SDS along with 125μl 2mg/ml Proteinase K (made from 1:5 dilution of Qiagen 
Pro K with molecular biology grade water (MBG) was then added to the 2ml tube containing 
the pelleted sample. This was then vortexed at 12,000rpm for 15 seconds to ensure 
complete disruption of the pellet.  The samples were then incubated at 37°C for 30 minutes, 
briefly vortexed to break up any new remaining solids and incubated again at 37°C for 30 
minutes. Samples were then vortexed and centrifuged at 14,000rpm for five minutes. 250μl 
of supernatant was transferred to a 2ml tube and combined with 250ml of Qiagen ATL 
buffer. These samples were then processed using the standard Qiagen DNA protocol 
described above in section 3.4.1, excluding the lysis stage. 
4.4.3.2. Seminal fraction 
500μl of wash buffer (10mM Tris HCl, 10mM EDTA, 50mM NaCl and 2% SDS, pH adjusted to 
7.5 using 2M NaOH and autoclaved at 121°C for 15 minutes to remove DNase/RNase) was  
added to the pellet retained in section 3.4.3.1 and vortexed at 12,000rpm for 60 seconds. 
Samples were then centrifuged at 14,000rpm for 5 minutes to create a pellet, the 
supernatant was discarded with the pellet reconstituted with 50μl of wash buffer. This wash 
step was then repeated three times. After this third wash step, the supernatant was 
discarded and reconstituted in1,000μl of MBG water by vortexing. The mixture was then 
centrifuged for a further 5 minutes at 14,000rpm and the supernatant discarded.  
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475μl of ATL Buffer, 25μl of Qiagen Proteinase K and 20μl 1M DTT were then added to the 
pellet and vortexed for 60 seconds at 12,000rpm. After a pulse centrifuge the samples were 
incubated at 56°C for 60 minutes with frequent agitation from a vortex at 900rpm. The 
samples were then spun at 8,000rpm for 60 seconds and then followed the wash process of 
the standard DNA protocol (3.4.1).   
  Quantification of Samples 
Quantification of molecular samples is crucial for many analytical techniques, with the 
recommended template volume of DNA for successful human identification is 0.5-2ng 
[205]. An input higher than this will result in too much DNA for a viable DNA profile 
electropherogram, demonstrated by a higher frequency of “pull ups”, “stutters” and 
heterozygous peaks that are not even and/or split peaks [205, 206] In relation to sexual 
assault, samples obtained from intimate swabs will contain a large volume of vaginal 
material with, if present a small volume of seminal fluid. As a result, a seminal profile would 
not be obtained due to a high concentration of vaginal sample causing a failed 
electropherogram, where dilution would likely remove trace of the seminal fraction.  
At the commencement of this research, no accepted method for quantifying miRNA was 
available. Therefore, for the studies performed, the DNA concentration obtained from 
quantification assays (3. 5.1) were used to calculate a normalised concentration for all 
samples. Recently, companies such as ThermoFisher scientific have developed 
quantification assays for miRNA (Qubit® microRNA Assay Kit released February 2015 [207]. 
This technique provides an overall quantification of all miRNA present within a sample 
however it not specific to a set marker, the technique also requires additional equipment, 
training, reagents and analysis. The aim of this research is to develop a viable BFID 
technique that can be implemented into current laboratory protocol. The addition of this 
technique would cause an increase to the cost and duration of analysis as well as increasing 
the required man power, training and equipment. All these factors, including the lack of 
specific marker quantification would decrease the likelihood of implementation into 
forensic laboratories and therefore normalisation through DNA concentration was 
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performed throughout the remaining studies. All DNA samples underwent qPCR 
quantification while RNA samples were quantified using a spectrophotometer at 
wavelength 260nm.  
4.5.1. DNA quantification utilising absolute qPCR 
Calculating qPCR results from samples can be achieved by absolute or relative 
quantification. Absolute quantification provides the exact copy number following 
conversion of the data via a standard curve of known DNA copy number. Relative 
quantification does not provide the total starting quantity of unknown template, instead 
the expression is represented relative to another gene or internal control.  
DNA samples were quantified using Quantifiler® Human DNA Quantification Kit on Applied 
Biosystems 7500 Fast Real-Time PCR machine. The Quantifiler® Human DNA Quantification 
Kit quantifies the total volume of amplifiable human DNA that is present in a sample using 
two 5′ nuclease assays, an internal control (IPC) and a human target specific assay. The target 
specific assay contains two primers that are specific to human DNA and a FAM™ labelled 
TaqMan® MGB probe. IPC contains template DNA, the sequence of which is not found in 
nature, two primers specific to this synthetic sequence and VIC® labelled TaqMan® MGB 
probe. Probes contain a non-fluorescent quencher (NFQ) at the 3′ end which supress 
fluorescence. Throughout qPCR, the TaqMan® MGB probe anneals specifically to a 
complementary sequence in the middle of the forward and reverse primer sites. If no 
amplification occurs the probe will stay whole keeping the reporter and quencher dyes in 
close proximity causing suppression of reporter fluorescence. Cycles are used to 
exponentially amplify any DNA present, once a threshold of total DNA has been reached 
the fluorescence caused by the disassociation of the quencher from the reporter will be 
detected by the instrument and alongside a standard curve, concentration is calculated 
[208].  
Serial dilutions using Quantifiler® Human DNA standard and water were made to 
encompass the range of samples being quantified to create a standard curve. The supplied 
control DNA was at a concentration of 200n g/μl. To ensure the samples that contained 
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large volumes of DNA were accurately quantified 1.5X serial dilution from 133.33ng/μl were 
made for quantifying vaginal material and menstrual blood samples, as seen in table 4.1. 
For saliva, semen, skin and venous blood samples, the 5X serial dilutions stated in the 
supplier’s protocol were made. The required volume of control DNA and water were 
transferred into a 0.2ml tube, tubes were vortexed thoroughly and pulse centrifuged, the 
required volume of the previous standard was then transferred into the next.  
 
 
Table 4.1: Dilution series for creation of standards for quantifying vaginal material. 
Each 12.5μL reaction contained of 5.25μL of Quantifiler® PCR Reaction Mix, 6.25μL of 
Quantifiler® Human Primer Mix and 1μL of either sample, standard or water.  Each 0.2ml PCR 
contained enough MM and sample, standard or water to create three technical replicates. 
Each tube was vortexed, pulse centrifuged and 12.5μL was then aliquoted into 3 designated 
wells of a 96 well plate. All samples, standards and negatives were run in triplicate. The 96 
well plate was then sealed with optical lids, pulse centrifuged and placed within the 7500 
FAST real time PCR instrument. Absolute quantification (FAST – Quantitation standard curve 
with expert mode) was selected with enzyme activation occurring at 95oC for 2 mins 
followed by 40 cycles of (denaturing at 95 oC for 2 seconds and annealing and extension at 
60 oC for 20 seconds).  
Standard Concentration 
(ng/μl) 
Volume 
(ml) 
Dilution 
factor 
1 133.333 10μL 200 ng/μL stock 15μL of water 1.5X 
2 88.888 10μL Std 1 15 μL of water 1.5X 
3 59.25925 10μL Std 2 15 μL of water 1.5X 
4 39.506 10μL Std 3 15 μL of water 1.5X 
5 17.55 10μL Std 4 15 μL of water 1.5X 
6 11.705 10μL Std 5 15 μL of water 1.5X 
7 7.803 10μL Std 6 15 μL of water 1.5X 
8 5.202 10μL Std 7 15 μL of water 1.5X 
9 3.46 10μL Std 8 15 μL of water 1.5X 
10 2.3122 10μL Std 9 15 μL of water 1.5X 
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4.5.1.1. Advantages to qPCR 
The main advantage of qPCR is the ability to observe amplification of target fragments in 
real time, target amplification is measured during the exponential phases as opposed to 
regular PCR where amplification can only be measured in the plateau phase. The benefit to 
this is that the exponential phase provides a true starting quantity of genetic material 
whereas the plateau phase is not always a specific. qPCR offers advanced specificity and 
sensitivity due to presence of TaqMan® probes which ensures that any recorded fluorescent 
signal is a result of amplification from a specific target sequence. The ability to design 
probes and primers with various dyes alongside the qPCR instruments multiple dye 
channels allows for multiple TaqMan® probes and primer combinations to be utilised to 
distinguish between closely related sequences or for different fluorophores attachment to 
probes which enables the development of multiplex qPCR protocols resulting in several 
required targets being co-amplified. Overall the use of hydrolysis probe qPCR is highly 
sensitive and specific in a protocol where assay design and run methods are relatively 
simple, reducing the requirement for extensive training of operators [209, 210] 
4.5.1.2. Disadvantages to qPCR 
The advancements within qPCR development have made it one of the most popular 
quantification techniques with the only disadvantage being the requirement that different 
probes must be designed and synthesised for multiplex analysis thus increases cost of 
analysis. When comparing to other techniques such as UV/VIS spectrophotometry, 
although superior in specificity it is a much more time consuming and costly method of 
quantification. 
4.5.2. RNA quantification using a UV-visible 
spectrophotometer 
RNA quantification was performed on the Thermo Scientific Nanodrop 2000 
spectrophotometer instrument. Spectrophotometry determines the ability of a chemical 
substance to absorb light; every chemical compound and molecule absorbs, reflects or 
transmits light particles when measured over a certain wavelength - spectrophotometry 
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records the samples absorbance.  UV-visible spectrophotometers measure absorbance 
of the RNA samples over the ultraviolet range of 184-400 nm and the visible range of 400-
700nm of electromagnetic radiation spectrum. This absorbance is then converted into a 
concentration value [211].  
After calibration and measurement with a blank, 1μl of sample was placed onto the pedestal 
and measured at 260nm (A260), purity values were checked and concentration values 
recorded. Concentration values were obtained in triplicate for each sample, with only a 
variation of 0.5ng/μl allowed between values.  
4.5.2.1. Advantages to UV-VIS spectrophotometry 
The advantage of UV-VIS spectrophotometry is that there is minimal sample wastage, 
concentration values are obtained quickly with minimal training required, it is cost effective 
due to lack of additional reagent requirement and analysis includes evaluation of the 
relative purity of samples [212].  Another benefit is that there is no direct manipulation of 
the samples being analysed therefore the integrity is not compromised.    
4.5.2.2. Disadvantages UV VIS spectrophotometry 
The disadvantages with this technique is that accuracy can be effected by a number of 
contaminants; if total RNA extraction eluted DNA, proteins, chaotrophic salts or other 
complexes such as carbohydrates it will cause an incorrect value will be determine. UV VIS 
spectrophotometry cannot distinguish between the target of interest and contaminants 
that absorb light at an equal wavelength, since all nucleic acids display peaks at 
approximately 260nm all DNA or RNA molecules will contribute to the accumulated total 
absorbance at 260nm. Accuracy can also be effected by impurities within the samples 
reflecting light, since all light reaching the detectors is recorded this reflection off impurities 
would cause inaccuracy in concentration calculation.  
Accurate light absorption is also controlled by the environment within the samples, 
absorbance is heavily influences by pH and temperature, which if combined with impurities 
will alter the absorption properties resulted in an incorrect concentration value for that 
sample. UV VIS spectrophotometry also displays inaccurate results at low concentration 
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samples, due to the high concentration with vaginal material this was not deemed a highly 
contributing factor to quantification [212]. 
 Determination of Semen through Haematoxylin & 
Eosin Staining 
When analysing semen samples the presence of spermatozoa must be confirmed, this is to 
ensure that any expression seen can be identified as coming from a ‘standard’ sample. A 
normal sample can be defined as having more than 20 million spermatozoa per millilitre of 
semen [213], this cannot be confirmed using a standard microscope however the 
identification of a large presence of semen is sufficient for this study. In the case of 
vasectomised samples the absence of spermatozoa must be confirmed; if spermatozoa are 
found then the miRNA expression will not distinguishable from the other semen samples 
collected.  
The presence or absence of spermatozoa can be confirmed using the Haematoxylin and 
Eosin (H&E). It is a widely used staining technique and utilises two dyes. Haematoxylin is 
referred to as a basic dye (when mixed with a mordant such as an aluminium salt that help 
it bind) that stains basophilic or acidic structures, such as the nucleus a purplish-blue colour. 
The mordant binds to any basophilic structure which is followed by the binding of the 
haematoxylin to the mordant. Eosin is a negatively charged, acidic dye which stains 
acidophilic or basic structures, such as most of the proteins in the cytoplasm, with a reddish 
pink colour. The combination of these two dyes provides a stain that highlights the nucleus 
and the areas of the cytoplasm where RNA is present in purple with the remainder of the 
cytoplasm being pink [214, 215]. In the case of staining semen, the basophilic heads of the 
spermatozoa will stain a purplish blue and thus make them detectable under a high 
powered microscope as seen in Figure 4.3. 
Semen samples (1μl) were placed on labelled glass slides. Each slide was then placed in 
haematoxylin dye for 15 seconds before being gently rinsed around the stain with tap 
water. The slide was then placed into the eosin stain for two minutes followed by a gentle 
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rinse around the stain. A cover slip was then placed over the stain and viewed under a 
microscope using 100x total magnification.  
 
Figure 4.3 A micrograph of a typical semen stain using H&E (1) [215] and a micrograph displaying the complete absence 
of spermatozoa in the vasectomised sample provided by volunteer 63 following H&E staining (2). 
 Stem-loop Reverse Transcription alongside qPCR for 
miRNA Analysis 
When analysing individual miRNA an extremely sensitive and reproducible method is 
needed. MicroRNAs range from 18 to 22nt in length with standard and quantitative PCR 
methods requiring a template that is a minimum of two times the length of either of the 
specific forward or reverse primers, each typically 20nt in length. Thus, the target minimum 
length is ≥40nt, meaning miRNAs are too short for standard RT-qPCR methods [216]. The 
solution to this problem is stem-loop reverse transcription followed by qPCR (RT-qPCR).  
RT-qPCR involves several components that are optimised for miRNA specificity and 
sensitivity. The RT-primer contains a highly stable stem-loop structure that lengthens the 
target miRNA to form complementary DNA (cDNA). The forward PCR primer adds additional 
length with nucleotides that optimize its melting temperature and enhance assay 
specificity. The reverse primer disrupts the probe to produce fluorescence. As previous 
described, specificity can be improved by placement of the probe over much of the original 
miRNA sequence. The disadvantage to this strategy is that multiple high cost probes would 
be required to analyse multiple miRNA targets. The solution is to incorporate a universal 
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probe sequence into the synthesised stem- loop RT primer which allows for a probe to be 
designed that can analyse any target marker. The T(m) of the probe is optimised by addition 
of a minor groove binding (MGB) complex [216].  
4.7.1. Hydrolysis probe and Oligonucleotide RT and PCR 
primer synthesis 
The oligonucleotides utilised within this research were commercially manufactured by 
Eurofins Genomics to the specifications of HPSF purification, 0.01μmol synthesis scale and 
lyophilised delivery.  Primers were initially centrifuged for 3 minutes at 14,000rpm and stock 
solutions of 100μM prepared via the addition of MBG water as per the synthesis report. RT 
primers were designed to incorporate a universal hydrolysis probe sequence into the stem, 
a universal reverse primer sequence (GTG CAG GGT CCG AGG T) into the loop and a 
complimentary target miRNA sequence overhang as observed in Figure 4.4. The universal 
probe was synthesised by ThermoFisher Scientific to the specification of HPLC purification 
and TCG CAC TGG ATA CG sequence. 
All stock RT primers were then made into a 1:100 dilution followed by a further dilution in 
MBG water to obtain a working stock of 12.5nM. Hydrolysis probe, universal reserve primer 
and all stock forward primers were then made into a working stock of 40μM. All stock and 
working stock were accurately labelled and stored at -20ºC. Primer sequences utilised 
within this study can be found in Table 4.2 within chapter 4.9.1.1 with a full list of all 
screened primers being available in Appendix C. 
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Figure 4.4: Sequences incorporated into the custom-built stem-loop primer. 
4.7.1.1. miRNA selection for validation through screening via RT-qPCR 
41 markers were selected from current literature: some already validated, some that had 
shown promising expression values but were not further replicated and some that 
surrounding research suggested may be a pre-cursor to identifying diseases linked to that 
body fluid. All 41 markers were custom designed and synthesised with TaqMan® assays 
ordered for 4 of those markers. Validation of custom assays was implemented and 5 of these 
markers and endogenous controls failed due to amplification in testing of negative samples. 
Markers were redesigned and failed again and were therefore removed from the study.  
 
 
 
 
 
 
 
Universal Hydrolysis 
Probe Sequence 
Universal Reverse 
Primer Sequence 
Complimentary target 
miRNA sequence 
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Target Name Primer Sequence (5’-3’) 
Size 
bp 
Ref 
vaginal 
material 
hsa-mir-124 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACG GCA TT 
50 
[17]
[184, 
185, 
198] 
 hsa-mir-124 PCR TAA GGC ACG CGG TG 14 
 hsa-mir-1260b RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA TGG TG 
50 [181, 
183] 
 hsa-mir-1260b PCR ATC CCA CCA CTG CCA C 15
 hsa-mir-654-5p RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACG CAC AT 
50 [181, 
183] 
 hsa-mir-654-5p PCR TGG TGG GCC GCA GAA C 21
 hsa-mir-372-3p RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA CGC TC 
50 [184, 
183] 
 hsa-mir-372-3p PCR AAA GTG CTG CGA C 13
 hsa-mir-617 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACG CCA CC 
50 
[185] 
 hsa-mir-617 PCR AGA CTT CCC ATT TGA A 16
Saliva hsa-mir-205 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC AGA CT 
50 [183, 
184, 
186, 
189]  hsa-mir-205 PCR TCC TTC ATT CCA CC 14 
 hsa-mir-124* RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA TCA AG 
50 
[187] 
 hsa-mir-124* PCR CGT GTT CAC AGC GGA C 16
 hsa-mir-138-2 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA ACC CT 
50 
[186] 
 hsa-mir-138-2 PCR GCT ATT TCA CGA CAC 15
 hsa-mir-223 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT GGG GT 
50 [181] 
  hsa-mir-223 PCR TGT CAG TTT GTC AAA 15
Menstrual 
blood 
hsa-mir-144-3p RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA GTA CA 
50 
[183, 
185, 
198, 
199]  hsa-mir-144-3p PCR TAC AGT ATA GAT GAT G 16 
 hsa-mir-144-5p RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC TTA CA 
50 [181, 
183, 
185, 
199]  hsa-mir-144-5p PCR GGA TAT CAT CAT ATA C 16 
 hsa-mir-412-3p RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA CGG CT 
50 [184] 
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 hsa-mir-412-3p PCR ACT TCA CCT GGT CCA C 16
 hsa-mir-142-3p RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT CCA TA 
50 
[181] 
 hsa-mir-142-3p PCR TGT AGT GTT TCC TAC 15
 
hsa-mir-199a-
5p 
RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACG AAC AG 
50 
[190]  
 hsa-mir-199-5p PCR CCC AGT GTT CAG ACT AC 17
 hsa-mir-214-3p RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA CTG CC 
50 
[183] 
 hsa-mir-214-3p PCR ACA GCA GGC ACA GAC 15 
Venous 
blood 
hsa-mir-451 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA ACT CA 
50 [124, 
183-
180]  hsa-mir-451 PCR AAA CCG TTA CCA TTA C 16 
 hsa-mir-16 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC GCC AA 
50 [181, 
183-
185]  hsa-mir-16 PCR TAG CAG CAC GTA AAT 15 
Semen hsa-mir-888-5p RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT GAC TG 
50 [186, 
188] 
 hsa-mir- 888-5p PCR TAC TCA AAA AGC TGT C 16
 hsa-mir-10a-5p RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC ACA AA 
50 [183, 
180] 
 hsa-mir- 10a-5p PCR TAC CCT GTA GAT CCG 15
 hsa-mir- 10b-3p RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA TTC CC 
50 [184, 
185, 
190]  hsa-mir- 10b-3p PCR CGC GCG ACA GAT TCG ATT CTA GGG G 25
 hsa-mir- 10b-5p RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC ACA AA 
50 
[183] 
 hsa-mir- 10b-5p PCR CGC GCG TAC CCT GTA GAA CCG A 25
 
hsa-mir-135a -
5p 
RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT CAC AT 
50 
[183-
185] 
 
hsa-mir- 135a-
5p 
PCR TAT GGC TTT TTA TTC 15 
 hsa-mir-135b RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT CAC AT 
50 
[185] 
 hsa-mir- 135b PCR TAT GGC TTT TCA TTC 15
 hsa-mir-508 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC ATG AG 
50 
[187] 
 hsa-mir-508 PCR GCC TGT ACT CCA GAG GGC GT 20
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 hsa-mir-507 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT TCA CT 
50 
[185] 
 hsa-mir-507 PCR GCG GCG GTT TTG CAC CTT TTG G 22
 hsa-mir-891a RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT CAG TG 
50 
[183] 
 hsa-mir-891a PCR TGC AAC GAA CCT GAG 15
 hsa-mir-2392 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC ACC TC 
50 [181] 
  hsa-mir-2392 PCR TAG GAT GGG GGT GAG 18
 hsa-mir-3197 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC GCC TT 
50 [181] 
  hsa-mir-3197 PCR GGA GGC GCA GGC TCG 15
Skin hsa-mir-203a RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC TAG TG 
50 
[183] 
 hsa-mir-203a PCR TGA AAT GTT TAG GAC 15
 hsa-mir-455-3p RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACG TGT AT 
50 
[199] 
 hsa-mir-455-3p PCR CGC GCA CTT CAC CTG GTC CAC 21
 hsa-mir-3169 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC TAT GT 
50 
[179] 
 hsa-mir-3169 PCR TAG GAC TGT GCT TGG 15
endogenous 
control 
SNORD-38b RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT CTC CT 
50 [183, 
196, 
197]  SNORD-38b PCR TGA CAG TAA GTG AAG ATA AAG TGT GTC 27
 SNORD-44 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA GTC AG 
50 [186, 
196, 
197]  SNORD-44 PCR ACT GAA CAT GAA GGT CTT AAT TAG CTC 27
 hsa-mir--93 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC TAC CT 
50 
[197] 
 hsa- miR-93 PCR GCT CGC AAA GTG CTG TTC GT 20
 SNORD- 47 RT GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA CCT CA 
50 
[196] 
 SNORD- 47 PCR GAT ATC ACT GTA AAA CCG TTC CAT TTT G 30
 
Table 4.2: Primer sequences utilised within screening study, categorised by literature proposed body fluid and 
corresponding publication. 
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 Stem-loop Reverse Transcription 
The result of stem-loop reverse transcription is the synthesis of cDNA that is used as a 
template for qPCR. This is performed by the RT enzyme MMLV, a monomeric protein 
obtained from the Moloney Murine Leukaemia virus. MMLV degrades RNA into a RNA-DNA 
hybrid because of its RNase H activity []. The miRNAs are reversed transcribed individually 
by using specific stem loop primers as seen in Figure 4.5 and are designed so that they are 
complementary to a short single-stranded region at the 3’ of the target miRNA.  They also 
contain a double stranded region known as the stem and a loop (optimally 4-8 bases long) 
which contains the universal primer and hydrolysis probe binding sequences. Once the 
stem-loop RT primers is hybridised to the miRNA molecule at the 3' region reverse 
transcription of the miRNA is initiated [218] 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Process of stem-loop reverse transcription. The single stranded overhang binds to the complimentary 3’ 
sequence of the target miRNA. MMLV then proceeds to bind circulating complimentary nucleotides to create cDNA. 
TaqMan® MiRNA Reverse Transcription kit (Applied Biosystems) was used on each sample 
[219]. Each 7.5μl RT reaction contained 2.5μl of sample, 1.5μl of 12.5nM RT primer, 0.095μl 
of RNase Inhibitor 20U/μl, 0.75μl 10X RT Buffer, 0.075μl 10mM dNTPs, 2.08μl of nuclease-
free water and 0.5μl of MultiScribe™ Reverse Transcriptase 50U/μl (MMLV). RT negatives 
 5’                                                     3’Target miRNA 
MMLV 
Free nucleotide 
bases 
Stem-loop RT primer
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included a RT+ and a RT-. RT+ contained samples and no MultiScribe™ while RT – contained 
reverse transcriptase and no sample, this eliminates false positives as a result of genomic 
contamination. A MM was made per body fluid sample and aliquoted into 0.2ml tubes, the 
appropriate RT primer was then added. Reactions were then incubated in a 96 well Applied 
Biosystems Veriti® Thermal Cycler for 30 minutes at 16oC, 30 minutes at 42 oC followed by 
five minutes at 85 oC. This was then held at 4 oC until collected and carried through to qPCR.  
 miRNA Expression through Relative qPCR 
The second stage of analysis involves RT products undergoing relative qPCR, this is the 
constant collection of fluorescent signals from a polymerase chain reaction over a certain 
range of cycles. The detected fluorescence is then converted from each reaction into a 
numerical value per sample. The RT products are amplified and monitored in real time using 
a miRNA-specific forward primer and the universal reverse primer, resulting in every target 
molecule being copied once per cycle [217]. When using qPCR, the reactions are defined by 
the moment in time throughout cycling that amplification of a target is initially detected, 
not the total amount accumulated overall the cycles. The greater the starting copy number 
of nucleic acid target the quicker a substantial escalation in fluorescence can be observed 
[220]. As opposed to the absolute quantification requiring a standard curve, relative 
quantification is performed by analysing expression of a target against the expression of a 
housekeeping gene known as an endogenous control. The endogenous control is present 
within all samples therefore comparisons can be made within analysis of samples. 
A universal RNA-based hydrolysis probe contains a fluorescent reporter dye at the 5’ end 
and a quencher of fluorescence dye at the opposite 3’ end of the probe, as seen in Figure 
4.6. The close proximity of the quencher to the reporter prevents detection of its 
fluorescence. The hydrolysis probe can only anneal if the target sequence exists, it anneals 
further down from one of the primer sites and Taq DNA polymerase cleaves the hydrolysis 
probe through its 5’ to 3' exonuclease activity when it is extending from the primer site. 
Degradation of the probe caused by the Taq polymerase removes the silence of 
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fluorescence caused by the reporter-quencher proximity and thus allows unquenched 
emission of fluorescence.  
This is detected and provides fluoresce data that is converted into a numerical value. The 
breakdown of the probe also enables the primer extension to continue to the template 
strands end-point completing the PCR cycle. Therefore, the addition of the hydrolysis probe 
does not hinder the overall PCR process in any way. An increase in the product targeted by 
the hydrolysis probe at each PCR cycle therefore causes a proportional escalation in 
fluorescence intensity due to the degradation of the probe and thus discharge of the 
reporter [220, 221].     
 
Figure 4.6: Processes involved within each cycle of qPCR: the cDNA is denatured and unravels; the custom forward primer 
then binds with the custom target sequence. Extension (direction indicated by arrows) by Taq polymerase creates a 
complimentary double strand which is subsequently denatured. The hydrolysis probe and universal reverse primer bind 
to the custom designed sequences within the loop of the RT primer. Extension of the reverse primer by Taq polymerase 
cleaves the hydrolysis probe causing the reporter to move away from the quencher and fluoresce. PCR product is 
determined by the 5′ termini of the forward and reverse primers. 
Forward primer binds to specific custom target sequence. Anneals and extends 
MGB FQ 
Q Quench
F Fluorescent Reporter 
F Q 
Cleavage of the hydrolysis probe due to extension of reverse primer. 
Reporter is released and detected by instrument. 
Probe and reverse primer bind to custom sequence built into the loop of the 
RT primer. Anneals and extends 
RT product: specific custom target sequence (orange) RT primer (purple) cDNA created through RT (blue) 
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qPCR was performed using an Applied Biosystems 7500 Fast Real-Time PCR System. 10X 
concentration assays were constructed for custom made assays and 20X concentration 
assays were used for validated primers. Working stock solutions (40μM) were made from 
the universal probe, forward primer and universal reverse primer. This was achieved by 
diluting the primers as directed from Eurofins genomics to make a 100μM solution. 40μl of 
this was this added to 60μl of nuclease free water to create the working stock. From the 
working stock 10x assays were prepared containing 3.75μl forward primer, 1.75μl reverse 
primer, 4.24μl nuclease-free water and 0.62μl probe per triplicate sample.   
Each qPCR reaction contained 5.5μl of 2x Luminaris MasterMix (Primerdesign: Precision 
FAST MasterMix with ROX at a lower level), 3.66μl of nuclease-free water, 1.1μl of 10X assay 
and 0.73μl of RT product. For the validated assays this was altered to 0.55μl of 20X assay and 
3.85μl of nuclease free water. Each reaction was made up in triplicate in a 0.2μl tube this was 
vortexed and centrifuged. 10μl was then pipetted into a predetermined well on a 96 well 
plate with the remaining reactions in consecutive wells. The 7500 Software v2.0.6 was set 
up in expert mode under ‘quantitation, comparative Ct ΔΔCt’ FAST conditions for each 96 
well plate. The reactions were incubated in a 96 well plate at 95oC for 2 minutes followed by 
50 cycles of 95oC for 2 seconds and 60 oC for 20 seconds.  
4.9.1. Negative controls 
All protocols were routinely performed with negative controls. MGB water was substituted 
for sample in all extraction, RT+ and qPCR negative controls, while MGB water was 
substituted for MMLV in RT- samples. Negative controls are essential for monitoring 
possible contamination and are required during each stage of analysis.  All negative controls 
showed no amplification during qPCR indicating no genomic or outside contamination.  
 Analysis 
Analysis of qPCR data is performed utilising ΔCq (Cq target–Cq of endogenous control). ΔCq 
is the normalisation of the target to a housekeeping control. Due to lack of suitable 
endogenous controls Δ1Cq values will be utilised (Max cycles (50)-Cq target). Once suitable 
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endogenous controls were identified ΔCq was calculated on all trace samples and displayed 
via heat map. 
Varying opinions occur in literature surrounding cycle threshold, generally a Cq value is 
determined upon a positive expression result however false positives can occur and 
therefore an arbitrary cut off is determined by laboratory operators. It is suggested that high 
Cq values can be produced through probe base fluorophore degradation or as seen in most 
PCR reactions, non-specific amplification of background nucleic acids [222]. Caraguel et al. 
assessed a selection of cut off values for qPCR and determined that although the application 
of Cq cut off values might be practical, its justification and assignment should be 
constructed on evidence. They assessed research with cut off values of 31, 42 and 45, all of 
which provided justifiable evidence for cut off selection [223]. Monleau et al. analysed 
miRNA expression in PBMCs (peripheral blood mononuclear cells) and human serum, due 
to lower quantity of starting material human serum had no cycle cut off, this differed  in 
PBMCs, where Cq values had a threshold of <32 [224].   
To ensure all possible positive results are taken into consideration and determine all cross 
reactivity within body fluids, max cycles will be set at 50. Due to probe based techniques 
being used and the high levels of specificity required for use in a court of law the threshold 
for inclusion into body fluid analysis will be 40 cycles (Lower than Δ1 Cq of 10). To display 
expression across all body fluids Cqs above 40 cycles will be presented in all results chapters 
but will not be taken forward as displaying miRNA expression. From current literature and 
self-determined requirements, the thresholds observed in table 4.3 were chosen to 
categorise strength of expression within this research. 
Cq Value Reaction Δ1Cq value
<3 strong reliable positive reactions indicative of abundant target within sample >21 
30-37 Positive reactions indicative of moderate levels of target within sample (Expected level from hydrolysis probe qPCR) 13< >20 
38-39.9 Poor reactions indicative of minimal levels of target within samples 10.1<>12 
40 - 50 Weak unreliable reaction <10 
 
Table 4.3: Categories for levels of expression observed throughout analysis by all qPCR experiments 
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4.10.1. Normalisation 
Normalisation is an important factor in the design of any experiment, two commonplace 
methods are the use of endogenous controls and the standardisation of concentration to 
the same value over all samples. As previously discussed normalisation was performed 
using DNA concentration and not miRNA concentration, the aim being that the ratio of 
miRNA to DNA is constant over samples and therefore will provide suitable normalisation. 
Due to the lack of universally accepted endogenous controls the second method of 
normalisation is also difficult to perform within this study. A range of SNORD and miRNA 
were selected from literature and analysed to find the most robust and efficient 
endogenous control. All samples were normalised to the same concentration as determined 
within study medication (4.13) and once identified, endogenous controls were used to 
further normalise samples.  
 Data Representation and Statistical Analysis 
Throughout this research Δ1Cq values will be displayed in box and whisker plots constructed 
in R version 3.3.2 using ggplots2 package and bar and line graphs constructed in Excel 2013.  
ΔCq values are displayed in heat maps created in R version 3.3.2. Heat map and box and 
whisker codes can be seen in appendix D-E. Each sample was analysed in triplicate, with 
standard error of mean (SEM) and average of all triplicates for that body fluid being shown 
on all bar and line graphs.  
When analysing statistical significant of expression across the different body fluids and 
across vaginal samples within a volunteer, such as within chapter 5 and 6.  A one way 
ANOVA with post hoc Tukey test (P threshold ranged from 0.01 to 0.001) was utilised. This 
determined any significant differences between the means of the six body fluids and the 
vaginal samples. When comparing volunteers of the same body fluid and therefore 
correlated, (DNA against RNA extraction, DTT against no DTT), such as within chapter 6 and 
7 a paired sample t-test was utilised to compare the two population means. (P threshold 
ranged from 0.01 to 0.001). 
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 MIQE Guideline Compliance  
The Minimum Information for Publication of Quantitative Real-Time PCR Experiments 
(MIQE) guidelines provide a reference check list that all data submitted for publications 
must comply with. All standards and requirements stated within the MIQE guidelines were 
observed in all experiments and analysis to ensure reliable and definitive qPCR were 
obtained [225]. 
 Experimental Modification to Standard Protocols 
4.13.1. Identification of miRNA markers  
Samples were extracted following Qiagen total DNA protocol (4.4.1) and quantified using 
qPCR (4.5.1). Sample were manipulated in 3 ways; for undiluted testing eluate was directly 
taken as template for stem-loop RT. For analysis of the LOD, vaginal material samples were 
normalised to 5ng/μl and diluted through a 1 in 10 serial dilution while low template DNA 
samples were all normalised to 0.7ng/μl. All samples then underwent stem-loop reverse 
transcription (4.8) qPCR (4.9.1) and analysis (4.11) 
4.13.2. Characterisation of markers over a 31-day period  
Daily samples were extracted through Total DNA (4.4.1) or total RNA protocol (4.4.2). 
Quantification of samples from DNA extraction was performed using absolute qPCR (4.5.1), 
while quantification of RNA samples was performed on the Nanodrop 2000 instrument 
(4.5.2). Samples were then diluted to 5ng/μl and underwent stem-loop RT followed by 
relative qPCR (4.8 and 4.9.1). Data is displayed via bar graphs for Δ1Cq +SEM and heat maps 
for ΔCq (4.11).  
4.13.3. Detection of semen markers within vaginal material 
following unprotected sexual intercourse 
Swab 1 from all sampling sets underwent total DNA protocol (4.4.1) with swab 2 from all 
sampling sets undergoing standard differential extraction (4.4.3). All samples were then 
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quantified using qPCR (4.5.1), diluted to 2ng/μl and underwent stem-loop RT followed by 
relative qPCR (4.8 and 4.9.1).  
For DTT analysis two semen stains were obtained from the same sample, swab 1 followed 
total DNA protocol (4.4.1) with swab 2 followed the same protocol but with the addition of 
20μl of 1M DTT during the lysis step prior to incubation. Vaginal material, venous blood and 
both semen samples were quantified as per (4.5.1) and normalised to 1ng/μl. Various mixing 
ratios were made, observed in table 4.4, one set with semen extracted with addition of DTT, 
the other with the semen samples that underwent standard total DNA extraction. All 
mixtures then underwent stem-loop RT followed by relative qPCR (4.8 and 4.9.1). Data was 
analysed via box and whisker plots (4.11). 
Body fluids 
Semen extracted 
without DTT 
Semen extraction 
with DTT 
vaginal material: semen 1:1 1:1 
vaginal material: semen 2:1 2:1 
vaginal material: semen 5:1 5:1 
vaginal material: semen 1:2 1:2 
vaginal material: semen 1:5 1:5 
vaginal material: semen: venous blood 1:1:1 1:1:1 
vaginal material: semen: venous blood 2:1:1 2:1:1 
vaginal material: semen: venous blood 5:1:1 5:1:1 
 
Table 4.4: Various mixing ratios of body fluids containing semen samples treated and untreated with DTT.  
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 Rationale 
Currently, a number of miRNA biomarkers have been identified as being body fluid specific 
(See section 2.6.1). The aim of the first component of this chapter was to validate the RT-
qPCR method proposed in this research. TaqMan® assays were selected as these are 
commercially available markers that would eliminate the possibility of reactions failing due 
to primer specificity issues. In addition, a number of custom primers were also selected to 
validate body fluid specificity. To ensure expression, an undiluted extracted sample was 
used as the template for RT-qPCR.  
In forensic casework, the amount of sample provided is likely to be low, and therefore it is 
important to identify the minimum template that can be used within these techniques. In a 
similar fashion, DNA profiling is a vital tool for forensic scientists and any techniques that 
could provide information on body fluid origin must not compromise the integrity of the 
original sample or the DNA profiling process. As such, it would be beneficial for the template 
used here to dovetail with other established BFID techniques. The UK Government forensics 
provider, LGC Forensics utilise Promega’s PowerPlex® ESI 17 Pro System for STR profiling. 
This protocol states that 0.5ng of template DNA is recommended for obtaining a full profile 
[226]. Cellmark Forensic Services follow AmpFlSTR® NGM SElect™ PCR protocol which 
suggests a higher template of 1ng of DNA is recommended to obtain a full profile [227].  
Once a LOD has been determined for these markers, the specificity of these markers at the 
lower limits of starting template concentration can be investigated. The third section of this 
chapter concludes these initial investigations by defining the specificity of the complete 
library of body fluid specific markers, acting to validate the specificity of each marker or 
suitability of markers as endogenous controls as identified within the literature.  
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 Sample Collection 
Thirty women, ranging in age from 18 to 65 provided LVS. LVS were selected due to these 
being the easiest swabs for self-collection. HVS using require a speculum for correct 
sampling and it was unlikely that all participants would be comfortable with obtaining HVS 
samples but also that LVS would likely contain the least sample to sample variation.  
Individuals were selected to ensure different factors were included in the sample group. 
Females varied in age, smoking habits, previous pregnancies, contraception, cervical 
cancers, ethnicity, sterilisation, medication and varying levels of sexual activity, a list of 
notable factors can be found in appendix F. Eight of these females along with ten other 
volunteers provided menstrual blood samples on the day they believed was the middle of 
menstruation. One volunteer provided two menstrual blood samples; the first while on no 
form of contraction, the second, one month later, while on the contraceptive pill. Volunteers 
also provided blood (10), saliva (10) and skin (5). Twenty volunteers provided semen 
samples and six volunteers provided semen samples with known absence of spermatozoa. 
All volunteers and their body fluid samples can be seen in Figure 5.1.  
Figure 5.1: Venn diagram displaying the number of volunteers who provided multiple body fluid samples 
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 Results  
5.3.1.  Expression comparison of TaqMan® and custom 
assays in undiluted sample 
5.3.1.1. Quantification 
The mean concentration (ng/μl) of DNA obtained from each sample type can be seen in 
table 5.1. The highest concentration observed in vaginal material and menstrual blood were 
85.95 and 95.31ng/μl respectively with lowest concentrations of 18.89 and 20.10ng/μl. 
While venous blood and semen observed highest concentration at 4.27 and 9.28ng/μl 
respectively and lowest concentrations of 0.74 and 0.87ng/μl. The concentration for all 
seminal fluid and skin sample were below 0.006 and therefore in all applications in this 
research were used undiluted.  
Body Fluid Mean concentration (ng/μl) SEM 
Saliva 8.97 2.63 
venous blood  2.43 0.39 
menstrual blood 49.37 2.81 
Vaginal material 41.64 2.66 
Semen 4.12 0.53 
Seminal Fluid 0.006 0.02 
Skin 0.0002 0.01 
 
Table 5.1: The average DNA concentrations (ng/μl) for all tested body fluids observed via qPCR.  
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5.3.1.2.  R-qPCR 
Markers hsa-mir-199a, 412, 135b and 507 (TaqMan® assays) were analysed on all body fluid 
types and the Δ1Cq values can be seen in Figure 5.2. In the case of hsa-mir-199a, no 
significant difference was seen in expression across all body fluids. A similar pattern was 
observed when marker hsa-mir-507 was screened, with the exception of slightly higher 
expression within vaginal material and menstrual blood. Where markers hsa-mir-412 was 
screened, high expression was observed in vaginal material, menstrual blood and saliva, 
with weak expression (<10) in the other body fluids samples. Marker hsa-mir-135b was 
moderately expressed in all body fluids screened, except for venous blood and skin (<10). 
 
 
Figure 5.2:  Expression of Applied Biosystems TaqMan® assays, measured using Δ1Cq (Cq max – Cq target) in all body fluids. 
Δ1Cq and SEM was calculated and plotted for menstrual blood markers hsa-mir-199a and hsa-mir-412 and semen markers 
hsa-mir-135b and hsa-mir-5. All body fluid samples were analysed, an absence of bar denotes no observable expression/ 
Δ1Cq of 0. Dotted line indicated threshold for inclusion in analysis.   
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Markers hsa-mir-124a, 205 and 451 were analysed on all body fluid types and the Δ1Cq 
values can be seen in Figure 5.3. Markerhsa-mir-124a showed significantly greater (p 
p<0.001) expression (16.3 and 19.3) in vaginal material and menstrual blood over all other 
body fluids. Saliva marker hsa-mir-205 displayed greater expression (16.8) in saliva but was 
found to be significantly greater (p<0.001) in menstrual blood (23.2). Marker hsa-mir-205 
expression was weak in vaginal material (<10) and completely absent in blood, semen, 
seminal fluid and skin. Venous blood marker hsa-mir-451 was significantly expressed in 
both blood types (25.66 and 24.72) with absent or minimal expression in all other body 
fluids (p<0.001).  
 
 
Figure 5.3: Expression of custom markers, measured using Δ1Cq in all body fluids. Δ1Cq and SEM was calculated and plotted 
for vaginal marker hsa-mir-124, saliva marker hsa-mir-205 and blood marker hsa-mir-451. (p<0.001). All body fluid samples 
were analysed, an absence of bar denotes no observable expression/ Δ1Cq of 0. Dotted line indicates threshold for 
inclusion in analysis.  
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Proposed semen markers hsa-mir-10a, 10b and 508 were analysed on all body fluid types 
and the Δ1Cq values can be seen in Figure 5.4. Markers hsa-mir-10a, 10b and 508 did not 
display Δ1Cq values in semen that were statistically different from any other body fluid. 
Markers hsa-mir-10a and 10b showed the highest expression value in menstrual blood (15.4 
and 11.8 respectively) but not venous blood. Marker hsa-mir-10a showed minimal 
expression in all other body fluids except semen and seminal fluid, while hsa-mir-10b 
showed significant expression only in menstrual blood (p<0.001). Marker hsa-mir-508 
showed universal expression >10 in all body fluids.  
 
  
Figure 5.4: Expression of custom markers, measured using Δ1 in all body fluids. Δ1Cq and SEM was calculated and plotted 
for semen markers hsa-mir-10a and hsa-mir-10b and hsa-mir-508. (p<0.001). All body fluid samples were analysed, an 
absence of bar denotes no observable expression/ Δ1Cq of 0. Dotted line indicates threshold for inclusion in analysis. 
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Proposed skin and vaginal material markers hsa-mir-203a, 372, and 617 were analysed on 
all body fluid types with Δ1Cq values observed in Figure 5.5. Vaginal markers hsa-mir-372 
and 617 showed limited or no expression in all body fluids (<6). Expression of skin marker 
hsa-mir-203a was observed in vaginal material (21.8), menstrual blood (24.8) and saliva 
(22.6), but was completely absent in blood, seminal fluid and skin. Minimal expression was 
also observed in semen samples (2.4).  
  
Figure 5.5: Expression of custom markers, measured using Δ1Cq in all body fluids. Δ1Cq and SEM was calculated and plotted 
for skin markers hsa-mir-203a and vaginal material markers hsa-mir-372 and hsa-mir-617. (p<0.001). All body fluid samples 
were analysed, an absence of bar denotes no observable expression/ Δ1Cq of 0. Dotted line indicates threshold for 
inclusion in analysis. 
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5.3.1.3.   Heat map analysis of custom assay expression across individual 
undiluted samples.    
A summary of the expression across this panel of markers can be seen in Figure 5.6. Marker 
hsa-mir-124 displayed high expression in all vaginal material and menstrual blood samples 
except for three vaginal material samples. One of these showed no expression while the 
remaining two displayed variation across triplicates. The complete absence of hsa-mir-124 
expression in remaining body fluids is clear. The expression of hsa-mir-10a within each body 
fluid was sporadic, and absent within saliva and skin. Only one vaginal material sample 
displayed high expression, whilst expression was high in all but one menstrual blood 
sample. Semen and seminal fluid showed great variation across samples, only 50% showed 
high expression and only 1 of the 3 seminal fluid samples expressed hsa-mir-10a.  
Although hsa-mir-10b was expressed in all menstrual blood samples, expression was varied 
and also expressed in two semen samples. Markers hss-mir-372 and 617 were not consistent 
between body fluids and showed large variation within each body fluid. Saliva marker hsa-
mir-205 was present in all saliva samples, again, with varying expression values. Expression 
was very high in all but one menstrual blood sample whist moderate/weak expression was 
only observed in 45% of the vaginal material samples. Marker hsa-mir-451 displayed high 
expression in both venous and menstrual blood but was also weakly detected in one saliva 
and one semen sample. Expression of hsa-mir-203a was consistently high within vaginal 
material, menstrual blood and saliva samples with sporadic expression detected within 5 of 
the 22 semen samples. Marker hsa-mir-508 showed moderate to high expression in all 
samples, with the exception of single venous blood and semen samples, in particular, 
expression was high in skin and seminal fluid. Expression of TaqMan® markers hsa-mir-135b, 
199a, 412 and 507 was universal across all samples; with high expression in both vaginal 
material and menstrual blood samples, with the exception of hsa-mir-412 displaying no 
expression in one sample of saliva. Expression of hsa-mir-412 and 199a was also absent in 
two semen samples.  
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Figure 5.6: Individual Δ1Cq (max Cq- (ΔCq of  target) value of each body fluid sample across proposed BFID markers utilised 
within undiluted screening.  
 - No sample 
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5.3.1.4. Discussion of Undiluted Samples 
The results obtained within this section of the work demonstrate that the extraction and RT-
qPCR methods employed are suitable for the determination of expression of a number of 
markers associated with BFID. Quantification of these samples showed significant 
differences in the volume of genetic material, where the degree of variation observed is 
most likely as a result of both the sampling area and technique. In many cases the use of 
directly extracted DNA resulted in a successful RT-qPCR reaction, thus eliminating the 
requirement for a quantification step within case work where time is a critical factor and 
quantity of sample is high.  
A number of markers showed a degree of specificity to certain body fluid types. In these 
cases, it could be argued that the lack of expression in other body fluids are a result of the 
variation in miRNA concentrations obtained. The TaqMan® assays and custom marker hsa-
mir-508 showed universal expression and could therefore act as positive validation that the 
concentration of sample was sufficient, but more broadly can act as an endogenous control 
for a successful reaction within case work.   
Despite variations in concentration of genetic material, hsa-mir-124a displayed complete 
specificity to vaginal samples however Δ1Cq values were absent or <10 in three of the 
samples. If a sexual assault occurred, on this data set the results would indicate no vaginal 
material present and therefore provide a false negative. Marker hsa-mir-124 therefore has 
the potential for BFID but may need another vaginal material specific marker.  
The specificity of hsa-mir-451 within blood makes it an ideal candidate for BFID, one saliva 
sample did show a high Δ1Cq value, thus giving a saliva sample a positive result for the 
presence of blood. Expression in this sample could be a true positive result; an individual 
having gum disease, ulcers or laceration within their mouth would cause blood 
contamination within the sample. This would thus alter the defence and prosecutions 
perspective of a case.  This may aid in providing additional information about the assailant, 
however it is likely to cause additional analysis to be required to avoid misidentification. 
 
 
 
155 | P a g e  
 
 
 
The varied expression of hsa-mir-205 within vaginal material, menstrual blood and saliva 
would not aid in a case where oral or penile intercourse occurred. All samples contained 
high DNA concentrations and therefore high respective miRNA levels would be expected. 
The results suggest that may be a reason these individuals are not expressing that miRNA 
when the majority of others are, factor such as disease, contraceptive methods, pregnancy 
history or age could cause this change in miRNA regulation. The absence of hsa-mir-205 
within venous blood and semen, even at high concentration could be useful in determining 
the absence of a body fluid from a crime scene stain, if suitable controls were in place. 
Most of the markers showed high uniform expression across one body fluid while also 
displaying expression that fluctuated from absent to strong in another. This would make 
identification difficult and decrease the validity of a body fluid marker. If hsa-mir-10b is 
highly expressed it would indicate menstrual blood, however, due to some semen samples 
with high Δ1Cq values that reliability of BFID is removed. For markers that were highly 
expressed in menstrual blood samples the same levels were not seen in vaginal material, 
they ranged from moderate to absent indicating a huge increase in miRNA involved within 
the menstrual cycle. Overall the least fluctuation can be seen in the high DNA concentration 
body fluids (vaginal material, menstrual blood and saliva) whereas fluctuation is greatest in 
the lower concentration body fluids (venous blood, semen, seminal fluid and skin). 
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5.3.2. Limits of Detection 
5.3.2.1. Sample Dilution series RT-qPCR 
As the results obtained in section 4.3.1 demonstrate, where concentration of miRNA sample 
is sufficient, a result can be obtained. Within the field, not all samples provided are likely to 
contain significant quantities of genetic material. It is therefore important to determine the 
lower limits for detection for the RT-qPCR method. Here, two candidate markers (one 
specific, one an endogenous control) were subjected to sample serial dilutions to estimate 
a LOD for the reaction.   
hsa-mir-124 displayed specificity to vaginal material and menstrual blood. When diluted the 
most uniform expression was seen at 5ng/μl (circled, Figure 5.7), and showed no significant 
difference in expression data seen in undiluted samples. Expression was consistent and 
although Δ1Cq values varied moderate and strong expression was observed when samples 
were diluted to 0.5ng/μl. At concentrations ≤0.05ng/μl, expression became variable across 
samples and in two samples, a complete cessation of expression was observed at 
0.005ng/μl.
 
Figure 5.7:  Δ1Cq values (max Ct - marker Ct) + SEM of hsa-mir-124 within vaginal material samples across serial dilutions. Dotted line indicates threshold for 
inclusion in analysis. 
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SNORD 47 was suggested as an endogenous control [228, 229]. Figure 5.8 shows expression 
values within samples diluted to 5ng/μl were comparable to those obtained from undiluted 
sample. Expression from samples was still consistent when diluted to 0.5ng/μl. Subsequent 
dilutions of sample to 0.05ng/μl resulted expression being detected in only 2 of the 6 
samples, with no expression detected at 0.005ng/μl.  
 
 
Figure 5.8: Δ1Cq values (max Ct - marker Ct) + SEM of SNORD 47 within vaginal material samples across serial dilutions. 
Dotted line indicates threshold for inclusion in analysis. 
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5.3.2.2. Discussion of detection limits  
Although variation in LOD between markers can be seen, all markers used within this 
component of the study displayed a strong, uniform positive reaction at concentrations 
>0.5ng/μl. The data generated here suggest that a working concentration for assays would 
be >0.5ng/μl. Marker hsa-mir-124 did however show strong expression could be detected 
when diluted to 0.05ng/μl. To investigate the specificity of low template DNA (ltDNA) 
samples, subsequent analyses were carried out following dilution of samples to 0.7ng/μl. 
5.3.3. Identification of body fluid specific markers and 
endogenous controls 
The aim of this section was to carry out a screening of body fluid specific and endogenous 
control miRNA markers described in the literature. To fully assess the robustness of a BFID 
marker its expression must be compared to the expression values in other body fluids. The 
data generated showed the volume of genetic material has a large effect on expression. A 
minimum of two endogenous controls must be identified as universally expressed in all 
body fluids to allow for comparisons across body fluids to be made. Since TaqMan® assays 
were carried out within section 4.3.1, the possibility of replacing these with custom assays 
was also investigated. In addition to screening a full panel of miRNA markers, the samples 
obtained in 4.3.1 were diluted to concentrations that would be confluent with other 
established molecular identification techniques.  
hsa-mir-451 was not analysed on ltDNA samples; the significantly high expression and 
specificity within blood samples supports current literature [165, 185, 195, 230, 231]. The 
inability of this marker to differentiate between venous blood and menstrual blood would 
not aid in cases where the identification of the type of blood left at a crime scene is 
important. Marker hsa-mir-617 showed no significant expression within any body fluid and 
was therefore deemed unsuitable for BFID and removed from the study. All the markers 
within this panel of screening were identified from the literature and in all cases, had been 
identified as being an endogenous control or a body fluid specific marker.    
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5.3.3.1. Low template RT-qPCR 
Expression of markers of proposed endogenous controls can be seen in Figure 5.9. Marker 
hsa-mir-93 and SNORD 47 showed high expression values in all body fluids, except for skin 
in SNORD47. Expression of SNORD 44, 38b and 7 was low or absent in all body fluids and 
was not consistent throughout samples of the same body fluid.  
 
Figure 5.9: Expression of custom made miRNA and SNORD markers, measured using Δ1Cq (Max Cq- Cq of marker) in all 
body fluids. Δ1Cq was calculated and plotted for endogenous control markers hsa-mir-93a and SNORD 47, SNORD44, 
SNORD38b and SNORD 7. All body fluid samples were analysed, an absence of bar denotes no observable expression/ 
Δ1Cq of 0. Dotted line indicates threshold for inclusion in analysis. 
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Proposed vaginal material markers hsa-mir-124a, 372, 654-5p and 1260b were characterised 
(Figure 5.10). Marker hsa-mir-1260b displayed high expression in all body fluids (>22.1), 
contrasting with hsa-mir-372, which showed low/negligible expression in menstrual blood 
and saliva samples, and hsa-mir-654-5p which showed negligible expression in vaginal 
material. Marker hsa-mir-124 displayed complete specificity to vaginal material and 
menstrual blood, with significant expression values observed that obtained within other 
body fluids (p<0.001).  
 
 
Figure 5.10: Expression of custom made miRNA markers, measured using Δ1Cq in all body fluids. Δ1Cq (Max Cq- Cq of 
marker) was calculated and plotted for vaginal markers hsa-mir-124a, hsa-mir-372, hsa-mir-654-5p and hsa-mir-1260b. 
(p<0.001). All body fluid samples were analysed, an absence of bar denotes no observable expression/ Δ1Cq of 0. Dotted 
line indicates threshold for inclusion in analysis. 
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Proposed saliva markers hsa-mir-124* did not express in any body fluid (Figure 5.11), with 
low expression of 138-2 observed in vaginal material, menstrual blood and semen. Marker 
hsa-mir-205 showed no expression in venous blood, seminal fluid or skin but showed low 
expression (<0.5) in semen and moderate expression in vaginal material (13.4). Marker hsa-
mir-205 showed the largest expression values in saliva (19.9) and menstrual blood (19.8). 
High, consistent expression was observed from marker hsa-mir-223 in vaginal material, 
menstrual blood, venous blood and saliva (20.3 - 20.9) samples, but was low in both semen 
and skin and moderate in seminal fluid samples.  
 
 
Figure 5.11: Expression of custom made miRNA markers, measured using Δ1Cq (Max Cq- Cq of marker) in all body fluids. 
Δ1Cq was calculated and plotted for saliva markers hsa-mir-205, hsa-mir-223, hsa-mir-124* and hsa-mir-138-2. All body 
fluid samples were analysed, an absence of bar denotes no observable expression/ Δ1Cq of 0. Dotted line indicates 
threshold for inclusion in analysis. 
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Proposed venous blood marker hsa-mir-16 showed significantly high expression in blood 
samples (menstrual blood 23.06 and venous blood 27.3) (p<0.001). However, expression 
was also present in vaginal material, semen and saliva (15.8 – 16.6) (Figure 5.12). Skin 
markers hsa-mir-3169 and 455 did not display high expression values in any body fluid. 
Marker 203a showed significantly high (p<0.01) expression in menstrual blood (22.1). 
Expression was also high in vaginal material and saliva (20.6 and 19.9). Expression was seen 
in skin and semen but these were weak signals (<10), a moderate expression was however 
observed in seminal fluid samples.  
  
Figure 5.12: Expression of custom made miRNA markers, measured using Δ1Cq (Max Cq- Cq of marker) in all body fluids. 
Δ1Cq was calculated and plotted for skin markers hsa-mir-203a, hsa-mir-3169 and hsa-mir-455-3p and blood marker hsa-
mir-16. (p<0.01). All body fluid samples were analysed, an absence of bar denotes no observable expression/ Δ1Cq of 0. 
Dotted line indicates threshold for inclusion in analysis. 
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Eleven proposed semen markers were included in the panel for ltDNA BFID analysis, Δ1Cq 
values can be seen in Figures 5.13 - 5.15. Both hsa-mir-10a and 135a were moderately but 
significantly (p<0.001) expressed in semen and seminal fluid over other body fluids, 
however weak expression was observed in menstrual blood in both cases (Figure 5.13). 
Marker hsa-mir-10b-5 showed weak expression in semen, menstrual blood and vaginal 
material, with weak expression seen in semen from has-mir-10b-3.  
 
 
Figure 5.13: Δ1Cq values of custom assays across all body fluids. Δ1Cq (Max Cq- Cq of marker) was calculated and plotted 
for semen markers hsa-mir-10a, hsa-mir-10b-5p, hsa-mir-10b-5p and hsa-mir-135a. (p<0.001). All body fluid samples were 
analysed, an absence of bar denotes no observable expression/ Δ1Cq of 0. Dotted line indicates threshold for inclusion in 
analysis.  
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Marker hsa-mir-135b showed no expression across body fluids with the exception of weak 
expression in vaginal material, this contrasts with the results of hsa-mir-508 which displayed 
universal moderate expression across all body fluids (Figure 5.14). Custom marker hsa-mir-
507 varied in expression values compared to those seen using TaqMan® assays where 
expression was observed in all body fluids. Expression was low/weak in blood, semen and 
saliva, low in vaginal material and skin (all <9) and poor in seminal fluid (10.6). The moderate 
expression observed in menstrual blood (15.28) was significantly higher than all other body 
fluids (p<0.001).  
 
Figure 5.14: Δ1Cq values of custom assays across all body fluids. Δ1Cq (Max Cq- Cq of marker) and SEM was calculated and 
plotted for semen markers hsa-mir-135b, hsa-mir-507 and hsa-mir-508. (P< 0.001). All body fluid samples were analysed, 
an absence of bar denotes no observable expression/ Δ1Cq of 0. Dotted line indicates threshold for inclusion in analysis. 
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Marker hsa-mir- 888 showed moderate, but significantly greater expression in semen and 
seminal fluid (p<0.001), with weak expression observed in other body fluids (Figure 5.15). 
Marker hsa-mir-892 and hsa-mir-3197 showed weak expression in all body fluids, with the 
exception of a moderate but not significant expression observed within vaginal material. 
Marker hsa-mir-2392 showed moderate expression in all body fluids except for seminal 
fluid, where no expression was observed. 
 
 
Figure 5.15: Δ1Cq values of custom assays across all body fluids. Δ1Cq (Max Cq- Cq of marker) and SEM was calculated and 
plotted for semen markers hsa-mir-888-5p, hsa-mir-892a, hsa-mir-2392 and hsa-mir-319 (p< 0.001). All body fluid samples 
were analysed, an absence of bar denotes no observable expression/ Δ1Cq of 0. Dotted line indicates threshold for 
inclusion in analysis. 
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Six miRNAs were proposed for menstrual blood identification, Δ1Cq values can be seen in 
Figures 5.16 and 5.17. Marker hsa-mir-142, 144-3 and 144-5 showed high Δ1Cq values in 
venous blood samples with significantly lower expression (p<0.001), being observed in 
menstrual blood (<12, Figure 5.16). Marker hsa-mir-412 displayed moderate expression in 
menstrual blood (12.68) with all other body fluids having weak or no expression (Figure 
5.17). Marker hsa-mir-199a and 214 were weakly or not expressed across the full range of 
body fluids. 
 
 
Figure 5.16: Δ1Cq values of custom assays across all body fluids. Δ1Cq (Max Cq- Cq of marker) and SEM was calculated and 
plotted for menstrual blood markers hsa-mir-142-3p, hsa-mir-144-3p and hsa-mir-144-5p. (p<0.001). All body fluid 
samples were analysed, an absence of bar denotes no observable expression/ Δ1Cq of 0. Dotted line indicates threshold 
for inclusion in analysis. 
0
5
10
15
20
25
30
hsa-mir-142 hsa-mir-144-3 hsa-mir-144-5
Δ1
Cq
 (C
qm
ax
 -
Cq
 ta
rg
et
)
Menstrual Blood Markers
Vaginal material Menstrual Blood Semen Seminal Fluid Saliva Skin
***
***
***
 
 
 
167 | P a g e  
 
 
 
 
Figure 5.17: Δ1Cq values of custom assays across all body fluids. Δ1Cq (Max Cq- Cq of marker) and SEM was calculated and 
plotted for menstrual blood markers hsa-mir-199a, hsa-mir-214 and hsa-mir-412-3p. (p<0.001). All body fluid samples were 
analysed, an absence of bar denotes no observable expression/ Δ1Cq of 0. Dotted line indicates threshold for inclusion in 
analysis.  
5.3.3.2.   Heat map analysis of custom assay expression across individual ltDNA 
samples.    
All BFID candidate markers were further analysed by calculating ΔCq (ΔCq of endogenous 
control - (ΔCq of target) on individual samples. Figure 5.18 displays expression levels for hsa-
mir-124, 412, 507, 205, 16, 203 and 223. Marker hsa-mir-124 displayed strong expression 
across all vaginal material and menstrual blood samples with a complete absence in all 
other body fluids. Although hsa-mir-412 showed statistically significant expression values 
in menstrual blood, some menstrual blood samples display weak or no expression, while a 
diverse range of expression values can be seen in vaginal material. High expression was 
seen in all menstrual blood samples using hsa-mir-507. Weak expression was seen in a large 
number of vaginal material, semen, seminal fluid and skin samples with occasional high 
expression in a minority of samples. 
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Marker hsa-mir-205 was strongly expressed in all saliva. The majority of vaginal material and 
menstrual blood samples also displayed strong expression. Absent or weak expression was 
seen in venous blood, semen, seminal fluid and skin. Marker hsa-mir-16 was highly 
expressed in all body fluids however absent and weak expression was seen in a small 
selection of samples in each body fluid. Marker hsa-mir-203a showed universally high 
expression across all samples in vaginal material, menstrual blood and saliva, a range of 
weak to strong expression across semen and skin samples and no expression in venous 
blood. This expression pattern was almost identical in hsa-mir-223 with the inclusion of 
universally high venous blood expression in all samples. 
Volunteers donating vaginal material and menstrual blood samples who had regular 
unprotected sexual intercourse (UPSI) are indicated by a circle. The duration from UPSI to 
sampling can be seen in sample information in appendix F. Samples obtained from 
volunteers from African descent are indicated by a star, neither of these volunteers 
demonstrated expression of markers 412 and 205 in vaginal material and menstrual blood. 
This may be significant but further studies with larger sample numbers would have to 
confirm this observation. 
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Figure 5.18: Individual ΔCq (ΔCq of endogenous control (Average of selected endogenous control’s) - (ΔCq of target) value 
of each body fluid sample across all markers used in the screening of the 0.7ng/μl samples. Sample from African females 
are denoted by a star.  
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Figure 5.19 displays expression levels for hsa-mir-142, 144-5, 144-3, 135a, 10a and 888. 
Marker hsa-mir-142 shows high expression in all venous blood samples, weak expression 
was seen in a small number of vaginal material and seminal fluid samples, hsa-mir-144-3 
and 144-5 displayed high expression in all venous blood samples as well as some menstrual 
blood samples. No expression was seen in any other fluid. Semen markers hsa-mir-10a and 
135a were expressed in all seminal fluid and over 90% of semen samples. No expression was 
seen in vaginal material, venous blood or saliva however high expression was seen in all but 
one UPSI samples of vaginal material and menstrual blood. Marker hsa-mir-888 was present 
in a small selection of vaginal material samples and weak expression is seen in one venous 
blood sample.  
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Figure 5.19: Individual ΔCq (ΔCq of endogenous control (Average of selected endogenous control’s) - (ΔCq of target) value 
of each body fluid sample across all markers used in the screening of the 0.7ng/μl samples. Sample where UPSI had 
recently occurred are indicated by a circle. White boxes indicate a ΔCq of 0 (no observed expression), grey boxes indicate 
no sample tested. 
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The expression of the endogenous controls established within this panel of screening can 
be seen in Figure 5.20. SNORD47, hsa-mir- 93, 508 and 1260b show universal and strong 
expression in all samples. Although hsa-mir-2392 displayed universal expression across 
body fluids, within body fluid samples expression values fluctuated between high, low or 
absent.  
 
Figure 5.20: Individual Δ1Cq (max Cq- (ΔCq of endogenous control target) value of each body fluid sample across all 
endogenous control markers used in the screening of the 0.7ng/μl samples. White boxes indicate a ΔCq of 0 (no observed 
expression), grey boxes indicate no sample tested. 
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5.3.3.3.  Discussion of low template analysis 
Initial investigations demonstrated that custom assays modelled upon TaqMan® assays 
gave comparable results that could allow for custom assays to be utilised within the 
screening panel and other downstream experiments. The aim of this section of work was to 
screen for markers that could be used individually or as part of a matrix to identify specific 
body fluids. In particular, being able to distinguish between vaginal material, saliva, semen, 
seminal fluid, skin and venous and menstrual blood would be of great benefit towards 
forensic case work. A number of markers generated weak or no expression across samples 
and were therefore unsuitable for BFID. 
Of the four vaginal markers tested, only one supported current literature in that the 
expression was specific to vaginal material. The high expression of hsa-mir-124a in vaginal 
material and menstrual blood coupled to a complete absence of expression in all other 
fluids in undiluted and 0.7ng/μl samples suggest it is an ideal candidate for vaginal material 
identification. At 0.7ng/μl the expression values in vaginal material and menstrual blood are 
high and stable in all samples. In cases where a suspect is identified and a penile swab taken, 
the expression of hsa-mir-124 would identify that vaginal penetration occurred and thus 
increase the support to the prosecution hypothesis. 
Saliva and vaginal material are very similar in appearance and genetic composition 
therefore it could be expected that in many markers the expression values may be similar. 
This was evidenced within expression data for marker hsa-mir-203a, where strong 
expression was observed within samples of vaginal material (including menstrual blood) 
and saliva. In a similar fashion, strong expression of hsa-mir-205 was observed in all saliva 
samples but also in 95% of menstrual blood samples and 73% of vaginal material samples. 
Despite expression in menstrual blood, the saliva associated expression was statistically 
significant, but not significantly greater than vaginal material. In this case, for presumptive 
classification of a clear stain suspected of being saliva, a panel of 203a, 205 and 124 would 
confirm saliva in the absence of 124 expression.  In case work, this matrix could be useful in 
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a situation where a victim claims the suspect forced them to provide/ receive oral 
intercourse. 
Five markers were capable of distinguishing between menstrual and venous blood, with 
hsa-mir-124, 412, 507, 205 and 203a all showing expression within menstrual blood with a 
complete absence of expression of venous blood. The caveat to these findings is that none 
of these markers were entirely menstrual blood specific, with expression in other body fluids 
being observed. Since weak/poor expression of hsa-mir-507 and 203a was also 
demonstrated expression in some semen, seminal fluid and skin samples, it could provide 
uncertainty for application into BFID casework. Interestingly, only marker 412 was identified 
as being a potential menstrual blood specific marker within the literature [179] 
In contrast, markers hsa-mir-142, 144-5 and 144-3 had all been identified in the literature as 
being specific to menstrual blood but showed significantly greater expression in venous 
blood. Expression of these markers in menstrual blood was sporadic across individuals, but 
was moderately/strongly expressed where expression was detected. Within this panel of 
markers therefore, a conclusive marker for venous blood could not be identified. In a case 
where the defence states that the suspect and victim had consensual intercourse, 
expression of markers hsa-mir-142, 144-3 and 144-5 with an absence of hsa-mir-412 being 
observed would provide increased support to the prosecution that venous blood was 
present within the sample. To include hsa-mir-142 in the BFID matrix increases the reliability 
of the analysis however extra care throughout analysis would be needed due to weak 
expression in certain vaginal material samples. 
Markers hsa-mir-135a, 10a and 888 were all capable of detecting expression from semen 
and seminal samples. The high expression of hsa-mir-10a, 135a and 888 in every seminal 
fluid sample supports them as potential candidates for the identification of semen with or 
without the presence of spermatozoa. In addition to this, these markers were detected in 
vaginal material and menstrual blood samples. The expression of hsa-mir-135a, 888 and 10a 
within vaginal material and menstrual blood correlated with the incidence of recent 
unprotected sexual intercourse. This detection therefore highlights the proposed semen 
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markers ability for BFID of casework samples where semen is suspected within vaginal 
swabs. Expression of hsa-mir-888 within vaginal material, although only strong in a small 
number of samples was observed in samples where no semen was present therefore 
impacting the specificity of this marker. 
Previously in cases where a vasectomised male sexually assaults an individual, the lack of a 
DNA profile would support the defence. The inclusion of markers hsa-mir-10a and 135a 
would now identify the presence of seminal fluid from vaginal swabs and therefore provide 
support to the prosecution. Where a penetrative sexual assault had occurred within a short 
time frame after a consensual sexual encounter, seminal fluid would be present from both 
individuals. When both individuals can produce semen, the use of DNA profiling would be 
used, however in instances of azoospermic assailants, these markers or other BFID 
techniques could not be used.  
The screening panel was unable to identify a marker for skin. Where those identified as 
being specific in the literature were found to not be detectable in the skin, rather than being 
expressed in all samples as a result of skin cells being present in all swab samples. Five 
markers were identified as being potential endogenous controls for subsequent 
experiments. Here, SNORD 47, hsa-mir- 93, 508 and 1260b were universally expressed. Of 
these, only SNORD47 and hsa-mir-93 have been identified as being endogenous controls, 
with the others being identified as specific to a body fluid within the literature.  
In current literature hsa-mir-205 is designated saliva specific in certain publication and 
present in multiple body fluids in others (see 2.5.6). This discrepancy could be due to the 
techniques used. It can be observed in Figure 5.21 that various forms of contraception could 
have an impact on the regulation of hsa-mir-205 within vaginal material. No expression was 
observed in any sample where contraception was not used by the participant, while all 
excluding one female on the contraceptive injection displayed moderate/ strong 
expression. This up-regulation could be due to the increase in hormones caused by most 
contraceptive methods, however the copper coil which contains no hormones and 
participants with cervical conditions also displayed high expression. It is therefore likely that 
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hsa-mir-205 has a regulatory role in maintenance and repair. The hormones within 
contraceptives alter the construction and destruction of the endometrium, while the IUD 
physically destroys it. Participants with cervical conditions included having sections of 
cervix removed and a hysterectomy, both involving large changes to the uterus and a need 
to repair and maintain healthy tissue. The only participant using contraception that did not 
display expression of hsa-mir-205 utilised the contraceptive injection and stated that it 
caused a complete cessation of her menstrual cycle. With no menstrual cycle, there would 
be no need for constant repair of the endometrium or an up-regulation of has-mir-205. 
 
Figure 5.21: Expression of hsa-mir-205 observed in vaginal material samples, categorised by contraceptive method. 
Cervical conditions include volunteers who have undergone a hysterectomy or have had sections of cervix removed). 
Dotted line indicates threshold for inclusion in analysis. 
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 Conclusion 
The data generated has demonstrated that the use of RT-qPCR has the potential to be a 
robust and reproducible method that could be applied to case work. The study has shown 
that custom markers can be easily introduced into the assay, potentially increasing in 
specificity and number as new miRNA markers are being researched and identified. The 
assay also allows for the use of concentrations of nucleic acid template which are 
comparable with those used in other established techniques allowing for a parallel testing 
to take place. In addition, a panel of miRNA markers have been screened for specificity. A 
number of markers within current literature were not found to provide reproducible results 
in this study. The data does however show that the use of multiple markers can be used to 
identify vaginal material, distinguish between venous and menstrual blood, distinguish 
between saliva and vaginal material and identify seminal fluid in the absence of 
spermatozoa, suggesting penetrative intercourse associated with an azoospermic assailant 
could be detected. Many of these were within a screening matrix, which aids in providing 
the robustness required to give confidence within a real case. In addition, a number of 
endogenous controls have been identified to validate the methodology. 
 Summary 
 Dilution and normalisation of samples is key to correctly identifying body fluid 
specificity of markers 
 The LOD for this technique lies between 0.05 – 0.5ng/μl when analysing using DNA 
quantification values. 
 A selection of BFID markers that can ascertain specific body fluids in a range of sexual 
assault case scenarios have been identified.   
 A panel of markers can be used to distinguish, when present in single stains, vaginal 
material from saliva, seminal fluid with or without spermatozoa and menstrual blood 
from venous blood.  
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 Custom designed assays show higher specificity to an individual body fluid than 
TaqMan® assays.   
 Four robust and reliable endogenous controls have been identified 
 Semen can be detected in vaginal material and menstrual blood samples within 48 
hours of UPSI 
 Contraceptive methods had a regulatory role in the expression of proposed saliva 
marker hsa-mir-205 
 Has the potential for cold case capability for BFID of archived samples that have 
undergone total DNA extraction. 
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6. Characterisation 
of Markers over a 31-
Day Period 
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 Rationale 
The aim of this component of the research was to fully analyse the robustness and 
specificity of the markers identified in the previous chapter by analysing their expression 
over a full menstrual cycle. The environment within the vagina is adaptively hostile as well 
constantly being prepared for the various stages of the menstrual cycle or pregnancy. The 
need for vigorous control over gene expression would likely involve fluctuation of many 
miRNAs, especially during menstruation.  For example, if a miRNA marker chosen for BFID is 
responsible for the continual inhibition of ovum release, then over the course of the cycle 
there will be a minimum of one day where this miRNA must be down-regulated. This 
decrease in expression of a miRNA designated for BFID would provide a false negative 
identification and provide incorrect evidence in court.  
In addition to the identification of body fluid specific markers, the previous chapter also 
identified candidates for endogenous control markers, which play a major role in 
experimental validation. If a significant change in expression is observed in a proposed 
body fluid specific marker, consistent expression of an endogenous control would eliminate 
the possibility of questioning sample integrity. Tentative links to factors such as 
contraceptive, ethnicity and possibly lifestyle choices affecting miRNA expression were also 
observed. It is therefore reasonable to hypothesise that miRNA expression over a full 
menstrual cycle as well as between individuals will not be universal and uniform. For a 
marker to be fully validated as a bio-marker or an endogenous control for BFID it must show 
consistent expression for that body fluid, regardless of any environment or internal factors 
affecting that body fluid.  
The study also aims to determine the most efficient method for extraction of miRNA. 
Numerous miRNA may be specifically expressed within a body fluid but if the extraction 
technique is not effective during elution they cannot be analysed for BFI. Current DNA 
profiling laboratories utilise standard protocol total DNA extraction methods to obtain high 
volume and purity DNA for profiling. To ensure miRNA analysis could be included within 
the standard protocol of DNA profiling the efficiency for miRNA extraction from total DNA 
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extraction must be tested. Various laboratories also utilise total RNA extraction methods for 
RNA analysis, although rarely used within forensic laboratories it could be proposed that 
this method could be more efficient at extracting miRNA due to its optimisation for 
extracting single stranded molecules. The most frequently used DNA kits used in forensic 
laboratories are purchased from Qiagen, these kits use spin column technology. To keep 
the method as similar as possible the RNA extraction kit from Qiagen will be use on the RNA 
samples with the DNA extraction kit for DNA samples.  
The results obtained in the previous chapter also suggested dilution had a large effect on 
marker specificity, especially in vaginal material and menstrual blood. Vaginal material 
samples obtained from crime scene samples will most like be retrieved from a LVS provided 
during a SARC examination or from a suspect’s penile swab. The volume of genetic material 
from these samples is likely to be high, and therefore dilution to trace would not be 
necessary or representative to real case scenarios. The most uniform expression seen within 
section 5.3.2 was at 5ng/μl compared to other dilutions. Therefore, to analyse fluctuation of 
miRNA a concentration of 5ng/μl was made from all vaginal material samples.  
6.1.1. Sample Collection 
Five women each self-collected two LVS every morning for 31 consecutive days, labelling 
the first swab ‘1’ and the second ‘2’. Volunteers completed questionnaires to determine 
current lifestyle choices, medical/ pregnancy history and contraceptive methods 
(Volunteers were asked to make no changes to current lifestyle/ daily habits, noting only 
when UPSI or vaginal oral intercourse (OI) occurred3. UPSI/ OI was noted on swab tubes and 
recorded for analysis, in these samples saliva and semen markers would be expected. If UPSI 
is not recorded and a semen marker was expressed within a vaginal material sample, it 
would suggest that the miRNA is present in vaginal material and therefore cannot be 
utilised for vaginal material and semen mixtures, instead of highlighting the specificity of 
the semen marker.  
                                                          
3 Throughout all research OI is only noted when the recipient is female. 
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All swabs were extracted within two hours of sampling, when this was not possible, the 
sample was stored at -20°C until extraction. The initial swab underwent total DNA extraction 
while the second underwent total RNA extraction. All eluates were stored in 1.5ml tubes at 
-20oC.The volunteers, seen in table 6.1, did not vary greatly in age but differed in length and 
flow of menstruation and also in contraception/ lifestyle and pregnancy history. 
Menstruation of all participants commenced on different days throughout the study, all 
results were therefore normalised so day 1 displayed the start of menstruation.  
Volunteer Age Ethnicity Menstruation Key information 
1 27 
White 
British (W/B) 
Day 20 / heavy/ 7 days 
of menstruation  
Contraceptive pill 
V2 in Screening study 
2 27 Asian Day 6 / light/ 8 days of 
menstruation 
Contraceptive pill 
V18 in Screening study 
3 22 W/B N/A 
Contraceptive injection ceases 
menstrual cycle/ Smoker. UPSI and OI 
day 10, 17 and 25 
V15 in Screening study 
4 29 W/B Day 20 / heavy / 5 days 
of menstruation 
Previous pregnancy 
V5 in Screening study 
5 29 W/B Day 15 / heavy / 7 days 
of menstruation 
Coil, Smoker, Previous pregnancies 
V12 in Screening study 
 
Table 6.1: Volunteer provided information on menstrual cycle, contraceptive, age and ethnicity. 
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6.1.2. Marker selection 
All markers displaying BFID specificity as well as miRNA displaying expression beneficial to 
BFID in specific crime scenarios were chosen for further validation. Markers displaying 
complete absence are only beneficial if that absence is permanent, just as body fluid specific 
expression must be permanent. Eleven markers were selected for a BFID matrix alongside 
four for use as endogenous controls, observed in table 6.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.2: Markers selected for analysis over a 31-day period categorised by specificity. 
 
 
 
 
 
 
 
Marker (hsa-mir / SNORD) Proposed role
124 Vaginal material specific 
507, 412 Menstrual blood specific 
10a, 135a, 888 Semen specific 
205 Saliva specific 
508, 47, 1260b, 93 Endogenous control 
144-3, 144-5, 142 Blood specific 
203a BFID through absence of expression 
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 Results 
6.2.1. Proposed Endogenous Controls 
6.2.1.1. Expression from DNA and RNA extracts over 31 days 
The expression of proposed endogenous control markers hsa-mir-93 and hsa-mir-508, from 
both DNA and RNA extracts, across the 31-day study can be seen in Figure 6.1 A-D. Strong 
consistent expression (>20) of hsa-mir-93 was observed across all 31 days of sampling from 
both DNA (A) and RNA (B) from all volunteers. In addition, a consistent expression of hsa-
mir-508 was observed in both DNA (C) and RNA (D) samples from all volunteers, however 
expression was moderate.  
 
Figure 6.1: Δ1Cq +SEM for proposed endogenous controls hsa-mir-93 (DNA (A) RNA (B)) and hsa-mir-508 (DNA (C) RNA (D)) 
of all volunteers across 31 days. 
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Proposed endogenous control markers hsa-mir-1260b and SNORD47 were both strongly 
expressed in DNA samples across all volunteers over the 31-day study (Figure 6.2 A, C). The 
expression observed was not as consistent between days within volunteers, however, these 
were not significantly different. Distinct decreases in expression was observed from these 
markers when RNA was used as a template from volunteer 4 (Figure 6.2 B, D). In these cases, 
weak-moderate expression of the marker was observed. 
Figure 6.2: Δ1Cq +SEM for proposed endogenous controls SNORD 47 (DNA (A) RNA (B)) and hsa-mir-1260b (DNA (C) RNA 
(D)) of all volunteers across 31 days.  
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6.2.1.2. Discussion of proposed endogenous controls 
Within a scientific study multiple endogenous controls are required to provide accurate 
normalisation of samples. The Δ1Cq values of the average of SNORD 47, hsa-mir- 508, 93 and 
1260b across extraction methods can be observed in Figure 6.3. The data generated 
suggests that when the original sample of miRNA was obtained from DNA, all four of the 
markers within this study represent suitable endogenous control markers. In contrast, the 
expression values obtained from RNA samples, although consistent across a number of 
volunteers, did reduce in one of the volunteers and was primarily associated with markers 
SNORD47 and hsa-mir-1260b.  
 
Figure 6.3: Δ1Cq + SEM of the average or all endogenous controls tested within vaginal material over 31 days, following 
DNA and RNA extraction. Each data point – N=15). 
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Sampling by volunteers is likely to be inconsistent, it is therefore important that an 
endogenous control marker is capable of highlighting these inconsistencies. Expression of 
markers hsa-mir-508 and 93 were consistent across all samples, where variation was 
observed with SNORD47 and hsa-mir-93. It is therefore possible that the quantities of hsa-
mir-508 and 93 are so numerous within all cell types, that expression is limited by the 
experimental factors (e.g. binding efficiencies, availability of probe) which mean that high 
Δ1Cq values are always obtained. An experienced sampler is likely to provide a sample which 
will contain enough material to detect expression of a specific marker (see Figure 6.4). 
Whereas an inexperienced or inconsistent sampler is likely to provide a sample that may not 
contain enough material to detect the presence of a specific marker. In these cases, no 
change in expression of hsa-mir-93 and 508 would be detected and a false negative would 
be obtained. An endogenous control marker therefore not only be expressed, but display 
variance based on the quality of sample material provided as an internal control. Since 
markers SNORD 47 and hsa-mir-1260b were capable of highlighting these variations, they 
are more robust at validating the test where hsa-mir-508 and 93 are markers capable of 
validating the RT-qPCR reaction has been successful. A combination of these markers is 
therefore beneficial for case work. 
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Figure 6.4: Differences in expression within a hypothetical sampler when utilising a good and poor collection technique. 
The sample obtained from the experienced sampler will show expression in all markers analysed. The same sample when 
taken by an inexperienced sampler will still display maximum expression in the most abundant miRNAs, but will display a 
reduced expression in the moderately abundant markers and a possible absence of miRNA that are not as abundant in the 
cells.  
 
 
 
 
 
detection 
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6.2.2. Body Fluid Specific miRNA 
6.2.2.1. Proposed vaginal material marker 
Marker hsa-mir-124 Δ1Cq values from DNA and RNA extractions can be seen in Figure 6.5. 
The expression values obtained throughout the 31 days following DNA extraction were 
consistently high (>17) across all volunteers and days and no significant difference was seen 
between each data set. Although a number of Δ1Cq values associated with RNA samples 
were higher than those seen from DNA extraction, a greater degree of fluctuation was 
observed. In five samples provided by volunteer 4, an absence of expression was observed. 
The absence of expression correlated with the decrease in expression of hsa-mir-1260b and 
SNORD 47 suggesting an issue within the sample. With the exception of these samples, no 
sample displayed weak or absent expression leading to an incorrect identification of vaginal 
material.   
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Figure 6.5: Δ1Cq + SEM of hsa-mir-124 in vaginal material over 31 days, following DNA (A) and RNA extraction (B). No 
significant difference observed across samples (each data point – N=3). Dotted line indicates threshold for inclusion in 
analysis. 
 
 
 
191 | P a g e  
 
 
 
6.2.2.2. Proposed saliva marker 
In the previous screening, it was determined that the assumption of saliva within a sample 
would require the absence of expression of hsa-mir-124 alongside the expression of hsa-
mir-205 with addition support from hsa-mir-203a. Marker hsa-mir-205 was included within 
the study to assess how the expression evolved over the 31 days, with focus on expression 
change following receipt of OI and to assess the validity of contraception’s effect on hsa-
mir-205 regulation.  Expression values for DNA (A) and RNA (B) can be seen in Figure 6.6. 
The expression patterns for samples within DNA extraction were either uniformly expressed 
or completely absent. V2, V3 and V4 displayed no expression throughout any time point. V1 
and V5 displayed very strong expression from the samples. A decrease in expression was 
observed at D23 of the V5 dataset, however expression was still moderate.  
In a similar fashion, expression of this marker from RNA samples of V1 and V5 was 
moderate/strong. V1 maintained a uniformly strong expression throughout the 31 days as 
per DNA samples, V5 displayed strong expression as with DNA samples but a complete 
absence of expression was seen at 4 data points. V3 was the only data set that remained 
absent of expression, V2 displayed two data points where a detection of expression was 
observed. A similar pattern was also seen within V2 however D25-D30 where a spike in 
expression was observed before returning to an absence. In the case of both of these 
markers, volunteer 3 received OI on 3 separate occasions, which did not result in any change 
in expression pattern with either marker. This lack of expression following OI is not 
unexpected as following the samples taking from a SARC examination, forensic scientist 
would have a higher expectation of detecting saliva on the external swab rather than an 
internal swab.  
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 Figure 6.6: Δ1Cq + SEM of hsa-mir-205 in vaginal material over 31 days, following DNA (A) and RNA extraction (B). Each 
data point – N=3). Dotted line indicates threshold for inclusion in analysis. 
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 Proposed duel-expression saliva and vaginal material marker  
Marker hsa-mir-203a has displayed high expression values across all vaginal material and 
saliva samples, it has been suggested that its presence in all body fluids bar venous blood 
could be useful in a panel of BFID markers. It was included to assess to robustness and 
stability within vaginal material across the menstrual cycle. Expression of hsa-mir-203a 
within DNA samples can be seen in Figure 6.7: A, with RNA samples observed in Figure 6.7: 
B. The Δ1Cq values across all volunteers and days in DNA and RNA samples were high (>19.7) 
indicating strong uniform expression across all samples. Although a degree of fluctuation 
within individual data sets is evident, no significant differences were observed that would 
indicate a false negative within vaginal material. As with hsa-mir-124, expression was, to a 
degree, higher in RNA compared to DNA extracted samples. Absence of expression was 
observed again around the same instances within the profile of volunteer 4. 
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Figure 6.7: Δ1Cq + SEM of hsa-mir-203a in vaginal material over 31 days, following DNA (A) and RNA extraction (B). Results 
observe no significant difference across samples (excluding outliers, each data point – N=3). Dotted line indicates 
threshold for inclusion in analysis. 
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6.2.2.3. Proposed menstrual blood markers 
Expression of marker hsa-mir-412 from both DNA and RNA can be seen in Figure 6.8. 
Expression values within V1, V2, V3 and V5 from DNA (A) were uniformly strong throughout 
the 31-day investigation, with no significant difference being observed throughout samples 
or these volunteers. Expression of this marker observed within the samples provided by 
volunteer 4 was sporadic and where expression occurred, it was moderate. Δ1Cq values 
observed were significantly lower than those observed in other volunteers at all time points 
(P<0.001). Excluding days 9-10 which although moderate, were still less that the other 
volunteers (P<0.01). In addition, these spikes in expression did not correlate with 
menstruation. Expression values from RNA (B) samples were similar to those observed 
within DNA extracted samples provided from volunteers V1, V3 and V5. The data generated 
from both volunteers 2 and 4 displayed variability across the sampling period, again 
demonstrating moderate expression which did not correlate with menstruation.  
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Figure 6.8: Δ1Cq + SEM of hsa-mir-412 in vaginal material over 31 days, following DNA (A) and RNA extraction (B). No 
significant difference observed across samples (each data point – N=3). Dotted line indicates threshold for inclusion in 
analysis. 
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Expression of the second proposed menstrual blood marker hsa-mir-507 from DNA was 
moderate across all 31 days from samples provided by volunteers 3, 4 and 5 (Figure 6.9: A). 
Strong expression was observed in the majority of the DNA samples provided by volunteer 
1 with the remaining samples demonstrating moderate expression of the marker. The 
samples provided by volunteer 2 were sporadic over the course of the study with an 
absence, weak and moderate expression observed in samples, these however did not 
correlate with menstruation within this individual. The samples provided from volunteer 1 
also moderately expressed marker 507 across all 31 days from RNA (Figure 6.9: B). The 
remaining samples provided from all volunteers demonstrated sporadic expression which 
ranged from absent to weak. Again, these variations in expression did not correlate with 
menstruation.  
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Figure 6.9: Δ1Cq + SEM of hsa-mir-507 in vaginal material over 31 days, following DNA (A) and RNA extraction (B). Each 
data point – N=3). Dotted line indicates threshold for inclusion in analysis. 
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6.2.2.4. Proposed venous blood markers 
Moderate to strong expression of marker hsa-mir-144-5 was observed across the first 7-10 
days of sampling from DNA samples provided by all volunteers with the exception of 
volunteer 3 (Figure 6.10: A). These observations correlate with menstruation occurring, and 
blood being present within the swabs provided by the volunteers. A similar expression 
pattern was observed from the RNA extracted from the samples (Figure 6.10: B), where 
expression was moderate rather than strong as it had been from DNA. Again, no expression 
was detected from samples provided by volunteer 3. All samples obtained at the start of 
menstruation correlated with a significant increase in expression (P<0.001). The small peaks 
in expression from V5 observed on D18 in DNA and RNA and D10 in RNA are likely due to 
probe degradation or unspecific priming. These values do not reach the threshold for 
inclusion and therefore would be disregarded as a positive result.  
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Figure 6.10: Δ1Cq + SEM of hsa-mir-144-5 in vaginal material over 31 days, following DNA and RNA extraction. A significant 
difference was observed in expression during menstruation (P<0.001). Each data point – N=3). Dotted line indicates 
threshold for inclusion in analysis. 
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Consistent moderate-strong expression of hsa-mir-142 was observed across the majority of 
both DNA (A) and RNA (B) samples provided by volunteers across the 31 days of sampling 
(Figure 6.11). The only fluctuation observed was seen in  DNA and RNA samples provided 
by V3 and RNA samples provided by V4, where absent or weak expression was observed. 
Within DNA samples expression associated with V3 was sporadic in nature, but only in time 
periods around and within the menstrual cycle. The reduction of expression during 
menstruation was also observed in RNA samples with similar patterns from V4. The decrease 
in V4 does however follow the decrease in expression observed in the endogenous control 
markers. RNA samples for V3 did not however display the consistent expression across 
samples where menstruation did not occur as in corresponding DNA samples. This trend 
was not observed within any of the samples provided by the remaining volunteers.  
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Figure 6.11: Δ1Cq + SEM of hsa-mir-142 in vaginal material over 31 days, following DNA and RNA extraction. No significant 
difference observed across samples (A) (each data point – N=3). Dotted line indicates threshold for inclusion in analysis. 
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Δ1Cq values for hsa-mir-144-3 from DNA extraction can be seen in Figure 6.12: A. Expression 
values within DNA V3 is stable and uniform across all vaginal material samples. V1 and V4 
display a significant increase in expression (P<0.001) during menstruation followed by high 
uniform expression throughout following samples. The majority of V5 DNA display positive 
expression, however sharp decreases and drop-outs are observed in 5 of the time points. V2 
displayed high fluctuation across time points, during menstruation expression is high, with 
the exception of D6 displaying a complete drop out as seen in hsa-mir-142. Expression then 
fluctuates from absent to around 10, lying within the weak expression category. Outside of 
menstruation moderately expression was only seen in D13 and D27. 
Δ1Cq values from RNA extraction can be seen in Figure 6.12:B. V1 displayed a significant 
increase in expression during menstruation however subsequent expression was not as 
stable with sharp decreases being observed. V4, following the sample pattern as V1 
however a decrease during menstruation was observed. Δ1Cq  values within V1 all fell below 
6, indicating no expression within vaginal material using RNA extraction. The expression 
within V2 and V5 in RNA samples was even more irregular than observed within DNA 
samples. V2 only displayed moderate expression the days of and immediately after 
menstruation, while Δ1Cq values within V5 were significantly lower across all samples 
(P<0.01).  
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Figure 6.12:  Δ1Cq + SEM of hsa-mir-144-3 in vaginal material over 31 days, following DNA (A) and RNA (B) extraction. 
Each data point – N=3). Dotted line indicates threshold for inclusion in analysis. 
*** 
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6.2.2.5. Proposed semen and seminal fluid markers 
The expression values of proposed semen markers hsa-mir-10a 135a and 888 can be seen 
in Figure 6.13.  Expression of marker hsa-mir-10a from DNA samples was moderate and 
consistent from DNA extracted samples originating from volunteers 1, 3 and 5, with 
sporadic expression that displayed no trend from volunteers 2 and 4 (Figure 6.13: A). 
Fluctuating expression was also observed from RNA extracted material across all volunteers, 
although consistently moderate expression was apparent within those samples obtained 
from volunteers 1 and 3 (Figure 6.13: B). 
Sporadic expression of hsa-mir-135a was also observed from both DNA and RNA extracted 
samples over the 31-day study (Figure 6.13: C-D). The expression values obtained varied 
from absent-moderate with no clear trend being apparent, however an increase in 
expression was observed where an incidence of UPSI occurred (Volunteer 3, day D17). The 
remaining instances of UPSI (volunteer 3, days D10 and D24) were however, not detected. 
Expression of hsa-mir-888 within samples of DNA and RNA obtained from volunteers 2 and 
4 also displayed no clear pattern of expression (Figure 6.13: E-F). Expression of this marker 
from samples 1, 3 and 5 displayed a reasonable consistent trend from miRNA obtained 
through DNA and RNA extraction, where expression was moderate. Volunteer 3 did have 
UPSI during the 31 days of study, however this is not reflected within the data obtained for 
this marker. 
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Figure 6.13: Δ1Cq + SEM of proposed semen markers hsa-mir-10a (DNA (A) RNA (B), 135a (DNA (C) RNA (D) and 888 (DNA 
E RNA F) in vaginal material over 31 days. Each data point – N=3). Dotted line indicates threshold for inclusion in analysis. 
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6.2.2.6. Discussion of Proposed body fluid specific miRNA 
Initial screening in the previous chapter identified hsa-mir-124 as being vaginal specific 
regardless of dilution factor. Vaginal material will be involved in almost all sexual assault 
cases, the bio-marker responsible for its detection must therefore be fully reliable with no 
false positive or negatives observed within any analysis. Within the 31-day screening, it is 
evident that this miRNA marker is strongly expressed within vaginal material at all times. In 
cases where a suspect is arrested for suspected sexual assault a penile swab could be 
obtained and analysed, an expression of hsa-mir-124 could only be due to the transfer of 
vaginal material to the penis and therefore provide support to the prosecution.  
One of the factors within any sampling is compliance with the instructions provided. The 
volunteers were not observed during the sampling process and training was provided via a 
verbal and written communication. The sampling methods were described in the 
information sheet of this study. If volunteers pressed deeply into the vaginal canal wall or 
increased the duration of sampling it may yield a larger volume of miRNA than volunteers 
who possibly did not sample for the required duration of time or avoided sampling the 
vaginal canal walls. Since expression of hsa-mir-124 was consistent, it suggests that this 
miRNA is abundant within vaginal material and demonstrates the robustness observed in 
endogenous control markers in that regardless of the quality of the sampling, expression 
can be detected. 
The physiological similarities between vaginal material and saliva described in 2.5.5.2 were 
also evidenced throughout the screening. The detection of moderate to strong expression 
of marker hsa-mir-203a within the samples provided by all the volunteers across 31 days 
leads to support that this miRNA is likely to be imperative to functional cellular processes 
associated with both of these secretions. Within DNA samples the expression of hsa-mir-
205 was consistently expressed or absent in each volunteer, with the only occurrences of OI 
in V3 not being detected. The strong expression of this marker within vaginal material 
means that when applied to forensic casework the occurrence of OI could not be detected.  
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The unsuccessful identification of saliva after OI does not necessarily reflect on the 
robustness of hsa-mir-205 to detect saliva; Swabs were taken inside the vaginal canal, unless 
penetration of the tongue occurred any saliva present would be deposited on external 
surfaces of the vagina and would therefore not be sampled. Since marker hsa-mir-124 is 
strongly expressed in vaginal material, this would become a discriminatory factor in stains 
as described in the previous chapter. This combination may also lend to the determination 
of vaginal material obtained from buccal swabs, but this would require further 
investigation.  
The previous chapter highlighted a possible link between contraceptive methods and 
expression of hsa-mir-205. Throughout this study the contraceptive method of V1, 2, 3 and 
5 remained the same as when screening samples were provided, the result was a similar 
expression value as observed at 0.7ng/μl. During screening V2 (V4 in screening) utilised the 
contraceptive pill while V18 did not use any form of contraception, throughout this study 
V2 ceased all contraceptive methods while V18 began taking the contraceptive pill and 
provided two LVS samples for screening, one a week after initial ingestion and the second 
2 months after. Data from both volunteers, on and off the pill can be seen in Figure 6.14. All 
samples were analysed at 0.7ng/μl with the expectation of ‘V18 no pill’ where the average 
of the 31 day results were taken. The absence of expression in ‘V18 no pill’, even at much 
higher concentrations of genetic material as well as the almost immediate increase in 
expression of hsa-mir-205 in V4 after using the pill support the indication that some 
contraceptive methods upregulate expression of hsa-mir-205. This cannot be observed for 
all contraceptive methods as V3 utilises the contraceptive injection and as per results 
observed in ltDNA analysis, an absence of hsa-mir-205 was seen in all samples. 
 
 
 
209 | P a g e  
 
 
 
 
Figure 6.14 : Δ1Cq + SEM of hsa-mir-205 in two volunteer’s vaginal material samples. Samples include V4 no pill (provided 
during screening while on no form of contraception) and V4 pill (obtained 7 days and 2 months after commencement of 
the pill) as well as V18 pill (provided during screening while on the pill) and V18 no pill (obtained through the average of 
all data points from 31-day screening). Dotted line indicates threshold for inclusion in analysis. 
Markers hsa-mir-412 and 507 were candidate indicators of menstrual blood, but only when 
expression of 124 was absent in the initial screening. The data here expose that these 
markers are likely expressed in vaginal material and menstrual blood, but lack the 
robustness associated with marker 124. Therefore, within case work, it would be 
inappropriate to use this testing scheme on swabs that are taken directly from the vagina. 
The use of a hsa-mir-124 in combination with these markers still has the potential for BFID 
where the sample was obtained from blood spots or stains present at a crime scene. 
A further two markers were identified in the previous study for the identification of venous 
blood, distinguishing it from menstrual blood. Marker hsa-mir-144-5 was expressed during 
the bleeding associated with menstruation and not expressed for the remainder of the 
study in all volunteers that were capable of menstruation. The results obtained here suggest 
that hsa-mir-144-5 must be a common component of both venous and menstrual blood. 
The second marker used within the study, has-mir-144-3 showed expression in all 
volunteers across the 31-day study with fluctuations showing no apparent correlation with 
the menstrual cycle. It is therefore likely that this marker is present within both vaginal 
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material and blood independently of one another, which could lead to false positives within 
a forensic case study. Again, the use of marker hsa-mir-124 within a combined marker panel 
screening would be the key to eliminate the prospect of the sample originating from the 
vagina (i.e. being menstrual blood) rather than a single marker being capable of this 
detection. In this case, the multiplex would again not be capable of being applied to blood 
obtained from vaginal injuries, but would be capable of eliminating suspected menstrual 
blood being present on a stain or other blood residue present at a crime scene.  
Proposed semen markers, hsa-mir-10a and 888 were expressed in all volunteers over the 
course of the 31 days, expression fluctuated, with no clear pattern over the course of the 
study within all volunteers. These results show that this test for semen identification is 
unsuccessful at this DNA concentration. If this was used in a court of law all markers would 
show expression, this would lead to the evidence highly supporting sexual intercourse 
occurred even if the reality was it had not. The consequences of this false negative could be 
a wrong conviction.  
The results suggest that markers hsa-mir-10a and 888 are expressed in the components of 
both vaginal material and semen. Since the samples in the previous chapter did not exhibit 
expression in the ltDNA, the data indicates that this marker is perhaps expressed more in 
semen that vaginal material. These two markers would therefore require a greater level of 
template concentration optimisation prior to being considered for robust BFID. This was 
also evidenced with marker hsa-mir-135a, however it would appear that this marker shows 
variation in expression between individuals. Of the three instances of UPSI that occurred, 
one of these was detected through an increase in expression. This detection of UPSI, 
although demonstrating a low success rate for detection within this study (33%), holds 
further promise and will be investigated further.  
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6.2.3. DNA v RNA Extraction Methods 
6.2.3.1. Proposed endogenous controls 
ΔCq values for SNORD 47, hsa-mir-508, 93 and 1260b are displayed in Figure 6.15. No 
significant difference was observed between extraction methods across endogenous 
control makers with the exception of the significantly decreased expression observed with 
V4 RNA D1-5, D7 and D28. 
 
Figure 6.15 Individual ΔCq (ΔCq of marker – avg. ΔCq of endogenous controls) of each sample over a 31-day period for 
markers SNORD 47, hsa-mir-508, hsa-mir-93 and hsa-mir-1260b.   
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6.2.3.2. Proposed body fluid specific markers 
The ΔCq was calculated for all samples utilising the average values obtained from the four 
endogenous controls, values for hsa-mir-124, 144-3, 412, 142 and 144-5 are displayed in 
Figure 6.16. Heat maps display the normalised expression values of all samples across both 
extraction methods. The endogenous controls identified a lack of miRNA present in V4’s 
RNA samples D3-5, D7 and D28, these samples are identified by a ’/’. 
ΔCq values for vaginal material marker hsa-mir-124 showed high expression in all samples, 
across all volunteers and all extraction methods. Although absence of expression was 
observed in a small number of DNA samples. The frequency of low or absent expression 
within blood marker hsa-mir-144-3 is high in the majority of RNA extraction samples. The 
absence observed in one extraction type did not always correspond with the alternative 
extraction type. Within hsa-mir-412, absence of expression was seen in DNA samples from 
V1, V2, V3 and V5, however irregular decreases were observed in corresponding RNA 
samples. The expression patterns are similar in V4 in that expression is frequently absent or 
low in both data sets, however higher expression values are seen in RNA extracted samples 
over DNA extracted samples. 
ΔCq values for hsa-mir-142 are fairly consistent between samples. Although the higher ΔCq 
tend to alternate across extraction methods all ΔCq displayed no significant difference 
between them. The decreases and absences observed in V2 can be seen the corresponding 
extraction technique. The ΔCq values for hsa-mir-144-5 indicate clear strong expression in 
all DNA samples when menstruation occurred, this was not observed in RNA samples. 
Expression was not as high as corresponding DNA samples and in some RNA samples, 
menstrual blood was not even detected. This would be a significant problem if used in 
evidence as it would give a false negative and provide incorrect support to the prosecution 
or defence. In a case where a suspect stated consensual intercourse while the female was 
menstruating occurred, a false negative for menstrual blood would strengthen the 
prosecutions defence that the blood originated from venous blood.  
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Figure 6.16: Individual ΔCq (ΔCq of marker – avg. ΔCq of endogenous controls) of each sample over a 31-day period for 
markers hsa-mir-124, hsa-mir-144-3, hsa-mir-412, hsa-mir—142 and hsa-mir-144-5. Instances of sample integrity are 
indicated by /. White boxes indicate a ΔCq of 0 (no observed expression). Black box indicates days where menstruation 
occurred. 
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ΔCq values for hsa-mir-10a, 135a, 507, 888, 203a and 205 are displayed in Figure 6.17. Days 
where semen should be identified by semen markers hsa-mir-10a, 135a and 888 due to UPSI 
are identified by a circle. Expression of hsa-mir-10a was varied between volunteers and 
across extraction methods, DNA V1 displayed instances of high expression which were 
mirrored in the majority of RNA samples. At some time points, such as D7 and D17 expression 
was significantly higher in DNA samples, whereas in days D24 and D28 expression was higher 
within RNA samples. Limited expression was seen within V2 RNA samples whereas DNA 
samples display high expression on multiple days that were not observed in RNA samples. 
V3 displayed high expression values across all DNA samples, expression was marginally 
lower in RNA samples where an absence of expression was observed within certain samples. 
The expression pattern of V4 fluctuated throughout the 31 days. Where expression was 
strong it was observed in both extraction methods, however days where expression was 
moderate, detection only occurred from DNA samples. V5 displayed moderate to high 
expression in all DNA samples, but poor to weak expression was seen in many RNA samples.  
The expression pattern for semen markers hsa-mir-888 was very similar to hsa-mir-10a, V1 
displayed strong expression in both DNA and RNA samples, with RNA exhibiting higher 
expression values. V2 exhibited weak expression in the majority of samples from both 
extraction methods with RNA presenting the higher expression values when expression was 
observed. Marker hsa-mir-888 was seen in all V3 samples with similar expression values 
across extraction types. V4 displayed weak expression across most samples, however RNA 
samples presented the absences of expression. V5 displayed equal expression patterns as 
observed in hsa-mir-10a; strong expression in both extraction methods but absent and 
weak expression observed in a high number of RNA samples.  
Marker hsa-mir-135a was absent or weak in the majority of samples. The highest expression 
was observed within V1 and V5 samples, this expression was erratic and abrupt and 
frequently followed by absent or weak expression. In the majority of samples both 
extraction methods displayed absence or presence across sample days. V2 display no 
expression across either extraction type. No significant expression was observed in V3 with 
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the exception of D17 which was highly expressed in both the RNA and DNA sample. High 
expression was only seen in 2 samples of V4 DNA with no significant expression being 
observed in RNA samples. The majority of absences observed in semen markers in RNA 
samples occur at the same time points; weak or absent expression is observed in V5 RNA D3, 
D12, V2 D2, D25 and V4 D17-18, equivalent absences were not observed within DNA samples.  
The expression of hsa-mir-507 varied greatly across volunteers and extraction methods. In 
V1 a strong expression is seen across all samples in both extraction methods, however 
higher values are observed in DNA compared to RNA. In V2 frequent occurrences of no 
expression are observed within DNA samples, however this was not always seen in 
corresponding RNA samples. Strong expression as often observed when the equivalent 
sample ΔCq value is 0. V3 displays uniform expression across all DNA samples except for a 
slight decrease in D12, in RNA this sample is complete absent. RNA samples for V3 show no 
uniformity, only irregular drop-outs where corresponding DNA samples display strong 
expression.  
Expression in hsa-mir-203a was consistent across all samples and extraction methods, no 
significant difference is seen between samples of different extractions. The ΔCq values for 
hsa-mir-205 within DNA extraction samples were uniform, volunteers displayed a complete 
absence or absolute presence across all samples. Variation was seen in equivalent RNA 
samples, V2 and V4 displayed expression in samples where DNA observed an absence and 
V5 samples exhibited absences where high expression was observed in corresponding DNA 
samples.  
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Figure 6.17: Individual ΔCq (ΔCq of marker – avg. ΔCq of endogenous controls) of each sample over a 31-day period for markers hsa-mir-10a, 135a, 507, 888, 
203a and 205. Instances of UPSI are indicated by a circle, with sample integrity indicated by /. 
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6.2.3.3. Discussion of extraction method comparison 
Comparisons of the DNA extraction and RNA extraction protocols for the obtaining of 
miRNA indicated that both methods were capable of extracting enough miRNA template 
to be detected with the RT-qPCR technique employed in the study. Despite this, the 
expression detected from both extraction methods were not always comparable and varied 
between samples and volunteers. The results obtained do however suggest that the use of 
the DNA extraction protocol is likely to provide the most reliable and robust method for the 
extraction of miRNA from tissue samples. The difference in capabilities of the kits could be 
due to the length of the miRNA, the difference of one nucleotide could mean the difference 
of adhering to the silica membrane or being removed with the wash buffers. The buffers 
within each kit may also have an effect on the binding of the miRNA to the silica membranes.  
 Conclusion 
The work presented within this chapter has identified a panel of endogenous controls 
suitable for the validation of BFID from vaginal material within case work. The previous 
chapter showed that these markers were expressed across all body fluid types and the 
results here confirm that the expression from these markers is not influenced by the 
complexities of the menstrual cycle.   
In a similar manner, vaginal material marker hsa-mir-124 was also confirmed as robust 
marker for this body fluid. This marker is therefore a key marker for any multiplex screening 
for the detection of the presence or absence of vaginal material within a sample. In 
particular, hsa-mir-144-5 used in combination with 124 would form a robust and 
reproducible method for discriminating between menstrual and venous blood. In addition, 
this marker is also the basis for the discrimination of hsa-mir-205 and 203a expression 
associated with saliva and vaginal secretions.   
One of the three miRNA markers, hsa-mir-135a showed promise as a semen marker, 
detecting an instance of UPSI within one of the samples. All the proposed semen markers 
appear to be to some extent expressed in vaginal secretions which leads to complications 
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when high concentrations of template are used. Therefore, the next chapter will look to 
determine whether expression of these markers can be detected when input template 
concentration is optimised.  
Finally, this study represents a comprehensive comparison of miRNA expression extracted 
from DNA and RNA extractions protocols. Although both methods were successful at 
determining expression, it would appear that DNA extraction protocols provided the most 
consistent data. This suggests that previously extracted DNA from past cases are likely to 
contain miRNA that could be used within these techniques if required.   
 Summary 
 Total DNA extraction has shown to be more reliable and predictable than RNA 
extraction 
 Vaginal material marker hsa-mir-124 is regulated at a consistent level throughout 
the entire menstrual cycle and is therefore an ideal candidate for vaginal material 
identification. 
 Markers highly expressed in vaginal material during screening displayed high 
expression in all samples, with no significant difference (P<0.001) across days. 
 Markers that showed absent expression in low template DNA vaginal material 
samples displayed high expression in some samples indicating many of the selected 
miRNA may be present within vaginal material.  
 Further dilution of samples is required to reduce the non-vaginal specific miRNA 
present in vaginal material beyond LOD.  
 Expression of hsa-mir-205 appears to be upregulated in volunteers using 
contraception methods compared to those on no form of contraception. 
 hsa-mir-144-5 is not specific to venous blood as ltDNA screening suggested but is 
highly specific to blood; expression was only seen throughout menstruation in all 
volunteers.   
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 When analysing sexual assault samples involving vaginal material, it would be highly 
beneficial for medical examiners to record any current form of contraception being 
taken.  
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7. Detection of 
Semen Markers 
within Vaginal 
Material Following 
Unprotected Sexual 
Intercourse 
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  Rationale 
The previous two results chapters have indicated that miRNA markers are capable of 
distinguishing between vaginal material, menstrual blood, venous blood, semen/ seminal 
fluid and saliva from varying sample types. The identification of robust endogenous 
controls has also allowed this to be carried out in a validated manner. The results of chapter 
6 identified semen and seminal fluid specific markers which were, at nucleic acid 
concentrations of 5ng/μl also expressed within extracts from vaginal material samples. The 
human body is capable of making complex body fluids consisting of a number of 
components. The commonality of these components (for instance RBC in venous blood and 
menstrual blood) means that as well as miRNA being specific to a body fluid, a body fluid 
may be characterised by the proportion of each miRNA. 
Where ltDNA samples are involved, the ability to detect proposed semen markers in vaginal 
material is removed or diminished (Chapter 5). Therefore, their detection in ltDNA samples 
would require the introduction of additional miRNA from a secondary source, i.e. the 
ejaculation of semen/seminal fluid into the vagina. This was observed in vaginal material 
and menstrual blood were UPSI had occurred within 48 hours and in one of the cases of 
UPSI within the 31-day study (Chapter 5 and 6), where expression of marker has-mir-10a 
was observed. Expression of this marker was not detected in the subsequent samples 
provided, raising the question as to the ability of the miRNA to be detected in the time 
following a penetrative sexual assault taking place. Many sexual assaults are not reported 
immediately, the longer reporting takes the higher the likelihood semen will not be 
identified.  
Crime scene stains involving sexual assaults will likely contain multiple body fluids, data 
presented within the previous chapters suggest that swabs obtained from victim 
examination would consist of a small genetic material contribution from semen which is 
overwhelmed by the genetic material form the vaginal material contribution. Techniques 
for BFID must therefore be detectable not only in a 1:1 ratio mixture but mixtures where 
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vaginal material is the majority contributor. Semen identification must also be made in 
multiple body fluid mixtures in varying mixing ratios. 
When samples from sexual assault cases enter a forensic laboratory, they are logged as 
‘major crime samples’ and are processed by specialist examiners. Currently, the only aim 
within this forensic process is to obtain as much male DNA as possible from the 
spermatozoa to produce a full DNA profile. To ensure this, an alternative extraction 
technique is utilised to the total DNA extraction of ‘scene of crime’ samples. Samples are 
extracted in two stages; first DNA from vaginal and epithelial cells is obtained followed by 
the elution of the DNA from semen cells by the addition of DTT. The hostile nature of DTT is 
ideal for breaking open the head of a spermatozoa however it could be detrimental to 
miRNA that are present. As such, the comparison of RT-qPCR data from a total DNA 
extraction and the same protocol with the addition of a DTT step must be made.  Semen 
markers were also highly detected in seminal fluid samples, suggesting these markers are 
present outside the spermatozoa and thus would be eluted with the vaginal fraction. 
Allowing the possibility of BFID to be performed on the vaginal fraction and DNA profiling 
on the semen elution treated with DTT.  
The aim of this section of work was to determine the ability of the miRNA RT-qPCR 
technique to identify semen and seminal fluid within vaginal samples following the ‘major 
crime’ extraction methods and compare them with standard total DNA extraction. The 
semen markers selected from screening were also analysed to determine if they could 
positively identify semen in a situation where natural mixing ratios would occur, what 
duration of time expression could still be detected and which of the various extraction 
techniques with or without the addition of DTT utilised in a forensic laboratory are the most 
efficient at miRNA extraction.   
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 Experimental Design 
Five females ranging from 22 – 28 years old currently engaging in regular UPSI volunteered 
for this study. Spermatozoa survival within the vagina can range from hours to days 
dependent on various conditions, if the spermatozoa do not travel to the cervix the acidic 
conditions within the vaginal canal make survival impossible, dependant on ovulation the 
cervix can secrete a more fertile mucus and therefore provide a less hostile environment 
allowing semen to survive up to 5 days [232]. Lutz Roewer assessed the ability to perform 
Y-STR analysis on vaginal material and semen mixtures and his results showed profiling 
could be successful 2–8 days after sexual assault [233]. This study shows a large range in the 
detectability of spermatazoa and is likely due to the variation of spermatazoa levels of 
individual males. Volunteers were therefore asked to abstain from sexual intercourse for a 
minimum of 7 days prior to initial sampling and the subsequent 4 days of sampling.  
During a SARC examination external, high/cervical and LVS will be taken, with semen 
expectation on the high/cervical swabs. As previously described for the comfort of 
participants and to maintain the same sampling technique throughout participants were 
asked to provide LVS swabs. LVS Control samples were obtained prior to UPSI, followed by 
two LVS samples at pre-determined time intervals (0 minutes, 20 minutes, 24 hours, 48 
hours and 96 hours). These time points were chosen so results could be comparable with 
currently available literature and so the initial movements of semen within the vagina could 
be further researched. Sample information can be seen in table 7.1.  The presence of semen 
obtained from the male participants within this study was assessed using a self-collected 
reference sample (unless previously provided in screening study) and underwent H&E 
staining.  
 
 
 
 
 
 
224 | P a g e  
 
 
 
 
Table 7.1: Samples information of UPSI volunteers, including contraception, days without UPSI and OI, and if samples were 
provided for previous studies. 
Due to the expression of the semen marker observed within vaginal material samples at 
concentrations of 5ng/μl, a lower concentration was used for this study. A LOD of hsa-mir-
888 within vaginal material displayed expression in some samples at 5ng/μl, supporting the 
fluctuating expression pattern seen over 31 days, absence of expression at 0.5ng/μl 
indicated that the threshold fell between these points (appendix G). The reference samples 
that would be obtained from the SARC kit would have a high concentration of genetic 
material therefore ltDNA analysis would not be required. Due to ltDNA analysis displaying 
no expression in vaginal material but difficulties in identification in >24 hours samples an 
increased concentration of 2ng/μl was set. Control samples were analysed for expression of 
semen markers, if this concentration showed expression a further dilution to 1ng/μl would 
have been applied.  
Six semen, vaginal material and venous blood samples were selected for comparative 
analysis of miRNA expression in total DNA extraction with and without the addition of DTT. 
All vaginal material, venous blood and semen samples underwent extraction following total 
DNA protocol (4.4.1)4. An additional extraction on each semen sample was performed 
                                                          
4 The normalisation followed by RT-qPCR of samples within the DTT vs no DTT experiment was carried out under my strict 
supervision by project student Ellis Fletcher-Heeley. Conception, development and all analysis was carried out by myself. 
 Age Days prior 
to UPSI 
Contraception Key information 
Volunteer 1 28 7 days Implant 
V2 – Screening study 
V1 – Menstrual cycle validation 
Oral intercourse occurred 
Volunteer 2 26 + 7 days Contraceptive Pill V 29 – Screening study 
Oral intercourse occurred 
Volunteer 3 22 + 14 days IUD (no hormones) V 28 – Screening study 
Volunteer 4 23 + 7 days Contraceptive Pill 
V22– Screening study 
Menstrual cycle started from 24hr swab 
Oral intercourse occurred 
Volunteer 5 24 + 7 days 
Contraceptive 
Injection 
(Depot) 
V 15 – Screening study 
V3 – Menstrual cycle validation 
Oral intercourse occurred 
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following total DNA protocol with DTT (4.13.3). Once normalised both semen samples were 
combined with vaginal material and venous blood over specific mixing ratios to create 
equivalent sample mixtures, the only differentiating factor being the presence of DTT.  
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 Results  
7.3.1. Identification of Background Expression of Specific 
Markers. 
Expression of endogenous control SNORD47 and proposed semen/seminal fluid markers 
hsa-mir-10a, 135a and 888 can be seen in Figure 7.1. As with previous chapters in the study, 
strong expression of SNORD47 was observed. Expression of hsa-mir-10a was absent in all 
samples except for one outlier displaying weak expression. The upper limit of expression 
from both hsa-mir-135a and hsa-mir-888 also displayed weak expression. As per the 40-
cycle cut off threshold outlined in 4.11, Δ1Cq expression values below 10 would not be 
included in analysis and therefore the background values for all proposed semen markers 
display an absence of expression.  
 
Figure 7.1: Δ1Cq values of expression of endogenous control and semen markers within vaginal material samples before 
UPSI occurred. The top and bottom of the box indicate the upper and lower quartiles with the median being represented 
by the central black line. Whiskers display the minimum and maximum values excluding outliers which are identified by a 
black diamond showing results lying 1.5x of the interquartile range. Dotted line indicates threshold for inclusion in 
analysis. 
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7.3.2. Identification of Proposed Semen Markers within 
Vaginal Material Samples across Various Extraction 
Methods.  
Δ1Cq values for expression of proposed semen markers hsa-mir-10a, 135a and 888 as well 
as endogenous control SNORD 47 utilising total DNA extraction can be seen in Figure 7.2 
and 7.3 (Purple boxes). Marker hsa-mir-888 (A) and SNORD 47 (B) displayed strong uniform 
expression values (>16.1) across all time points and all volunteers following UPSI. Marker 
hsa-mir-135a (C) displayed stable high expression across all time points with the exception 
of V2 showing weak expression at T48. Marker hsa-mir-10a (D) displayed moderate to high 
expression in all samples at T0, T24 and T96, except for V4 at T24 that displayed no expression.  
Expression ranged from weak to high across samples in T20 and was only high in one samples 
at T48. 
Expression of hsa-mir-888 (A) within vaginal elution (green boxes) displayed moderate 
expression (13.5-19.5) across all time points and all volunteers following UPSI. Fluctuation 
of SNORD 47 median expression was seen across all time points (B). No sample within T0 
displayed expression that surpassed 5.2. Expression was seen in all samples within T20 
however only V1 and V3 surpassed the cycle threshold for positive expression while T24 
exhibited strong expression in all but V4. Expression values were high within T48 with the 
exception of V2 which displayed moderately weak expression, this was replicated within T96 
with the moderately weak expression seen in V1.  
The majority of vaginal extraction samples showed strong expression of hsa-mir-135a (C) at 
T0, with only V4 falling below 10. Expression was similar within T20 with an additional 
decrease in expression seen from V5. Moderate to high expression was only seen in sample 
V2 at T24 and V2 and V3 at T96 in remaining time points. High expression of hsa-mir-10a (D) 
was seen in 4 samples across all times points; V1 T0, V2 T20, V3 T20 and V4 T96, all other Δ1Cq 
fell below 10 or were 0.  
The seminal elution (blue boxes) displayed strong expression of hsa-mir-888 (A) in all but 
one sample at T0.  At T20 3 samples display no expression while 2 samples displayed strong 
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Δ1Cq values.   At T24 all but one samples showed expression values within the moderate to 
strong range, V4 displayed weak expression that did not surpass the cycle threshold.  4 of 
the 5 T48 showed positive expression however much weaker than previous time points, with 
V4 displaying no expression. Only one sample (V1) at T96 showed strong positive expression 
while all others displayed weak Δ1Cq values below. Overall the Δ1Cq values in seminal 
extraction across all time points were lower than those seen in total DNA and vaginal 
extraction.  
Within the seminal fraction 2 of the 5 samples displayed weak to absent expression of 
SNORD 47 at T0 (B). Except for V3 at T24, all expression values across T20 and T24 fell below 5. 
At T48 V3 was the only samples to not display moderate to high expression, within T96 
expression fluctuated from absent to high across all samples. Expression of hsa-mir-135a (C) 
was only seen in V1 and V2 at T0. V1 at T20 was the only sample from the subsequent time 
points that displayed moderate expression, all other Δ1Cq values were below 9. No sample 
displayed moderate or high expression of hsa-mir-10a (D) at T0, expression was marginally 
higher but similar at T20, T24 and T48 with 3 of 5 samples lying on the 10 Δ1Cq cycle threshold 
but none exceeding it.   At T96 V4 displayed strong expression whereas in all other samples, 
weak or absent expression was observed 
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Figure 7.2:Δ1Cq values for markers hsa-mir-888 (A) and endogenous control SNORD 47 (B) within UPSI samples across various time points using 
different extraction methods. The top and bottom of the box indicate the upper and lower quartiles with the median being represented by the 
central black line. Whiskers display the minimum and maximum values excluding outliers (identified by a black diamond and show results lying 
1.5x outside the interquartile range’. Dotted line indicates threshold for inclusion in analysis. 
Semen marker hsa-mir-888
Endogenous control SNORD 47
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Figure 7.3: Δ1Cq values for markers hsa-mir-135a (C) and hsa-mir-10a (D) within UPSI samples across various time points using different 
extraction methods. The top and bottom of the box indicate the upper and lower quartiles with the median being represented by the 
central black line. Whiskers display minimum and maximum values excluding outliers (identified by a black diamond and show results 
lying 1.5x outside the interquartile range). Dotted line indicates threshold for inclusion in analysis. 
Semen marker hsa-mir-10a
Semen marker hsa-mir-135a
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7.3.3. DTT Addition to Total DNA Extraction. 
The addition of DTT to semen samples had a detrimental effect on the expression of hsa-
mir-10a in all samples (Figure 7.4). Δ1Cq values were significantly lower than equivalent 
samples without DTT (P<0.001). No sample displayed a Δ1Cq value corresponding to strong 
expression and the majority of samples showed a complete absence of hsa-mir10a 
regardless of mixing ratio. Without DTT Δ1Cq values of hsa-mir-10a were uniformly high 
within all samples, regardless of mixing ratio or additional body fluid presence.  
 
 
Figure 7.4 Δ1Cq values of hsa-mir-10a across various mixing ratios in samples with and without DTT. N= 6 (P<0.001). All 
normalised at 1ng/μl. Dotted line indicates threshold for inclusion in analysis. 
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DTT had a less detrimental effect on the expression of hsa-mir-888 compared to has-mir-
10a in all semen samples (Figure 7.5). All Δ1Cq values were lower than equivalent samples 
without DTT with the largest variation being 5 cycles at a 2:1:1 of vaginal material: semen: 
venous blood. Significantly higher expression was observed in a number of samples 
without DTT (p<0.01-0.001) however this did not correlate to a pattern dependant on which 
was the higher ratio body fluid. All samples, regardless of addition of DTT or mixing ratio 
displayed positive reliable Δ1Cq values corresponding to moderate to high expression.  
 
 
Figure 7.5: Δ1Cq values of hsa-mir-888 across various mixing ratios of vaginal material, semen and venous blood in samples 
with and without DTT. N= 6, (p<0.001). – All normalised at 1ng/μl. Dotted line indicates threshold for inclusion in analysis. 
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7.3.4. Discussion 
The minimal expression of hsa-mir-10a, 135a and 888 in controls samples indicate that these 
markers, at concentrations of 2ng/μl or below, will not display a false positive when 
analysed on vaginal material that is absent of semen. Control samples were obtained from 
volunteers abstaining from UPSI for a minimum of 7 days before initial sampling, due to 
control samples indicating no positive identification for semen it can suggested that BFID 
would likely be unsuccessful if samples were obtained 7 days after a sexual assault occurred.  
Markers hsa-mir-888 and 135a showed consistent expression across all time points from 
total DNA extracted samples, reliably identifying semen presence within a vaginal material 
mixture. In cases where sexual assaults have occurred and samples are known to contain 
vaginal material and suspected semen, total DNA extraction will provide reliable 
identification of semen up to 96 hours after UPSI occurred. An increased expression of hsa-
mir-10a was also observed compared to background expression, however variability in 
expression was detected across time points. This may raise potential concerns with regards 
to its reliability as a semen identification marker. The use of all three markers within a 
combined BFID panel would be necessary to provide the robustness required within 
casework.   
The differential extraction technique currently utilised for major crime samples does not 
show reliable and reproducible results for BFID using miRNA. Positive identifications were 
made; however, the number of false negatives were greater in number. If BFID were utilised 
on differential extraction samples a positive result would be confirmatory however a 
negative result would support neither prosecution nor defence. Within the vaginal and 
seminal fractions SNORD 47 did not display stable high expression across all samples and 
therefore full analysis could not be performed using this endogenous control, 
compromising the validatory nature of this marker. 
The addition of DTT proved to have a negative effect on the expression of miRNA within the 
seminal fraction and from total DNA extraction utilising DTT. Analysis with hsa-mir-10a in 
total DNA extracted samples displayed similar expression patterns to the seminal fraction 
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of standard differential extraction. When expression from total DNA extraction with DTT was 
observed it was at least 6 cycles after expression within the same sample mixture without 
DTT, an approximate 64-fold reduction. No Δ1Cq values within the strong expression 
classification were observed and the majority of samples displayed no expression at all. 
Expression of hsa-mir-888 was detected in all mixing ratios thus indicating the presence of 
semen, however on average expression was observed at least 3.5 cycles after their 
counterpart samples without DTT. This would indicate an approximate 10-fold reduction in 
the volume of miRNA present with samples treated with DTT. Since previous results have 
already determined hsa-mir-888 dual expression in vaginal material it could be suggested 
a proportion of the expression observed came from vaginal material and the true effect of 
DTT is not reflected.  
The addition of DTT allows for higher yields of DNA which are subsequently used for DNA 
profiling, within this study samples that were extracted using the total DNA extraction 
method typically had a DNA concentration of 1.5ng/μl, the same samples when treated with 
DTT yielded around 45ng/μl. Since normalisation was based on DNA concentration it could 
be suggested that the large dilution factor applied to the seminal fraction of differential 
extraction and the DTT DNA extraction reduced the miRNA abundance to below LOD. A 
possible solution would be to perform analysis on undiluted semen fractions. Due to the 
strong consistent expression of the semen markers in vaginal material following total DNA 
extraction and the unreliable and weak expression observed with DTT, it can be concluded 
its addition into BFID techniques should be avoided. Forensic examiners then have the 
problem of the requirement of DTT and therefore differential extraction to increase DNA 
concentration for successful profiling and the need for a lack of DTT to ensure miRNA are 
preserved for BFID analysis. 
Two solutions could be proposed; removing an aliquot of the differential extraction after 
agitation before undergoing vaginal and seminal protocols, as seen in Figure 7.6, or an 
additional swab being taken within the hospital or SARC unit during the victim’s sexual 
assault examination. 
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Figure 7.6: proposed additional workflow stage for differential extraction. 
The advantage to removal of an aliquot of eluate would be that free circulating miRNA could 
be analysed without risk of damage from cell lysis. The disadvantage would be that due to 
lack of cell lysis it would be unlikely to obtain expression values of miRNA being regulated 
within the body fluid’s cells.  
An additional examination swab would allow for a swab to follow the usual route of 
differential extraction for ‘major crime’ samples and the other the standard total DNA 
protocol of ‘scene of crime samples’. Once extracted the samples would then fall back into 
the regular workflow of analysis utilising RT-qPCR. This has the advantage of providing a 
more reliable miRNA expression analysis as well as providing the best sample for DNA 
profiling. The requirement for BFID would be case dependant and therefore the additional 
swab could be stored to avoid the cost of additional extraction until the requirement for 
BFID occurs, as well as providing a back-up sample if the original became contaminated. If 
the sample has already undergone total DNA extraction the semen concentration may be 
low but provides an additional route for analysis. If BFID is not needed it would allow for an 
additional differential extraction to occur. The disadvantages of this solution include 
additional stress and examination time of the victim as well as the additional cost and man 
power of processing the same samples over two extraction methods. 
In comparison to current literature, the results from total DNA extraction showed positive 
identification could be made from all participants at 96 hours, this is a great improvement 
on Davies work which showed frequent negative results at 96 hours [116]. Wilsons work did 
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display positive results up to 10 day which would support this results however not all 
samples displayed positive results showing a higher level of successful identification using 
miRNA and RT-qPCR. 
Overall all samples from differential extraction displayed variability across volunteers and 
time points in all markers, including endogenous control, suggesting it is not a reliable and 
robust technique for BFID. Despite this, the method developed here utilising total DNA 
extraction has reliably identified the presence of semen with at least two markers 
throughout every time point for each volunteer. Sample mixtures from total DNA extraction 
also successfully identified semen presence regardless of large volumes of genetic material 
from vaginal material and additional body fluids. This technique has the potential for the 
identification of sexual assaults where the assailant may not leave a DNA profile (i.e. those 
with azoospermia) and could potentially be applied to cold case work provided a) DNA 
extraction was carried out and b) the extraction occurred within 96 hours of the assault.  
 Conclusion 
The work presented in this chapter shows that there is potential for miRNA based BFID 
techniques to be employed within casework. The markers currently available for the 
identification of semen and seminal fluid are also expressed within vaginal material, and 
therefore the identification is reliant on analysis being performed on samples below their 
LOD in vaginal material. Overall total DNA extraction provided the most reliable 
identification of semen, regardless of duration after UPSI (up to 96 hours) and presence of 
menstrual blood. Considering all three markers would be used, with the requirement of at 
least two displaying high expression values for semen identification, positive identifications 
were made across all time points using total DNA extraction. 
Total DNA extraction has demonstrated its potential for cold case BFID. In current literature 
studies have shown that miRNA show little change in stability when stored up to five years 
[173-175] therefore it is likely these body fluid markers would also be highly expressed. 
Dependant on the body fluids involved, the identification of body fluid in cold case samples 
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is also achievable with differential extraction: All body fluids not relating to semen could be 
identified in the vaginal fraction, with a reduced likelihood of identifying semen within 
either vaginal or seminal fractions. Over most of the times points at least one semen marker 
showed expression, it was not observed within the same volunteer at each time point 
therefore it is likely expression identifying seminal presence will be observed, although it 
may not provide robust evidence in a court of law. The successful identification of semen 
markers within UPSI samples coupled with the high expression in all constructed various 
ratio mixtures demonstrates the ability of this BFID technique for semen identification in 
forensic case work. 
Overall, the miRNA BFID technique is not compatible with the DTT extraction method 
currently applied to ‘major crime’ samples. Throughout both extraction methods DTT 
appears to play a role in the degradation of miRNAs, resulting in the observation of 
unreliable expression, in particular of the endogenous control markers used to validate the 
technique. The result being unreliable evidence in a court of law. In conclusion, the method 
could be implemented to casework, but does not demonstrate the potential to transition 
directly into the methods currently used within forensic laboratories for analysis of sexual 
assault samples.  
 Summary 
 Currently semen identification by miRNA analysis would not be reliable on major 
crime samples that enter forensic laboratories and undergo differential extraction. 
Analysis can be performed and if expression is seen a positive identification can be 
made however if absent the presence or absence of semen cannot be confirmed.  
 Dilution of the seminal fraction may have caused the lack of semen marker 
expression. Within these samples the DNA is unlikely to be proportional with miRNA 
and therefore heavy dilution may have reduced miRNA presence past the LOD.  
 A concentration of 2ng/μl is more likely to correctly identify semen in samples 
greater than 24hr following UPSI than concentrations of 0.7ng/μl 
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 BFID on cold cases could be achieved from samples that have undergone differential 
extraction. This capability would be body fluid dependant with the likelihood of 
semen identification being reduced. 
 The most suitable method for BFID identification is total DNA extraction which 
resulted in identification of semen in all semen samples, across all time points. This 
was also observed when combined with additional mixtures of venous blood and 
menstrual blood.   
 DTT is very detrimental to miRNA, regardless of extraction technique. Although 
beneficial for DNA profiling it should be avoided within BFID techniques.  
 To utilise total DNA extraction a subsequent swab would be required. This would 
ensure the maximum chance for a full male DNA profile to be obtained through 
differential extraction and BFID to be successful through total DNA extraction.  
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8. Discussion 
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Incidences of sexual assault are serious offences which are likely to cause a significant 
amount of stress to a victim and in the case of false allegations, someone who is accused of 
carrying out such and offence [39-41, 73]. Determining the exact events surrounding a 
sexual assault claim is a near impossible task, however it is the role of the forensic scientist 
to remove doubt and provide evidence that may support claims made by both parties. The 
determination of the presence/absence of a body fluid within a crime scene is often a key 
piece of evidence of any case [116]. The identification of semen or seminal fluid on a victim, 
or the presence of vaginal material on a penile swab may be key to determining whether 
penetrative sexual intercourse occurred. The ability to detect saliva and skin may also 
indicate the type of sexual offence committed, and where bleeding occurs the 
differentiation between menstrual and venous blood may add significant weight to the 
defence or prosecution hypothesis. 
There are currently many techniques employed to provide presumptive tests for a number 
of these body fluids comprising of catalytic [113, 114], immunological [118, 119] and 
spectroscopic techniques [116]. DNA profiling is one of the most well-known techniques for 
the identification of individuals involved a crime scene, frequently being the only 
identification evidence presented in the courts [234].  DNA profiling can now be 
complemented with a number of emerging molecular biology techniques. The research 
carried out within this body of work utilised miRNA as a potential route to body fluid 
identification. MicroRNA are non-coding RNA molecules which regulate gene expression, 
by controlling the translation and repression of RNA [151, 158, 159]. Since translation and 
repression profiles of genes within cells associated with body fluids are likely to be unique, 
miRNA represent a novel method for the discrimination between body fluid types.  
The use of miRNA is an emerging technique, in that a number of authors have already 
explored the possibility of using this technique for body fluid identification, with varying 
and often contradictory findings. It was therefore important within the initial sections of this 
work to validate the RT-qPCR technique; not only as a methodology, but to provide 
comparisons with current literature and place the research within current case work. The 
preliminary findings within Chapter 5 showed that the RT-qPCR technique could be 
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validated not only through the use of negative controls, but also through the identification 
of endogenous controls. In this case, the endogenous controls were miRNA markers which 
were present universally across cell types.  
 Total DNA extraction coupled with stem-loop RT-
qPCR as a robust and efficient method for body fluid 
identification 
Two important considerations for a technique to be integrated into case work is that of time, 
and cost. The current cost for a single tube TaqMan® gene expression assay from Thermo 
Fisher Scientific is £2305 for 200 reactions [235]. For BFID analysis, the full marker panel 
would be required to confirm absence and presence of miRNA. The need for a minimum of 
one assay, particularly where a casework sample may not require a full complement of BFID, 
means the technique could become unnecessarily expensive. The BFID matrix was 
therefore redesigned to incorporate custom designed assays to minimise costs using 
alternative suppliers (for example: Eurofins Oligonucleotide design: £6.95 forward primer, 
£6.95 reverse primer, £15.95 reverse transcription primer [236]1).   
In current literature extraction techniques involve RNA isolation techniques and protocols 
regularly utilising reagents such as guanidine isothiocyanate-phenol/chloroform followed 
by precipitation by isopropanol [179], with only Omelia et al. displaying efficient miRNA 
extraction with Qiagen’s total DNA protocol [190]. The majority of protocols were followed 
with DNA digestion to ensure pure miRNA was eluted. All data from Chapter 5, 6 and 7 
shows that total DNA extraction is the more reliable miRNA extraction method compared 
with RNA and differential extraction. The efficiency of miRNA expression analysis 
throughout this research also suggests that DNA digestion is not a vital component of 
miRNA analysis and can therefore be removed to reduce costing, timing and work-load 
within the laboratory.  
                                                          
5 Prices correct as of 01/11/16 
 
 
 
242 | P a g e  
 
 
 
The data generated within Chapter 5 showed that RT-qPCR could be used with the custom 
designed assays for detecting miRNA expression. The assays could be used on undiluted 
samples obtained from DNA extractions to obtain positive identification of body fluids, 
however, dilution of the samples increased the body fluid specificity and reliability of miRNA 
detection. For current DNA profiling protocols the concentration for required template DNA 
would be 0.03ng/μl (LGC [226]) and 0.1ng/μl (Cellmark [227]). Both concentrations are 
below the tested 0.7ng/μl however LOD results indicate BFID would be successful with 
AmpFlSTR® NGM SElect™ but may be unsuccessful with Promega’s PowerPlex® ESI 17. The 
solution would be to perform a duplicate sample dilution to 0.75ng/μl, a time-consuming 
process or to increase the total sample input into the stem-loop RT reaction. The improved 
resolution of identification following dilution alongside the requirement to these levels for 
DNA profiling allows for implementation into current laboratory protocols.  
The use of the same DNA extract as these techniques as a stem loop RT-qPCR template 
means that no additional time or cost is required, with the time of reaction set-up to a result 
(when optimized) is under 3 hours. In addition, the results of Chapter 6 also identified that 
the isolation of miRNA could also be achieved using RNA extraction protocols, obtaining 
expression profiles that were comparable to DNA extraction methods. Within the study, we 
were unable to identify a marker for skin, despite previous studies suggesting that this was 
possible [183, 199]. Despite this, the data obtained within this chapter showed that a 
combination of markers could be utilised for correct identification of a number of single 
body fluid stains within a sample (Figure 8.1). 
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Figure 8.1: flow chart for the Identification of a full range of body fluids. For forensic application each marker would require 
a strict pass criteria, with thresholds for each marker and EC’s Cq value. This would be determined by the various forensic 
bodies and criminal institutes.  
Marker hsa-mir-124 presented itself as one of the key discriminatory markers within this 
technique. Previous research has shown that this marker is present in a number of tissue 
types, including the colon, breast, and lung [237], with Wilting et al. identifying its regulation 
within those affected by cervical cancer [180]. Wilting suggested that hsa-mir-124 was 
suppressed in cervical cancer cells. V8 provided vaginal and menstrual samples with partial 
removal of cervix due to stage 1A cervical cancer provided in her information. They were 
currently diagnosed with stage 2 cervical dysplasia, although these cells are not cancerous 
they are considered pre-cancerous and are closely monitored. It would therefore be 
expected that V8’s samples would show weak or absent repression of hsa-mir-124a. Both 
samples displayed extremely high Δ1Cq values disagreeing with Wilting’s conclusions and 
further displaying the stability of hsa-mir-124. The data generated here indicates that 
although current research suggests this miRNA may be present within a number of tissue 
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types, its expression is significant within the vagina and associated material. Therefore, 
presence or absence of its expression provides most information as to the origin of a body 
fluid sample or stain.  
The detection of this marker was then employed to confirm the presence of menstrual 
blood using markers hsa-mir-412 and 507. Here, our findings confirmed the findings of 
Hansen et al. that marker hsa-mir-412 could be used for detecting menstrual blood, but with 
the requirement that hsa-mir-124 detection must also be employed. Contrary to the 
findings of Zubakov et al. our findings show that marker hsa-mir-507 was not suitable for 
use as an endogenous control, but could be used for menstrual blood detection. The 
compositional similarities between menstrual and venous blood and associated expression 
of miRNA provided evidence throughout this screening that a number of markers were 
simply capable of detecting ‘blood’. Therefore, it was proposed that these two 
aforementioned markers be utilized for detection of menstrual blood.  
Four other markers (hsa-mir-451, 144-5, 144-3 and 142) were therefore proposed for the 
identification of venous blood. Expression of any two of these markers coupled to an 
absence of marker hsa-mir- 124 could be integrated to achieve this. The abilities of these 
markers to detect the components of blood confirm previous work for the use of hsa-mir-
451 and 142 [238]. In the same way that menstrual and venous blood share similar 
properties, so too do vaginal material and saliva, here the use of markers 203a and 205 were 
capable of distinguishing saliva through the absence of marker hsa-mir-124 expression. 
Interestingly, these markers were also confirmed to be saliva specific by Hason et al. [179] 
and non-saliva specific by Park, Zubakov and Sauer [181, 183, 185]. The detection of hsa-
mir-144-5 and 144-3 contradict the findings of Sauer in that although it was highly present 
in menstrual blood, it displayed no ability to differentiate venous and menstrual blood. 
Again, coupled to the absence of marker hsa-mir-124, semen could be detected using 
markers hsa-mir-888, 135a and 10a, which agrees with the findings of Zubakov, Hanson, 
Sauer and Wang [183-185]. 
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Many sexual assault cases involve the analysis of multiple body fluids, the most common 
being a mixture of semen and vaginal material. The results obtained from this chapter also 
demonstrate that, to an extent these markers when used in combination could be 
implemented to discriminate between the presence of multiple body fluids within mixtures. 
When two body fluids are present within a mixture, the range of detection for these 
mixtures can be seen in Figure 8.2. When three or more body fluids are present within a 
mixture the ability for discrimination becomes more limited (Figure 8.3). Although a large 
combination of multiple body fluids can be identified using this miRNA BFID panel it is 
limited in mixtures involving saliva and vaginal material. Although hsa-mir-124 is only 
expressed in vaginal material, miRNA that display high expression in saliva (hsa-mir-205 and 
203a) often share expression with vaginal material and therefore mixtures containing both 
cannot be confirmed for saliva presence. In these cases, the screening would likely be 
supplemented by non-molecular techniques but would still act as a useful tool within the 
forensic scientist’s arsenal.  
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Figure 8.2: Example flow chart for the identification of a range of body fluids when present in a two body fluid mixture. For forensic application each marker would require a strict pass criteria, with thresholds for 
each marker and EC’s Cq value. This would be determined by the various forensic bodies and criminal institutes.   
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Figure 8.3: Example flow chart for the identification of three body fluid mixtures in crime scene stains. For forensic 
application each marker would require a strict pass criteria, with thresholds for each marker and EC’s Cq value. This would 
be determined by the various forensic bodies and criminal institutes. 
  MicroRNA expression fluctuates across the 
menstrual cycle, with the exception of hsa-mir-124 
The significant physiological changes within the vaginal environment over the course of the 
menstrual cycle mean that expressional change of certain miRNA is certain. Since the 
identification of body fluids using the stem-loop RT-qPCR technique was heavily reliant on 
the detection of expression of hsa-mir-124, it must show consistent expression across the 
menstrual cycle. Although previous research conducted by Rekker et al. identified a panel 
of markers which were expressed within plasma and blood, no expression values for hsa-
 
 
 
248 | P a g e  
 
 
mir-124 were obtained and only two sampling points throughout the entire cycle were 
taken [239]. Therefore, the results described in Chapter 6 are the first to provide a 
comprehensive description of expression profiles across the full menstrual cycle of a range 
of miRNA markers, including hsa-mir-124.  
The expression of this marker was relatively consistent across the full menstrual cycle 
regardless of the extrinsic factors associated with each volunteer (age, contraception, 
pregnancy etc.). Where changes in expression occurred, the data showed the importance 
of endogenous control selection. With SNORD47 and hsa-mir-93, the expression of these 
markers correlated with that of marker hsa-mir-124, revealing where sample consistency 
fluctuated most likely as a result of a poor sampling technique or loss of sample integrity on 
collection. The other candidate endogenous control markers hsa-mir-508 and hsa-mir-
1260b did not demonstrate this fluctuation, most likely as a result of the high abundance of 
miRNA within the original sample.  
The results obtained show that the use of multiple endogenous controls is key to ensuring 
the robustness of these test methods. Here, four markers were identified (hsa-mir-508, hsa-
mir-1260b SNORD47 and hsa-mir-93). Within the literature, only markers SNORD 47 [196] 
and hsa-mir-93 [197] have been described as suitable endogenous controls, where hsa-mir-
508 has been described as specific to semen [187] and hsa-mir-1260b as specific to vaginal 
material [181, 183].  
The results obtained within Chapter 5 and 6 also confirmed that a number of markers (hsa-
mir-203a, 507, 508, 205, 142) were expressed within both vaginal material as well as their 
candidate body fluid. These findings further reinforced the role of marker hsa-mir-124 in 
confirming the absence of vaginal material from samples to provide the correct 
identification of body fluids from stains. Marker hsa-mir-144-5 however showed robust 
specificity for blood, with no expression observed in volunteers who did not menstruate, 
with no background expression associated with vaginal material. The data also suggest a 
potential limitation to the RT-qPCR technique when samples originate from the vagina. The 
differentiation of venous and menstrual blood would not be possible since marker hsa-mir-
124 expression will always be detected; for menstrual blood to be confirmed hsa-mir-412 
and 507 must be present in the sample but absent in a reference sample of vaginal fluid. 
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The technique however, does still have significant potential in the identification of body 
fluids from stains.    
 The Technique is capable of detecting instances of 
UPSI from vaginal swabs up to 96 hours after penetration 
following standard DNA extraction. 
The time from a sexual assault taking place to being reported to the relevant authority can 
vary considerably. In cases where non-consensual unprotected vaginal intercourse is being 
alleged, which in itself can increase a sentence following conviction from lesser sexual 
assault to rape [4], providing evidence to support or disprove these allegations is critical. 
The results obtained within the 31-day study (Chapter 6) demonstrated that the detection 
of the occurrence of UPSI could be possible. The results obtained here also suggested that 
these markers were also expressed in vaginal material, but could only be detected when 
template concentration was high. The initial results of Chapter 7 demonstrated that when 
the initial template concentration used in the technique was reduced, that the presence of 
these markers were well below threshold up to seven days prior to an instance of UPSI. As a 
result, the increased detection of these markers would have to be as a result of the 
introduction of material containing these markers (i.e. the ejaculation of semen).  
Stem loop RT-qPCR of the miRNA extracted from vaginal swabs immediately after UPSI 
showed a marked increase in the detection of all three markers. In addition, these markers 
could be detected up to 96 hours following UPSI. Previous research has suggested that 
these markers were specific to semen [167-175, 177] and therefore the data generated here 
provide further evidence for this. Importantly, where a male produces no sperm, the 
markers were also capable of detecting the presence of seminal fluid. This provides the 
technique with a significant advantage over current methods, where a DNA profile would 
not be provided and a conviction would not be obtained. 
Currently, the accepted method within casework is that genetic material is obtained 
through the use of differential extraction methodology (described in 4.4.3). Using this 
method, in particular the use of DTT, severely impacted on the integrity of the miRNA 
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present within the sample and most importantly that of the endogenous control. As a result, 
for use within casework, a modification would be required to the extraction process. The 
modification was described within Chapter 7, however, in short, an aliquot of the sample 
would be taken following the initial lysis stage and carried through to a standard DNA 
extraction or an additional swab during examination would be taken for BFID analysis 
following total DNA extraction.  
 The expression of hsa-mir-205 within vaginal 
material is regulated by contraceptive methods 
Conflicting results explaining the specificity of hsa-mir-205 has been observed in current 
literature, even between methods using similar analysis techniques. The results obtained 
from this study suggest a reason for this discordance. All females on some form of 
contraception, be it hormonal or non-hormonal display high expression of hsa-mir-205 in 
vaginal material samples, whereas all samples obtained from females currently not utilising 
a contraceptive method displayed no expression of hsa-mir-205. This was further supported 
in samples obtained where contraceptive methods had been changed. Expression seen 
during screening disappeared throughout all 31-day study samples when the contraceptive 
pill no longer taken, while expression in another volunteer that was absent in initial 
sampling displayed strong expression 7 days prior to commencing the contraceptive pill. 
This expression increased in an additional sample taken two months later. Likely due to hsa-
mir-205 role in the regulation and repair, this regulation over hsa-mir-205 would explain 
why certain research groups, if using hydrolysis probe qPCR obtained dual expression in 
saliva and vaginal material. 
 Applications to case work 
Although the results show that BFID can be carried out using miRNA markers, it is important 
to apply the technique into the perspective of real case work scenarios to give the results 
context. The following examples show how these techniques could be applied to case work.  
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Example 1. Male is accused of sexual assault, states it never occurred/ was consensual. Penile 
swab is taken 
Where a suspect claims no sexual assault took place, the detection of vaginal markers hsa-
mir-124 from a penile swab would indicate that vaginal penetration occurred. DNA profiling 
of the material would indicate if this was a result of the complainant’s material being 
present, eliminating the defence that the intercourse was with someone else. The 
identification of semen would not however be useful if the defence states that intercourse 
was consensual. 
Example 2. Complainant is sexually assaulted by penile penetration, male ejaculates and leaves. 
Defence claims it never occurred.  
As above the identification of hsa-mir-124 from a penile swab would indicate that vaginal 
penetration occurred. The identification of two of the markers hsa-mir-888, 135a and 10a 
from the victim internal intimate swabs would show ejaculations took place, if the suspects 
DNA profile can also be identified this would remove any support for the defence that the 
event didn’t happen. Semen identification would also be reliant on the time since 
intercourse and sampling. 
Example 3. Complainant is sexually assaulted by penile penetration, a vasectomised male 
ejaculates and leaves. Defence claims it never occurred. 
The detection of at least two of the markers hsa-mir-888, 135a and 10a confirms that semen 
is present within the vaginal canal and sexual intercourse occurred. Within Example 1, the 
data could be combined with a DNA profile, providing significant support to the defence. 
With respect to Example 2, these markers have shown a higher expression value in 
vasectomised males, therefore if two or more markers display expression it would confirm 
that sexual intercourse did occur without the need for an additional DNA profile - as long as 
the defendant had not had UPSI with anyone else in the preceding 7 days. Semen 
identification would also be reliant on the time since intercourse and sampling. 
Example 4. Victim claims penile penetrative sexual assault occurred while suspect claims 
consensual oral intercourse was the only act that happened. Vaginal swabs are taken. 
As with examples 2 and 3, the expression of semen markers would indicate that penile 
penetration occurred and therefore provide support to the defence. If a penile swab was 
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taken at the time of the incident, or before the suspect had the opportunity to remove any 
residues (i.e. by washing) then the detection of saliva marker hsa-mir-205 may be possible. 
If the victim had removed any residues then an identification would be extremely unlikely. 
If the female was on no form of contraception, a presence of hsa-mir-205 would identify 
saliva presence (This could be confirmed via absence in a reference swab taken a while after 
the initial examination). Research was however unable to successfully identify OI from 
vaginal samples therefore the additional of an external vaginal swab could be more 
successful at sampling any saliva present. In the instance that semen markers are not 
detected in vaginal swabs, but hsa-mir-205 detection combined with a DNA profile the 
suspect there would be evidence that oral intercourse did in fact take place.   
Example 5. Male is accused of sexual assault. A red stain is visible on the penis and he states 
consensual intercourse occurred while menstruating. 
The use of a combination of markers (hsa-mir-451, 144-5, 144-3 and 142) would confirm that 
the red stain is in fact blood. Failure to detect menstrual blood markers hsa-mir-507 and 412 
would confirm that the blood did not originate from the vagina, which would confirm that 
the blood was as a result of other injuries potentially sustained by the victim. The 
confirmation of menstrual blood is however more difficult to determine. Since hsa-mir-507 
and 412 were weakly displayed in a number of vaginal material samples expression cannot 
be reliably stated as originating from menstrual blood and not vaginal material. A solution 
would be to obtain a reference sample from the victim where no menstruation occurred, 
absence within the reference sample and presence within the crime stain sample would be 
confirmatory of menstrual blood. The aim of this research was to be able to distinguish 
menstrual and venous blood, even when in a mixture. The markers identified within this 
body of work were unable to differentiate these two body fluids when in the same mixture, 
therefore if a trauma caused venous blood to mix with any menstrual blood that may be 
present during the assault it could not be identified.  
Example 6. As per case study 2.1: A murder suspect is found with blood on the passenger seat of 
his car and states it was left after a female menstruated.  
The use of blood markers hsa-mir-451, 144-5, 144-3 and 142 would confirm the presence of 
blood. Ultimately the absence of hsa-mir-124 would confirm the sample did not originate 
 
 
 
253 | P a g e  
 
 
in the vagina with further confirmation from the absence of hsa-mir-412. The incorporation 
of hsa-mir-203a into the panel would also confirm blood origin; the absence of expression 
would only be observed in venous blood. The confirmed blood stain must therefore have 
been a result of an injury potentially sustained by the victim. Reference samples would also 
be required from other areas of the crime scene to ascertain whether any background levels 
of miRNA were present. 
Example 7. Victim is not vaginally penetrated but claims they were forced to receive oral 
intercourse. 
The use of hsa-mir-205 failed to detect the presence of saliva following instances of oral 
intercourse. The robustness of hsa-mir-124 however highlights the potential for buccal 
swabs of suspects to be taken and positive identifications to be made, thus confirming oral 
intercourse had occurred.  This would be strengthened with the addition of DNA profiling.  
Example 8. Victim is non-consensually digitally penetrated. Defence state it did not occur 
The results of this research were unable to identify a skin specific marker. In cases where 
digital penetration occurs, where DNA profiling is likely to be unsuccessful, BFID would 
provide no provide suitable evidence for the defence or prosecution. During digital 
penetration cases usual practise would be to examine the suspect’s fingernail cuttings, as 
seen in R vs Weller [62]. If hsa-mir-124 was identified on these fingernail cuttings it would 
lend a higher level of support to the prosecution that digital penetration occurred, 
especially if a DNA profile could also be obtained.  
Example 9: DNA is found on a male penile swab. Prosecution state the suspect vaginally 
penetrated the victim while the defence states consensual oral intercourse was given.  
Due to the up-regulation of hsa-mir-205 caused by contraceptive methods in vaginal 
material the expression of hsa-mir-205 cannot confirm the present of saliva when vaginal 
material is present. If both hsa-mir-124 and 205 are expressed, saliva presence or absence 
cannot be confirmed. If, however hsa-mir-124 is expressed while hsa-mir-205 is absent it 
would confirm the absence of saliva, confirming vaginal penetration occurred and not oral 
intercourse. In a case where vaginal and oral penetration occurred the body fluid panel 
would be able to identify the presence of vaginal material but not saliva. 
 
 
 
254 | P a g e  
 
 
 Comparisons of miRNA and mRNA for BFID 
Current literature has shown that RT-qPCR can be performed successfully with mRNA and 
miRNA. Comparisons can therefore be made from this body of work and current research. 
The main factors involved in both techniques can be observed in Table 8.1. 
 miRNA mRNA 
Flow in forensic 
casework 
Standard DNA extraction, can be 
used on diluted eluate then moved 
onto RT-qPCR 
Adaption to standard protocol, DNase 
treatment can be used on diluted sample 
then moved onto RT-qPCR 
Sensitivity Equivalent to DNA profiling Equivalent to DNA profiling 
Storage Storage as per standard DNA eluate 
achieving system [172-175] 
-80oC freezer, no long term storage unless 
reverse transcribed immediately [171-172] 
* 
Cold case capability Potential on total DNA extraction, 
limited with differential extraction 
[172-173] 
No cold case capability as the eluate 
removed during standard protocol is not 
performed during standard extraction 
[171-172] 
Contamination by 
gDNA 
Stem loop primers are not affected 
by gDNA contamination therefore 
will not produce false positives 
gDNA contamination must be removed, 
treatment with DNase 
Cost per reaction With custom primers very low With custom primers very low (additional 
expense being DNase) 
Primer design Forward, stem loop primer with 
universal reverse and probe site 
Forward and reverse and probe site 
Extraction Total DNA, Total RNA Total RNA 
Degradation of 
crime scene samples 
Highly stable [172-175] Many factors affect degradation, 
dependent on length of mRNA and 
environmental factors [171-172] 
Marker abundance Still in validation Many markers that have been verified by 
multiple laboratories for reproducibility* 
BFID capability Most body fluids with many 
combinations unable to identify 
Full marker panel current being used in 
case-work (still an issue with saliva)* 
EC Still contested in literature however 
many have been found to be stable 
and suitable 
Multiple confirmed EC’s selected and 
available – currently being used in 
casework* 
Quantification Non-specific, new technology, quant 
value for all miRNA present 
UV-VIS spectroscopy –purity and yield, can 
test integrity with gel or bio analyser 
Specificity Likely to code for multiple mRNAs Longer sequence so likely to be more 
specific 
Ideal usage Potential for degraded sample/ old 
samples/ archived DNA samples/ low 
and abundant samples [172-175] 
Abundant fresh samples, degraded 
samples can be difficult and may alter 
cDNA primer choice (e.g. Random or Oligo 
dT) [171] 
 
Table 8.1: List of conditions and factors for RT-qPCR analysis with equivalent advantages and disadvantages for each 
technique. *Information obtained from senior forensic scientist Tim Clayton who supervises and carries out mRNA BFID.  
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Overall both miRNA and mRNA have factors that make then ideal for use in RT-qPCR BFID. 
Although mRNA is currently being implemented in some forensic laboratories and they are 
likely to be more specific than miRNA the results from this research suggest that miRNA, 
once further markers are identified would be the more suitable method. MiRNA analysis 
would require the least deviation from current DNA profiling protocols to obtain a BFID and 
DNA result. The stability of miRNA and lack of gDNA contamination would also make it a 
more robust tool for BFID with less likelihood of false positives. The storage of miRNA at -
20oC within the already extracted DNA samples would additionally save equipment and 
storage space as opposed to the -80oC required for storing an additional elute of mRNA.  
 Future Perspectives  
The research presented here has demonstrated the viability of miRNA as a BFID technique, 
however further studies would increase confidence in the technique for casework 
applications. For miRNA to be implemented into casework a large collaborative exercise 
between academic and industrial laboratories must be performed following the same 
protocols as stated within this research. Currently, previous studies within the literature 
have used varied protocols, for instance, using SYBR or TaqMan® assays or various RNA 
extraction techniques. Reproducibility across all laboratories would validate the robustness 
and specificity of these miRNA. Although this research was successful in identifying a 
number of body fluids, it was unable to determine skin and saliva when in a mixture of 
vaginal material. Further screening of current and emerging miRNAs may identify a body 
fluid specific marker which would address the limitations of this technique. An increase in 
the number of miRNA within the BFID panel may also be increase the capability for body 
fluid origin, if further investigation into blood markers is performed, the site of injury might 
be possible to identify.  
The detection and duration of detection of hsa-mir-124 collected from penile swabs 
following UPSI and ‘suspect’ buccal swabs following vaginal oral intercourse would 
continue to further demonstrate the robustness of this technique. The detection of semen 
markers within body fluid stains found in underwear following UPSI also presents an 
interesting application of the technique. This research would also be benefit from the 
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design and implementation of a custom miRNA quantification kit that would quantify 
specific miRNA within a sample as well as fit into current DNA profiling/ miRNA BFID 
protocol.  
Once validated; the testing on archived crime scene samples would be imperative in 
concluding its complete robustness for BFID: If samples retrieved from airbags that tested 
positive for saliva when examiners utilised Phadebas testing also displayed positive for hsa-
mir-205 (and any future propose saliva markers) in the absence of the remaining BFID panel 
it would show the specificity and suitability of miRNA BFID.  
 Concluding Remarks 
The data generated in this thesis highlight that miRNA is a common component of the cells 
associated with body fluids. The variance in composition between forensically relevant 
body fluids, coupled to the ubiquitous nature of certain markers provide a stable platform 
from which specific body fluids can be identified with confidence. The use of the stem-loop 
RT-qPCR technique uses instrumentation and reagents that are common in most molecular 
biology laboratories, and routinely in use in forensic laboratories. The stem loop RT is reliant 
on custom designed primers which are fully compatible with current RT-qPCR protocols and 
are relatively inexpensive to purchase.  
Within the study a number of miRNA markers were identified that could be used in 
combination with each other to successfully identify body fluids. In particular, the ability to 
determine whether a sample originated from the vagina and the ability to detect seminal 
fluid of azoospermic males provides significant support to the forensic scientist. A panel of 
endogenous controls are described which provide validation to the technique that could 
be potentially used within a court of law. The technique does not require specialist 
equipment and can be carried out on genetic material obtained from standard practice DNA 
extractions, providing cold case capability.   
A number of examples in which these techniques would be relevant to casework are 
provided. The data also suggest that there are some instances in which the use of miRNA as 
a marker would not be suitable. As of January, there are 2588 mature Homo sapien entries 
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within the 21st iteration of the database of miRNAs [151]. miRBase - version 1.0 (2012) 
contained 218 miRNA encompassing the entire animal kingdom. Clearly as the 
identification of miRNAs continues, the number of potential markers that could be screened 
is also growing, which could eventually eliminate these uncertainties. Above all, forensic 
science will never be capable of addressing the issue of consent, however the work 
presented here provides a platform for improving the confidence in the testimony of both 
the defence and prosecution, which can only serve to aid the criminal justice system.  
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A) Female Sampling Questionnaire  
 
 
 
 
The University of Huddersfield, Queensgate, Huddersfield, HD1 3DH 
CONSENT FORM 
Researcher: Kimberley Bexon; kimberley.bexon@hud.ac.uk – PhD researcher, School of Applied Sciences, 
The University of Huddersfield.  
Supervisor: Dr Graham Williams; g.a.williams@hud.ac.uk – School of Applied Sciences, The University of 
Huddersfield. 
The project aims to identify body fluids associated with sexual assault cases, such as vaginal material 
and menstrual blood, using short RNA markers. A selection of short RNA markers has been selected 
that are suggested to be highly specific to vaginal material and menstrual blood. Intimate samples are 
therefore  required  to  explore  and  validate  the  short  RNA  markers  with  respect  to  forensic 
investigations.  
You will be provided with two buccal swabs to take home with you. A  low vaginal swab can then be 
collected  in any manner  that you are comfortable with. The swabs should  then be delivered  to  the 
University of Huddersfield by the next day, or placed into freezer storage. Please do not use freezers 
designated for domestic usage for this purpose. 
All samples collected will be anonymised. Once received at  the research  laboratory, all samples will 
undergo DNA and RNA extraction. Once the DNA and RNA have been extracted, the rest of your sample 
will be disposed of in accordance with Human Tissue Authority guidelines. Your DNA and RNA sample 
will then be retained for analysis. The analysis includes measuring the amount of the short RNA markers 
present using standard molecular biology techniques. Once this analysis is completed, your DNA and 
RNA samples will be disposed of. No further testing will be conducted such as DNA profiling.  
To aid analysis certain information is required about the donated samples, all information provided is 
strictly confidential and will be held by myself and Dr Graham Williams in order to comply with the Data 
Protection Act and the Human Tissue Act.  
Please enter  the following  information.  If you are uncomfortable or unable  to answer the  following 
question, then please leave the section blank. .  
1. Age and ethnicity: 
 
2. What day of your cycle was the sample taken: 
 
3. How regular is your cycle, how heavy: 
 
4. Are you currently on any form of contraception: 
 
5. Do you smoke ‐ If so how many a day: 
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6. What is your pregnancy history? Are you currently or did you breast feed: 
 
7. Have you had a medical condition that affected your menstrual cycle or uterus: 
 
8. Do you take any medication: 
 
9. Have you been through the menopause: 
 
10. Have you had operations on any of your reproductive organs: 
 
11. How many unit of alcohol per week do you consume on average: 
 
12. Have you have unprotected sexual or oral intercourse within the past 96 hours 
 
13. Is there any other comment you can provide that you feel may have altered your menstrual 
cycle? 
 
 
 
Please initial all boxes  
I confirm that I have read and understand the information for the above study.              I have 
had the opportunity to consider the information, ask questions and have                 had these 
answered satisfactorily.   
I understand that my participation is voluntary and that I am free to withdraw my consent at 
any time without giving any reason. I also understand that if I withdraw my consent, I will 
not have my sample(s) returned to me. 
I agree to take part in the above study.       
 
                       
Name of Participant      Date        Signature 
                     
Thank you again for helping with my project, it is greatly appreciated. If you have any queries please 
feel free to contact me or my supervisor at kimberley.bexon@hud.ac.uk or g.a.williams@hud.ac.uk 
Kimberley Bexon MSc ACSFS 
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B)  Male Sampling Questionnaire  
CONSENT FORM 
Researcher: Kimberley Bexon; kimberley.bexon@hud.ac.uk – PhD researcher, School of Applied Sciences, 
The University of Huddersfield.  
Supervisor: Dr Graham Williams; g.a.williams@hud.ac.uk – School of Applied Sciences, The University of 
Huddersfield. 
The project aims to identify body fluids associated with sexual assault cases, such as semen, using short 
RNA markers. A  selection of  short RNA markers has been  selected  that are  suggested  to be highly 
specific to semen. Semen samples are therefore required to explore and validate the short RNA markers 
with respect to forensic investigations.  
You will be provided with a collection tube to take home with you. You will then deposit a semen sample 
in to the collection tube in any manner that you are comfortable with. The collection tube should then 
be delivered to the University of Huddersfield by the next day, or placed into freezer storage. Please do 
not use freezers designated for domestic usage for this purpose. 
All samples collected will be anonymised. Once received at the research laboratory, all semen samples 
will undergo DNA and RNA extraction. Once the DNA and RNA has been extracted, the rest of your 
sample will be disposed of in accordance with Human Tissue Authority guidelines. Your DNA and RNA 
sample will then be retained for analysis. The analysis includes measuring the amount of the short RNA 
markers present using standard molecular biology techniques. Once this analysis  is completed, your 
DNA and RNA samples will be disposed of. No further testing will be conducted such as DNA profiling.  
To aid analysis certain information is required about the donated samples, all information provided is 
strictly confidential and will be held by myself and Dr Graham Williams in order to comply with the Data 
Protection Act and the Human Tissue Act.  
Please enter  the following  information.  If you are uncomfortable or unable  to answer  the  following 
question, then please leave the section blank.  
a) Age: 
b) Have you had a vasectomy? 
c) Are you currently aware of your sperm count? 
 
Please initial all boxes  
1. I confirm that I have read and understand the information for the above study.                   
I have had the opportunity to consider the information, ask questions and have                 
had these answered satisfactorily.   
2. I understand that my participation is voluntary and that I am free to withdraw my 
consent at any time without giving any reason. I also understand that if I withdraw my 
consent, I will not have my semen sample returned to me. 
3. I agree to take part in the above study.       
                       
Name of Participant      Date        Signature 
Thank you again for helping with my project, it is greatly appreciated. If you have any queries please 
feel free to contact me or my supervisor at kimberley.bexon@hud.ac.uk or g.a.williams@hud.ac.uk 
Kimberley Bexon MSc ACSFS 
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C) Full Primer Sequences 
  BF RT Sequence F Sequence 
SNORD- 7 EC GTC GTAT TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACC  
CCA GGG TAT GAT CTC TTA ATC TTC TC
hsa-miR 10a-5p Semen GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC ACA AA  
TACCCTGTAGATCCG  
hsa-miR 10b-3p Semen GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA TTC CC 
CGC GCG ACA GAT TCG ATT CTA GGG G
hsa-miR 10b-5p Semen GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC ACA AA 
CGC GCG TAC CCT GTA GAA CCG A 
SNORD- 38b EC GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT CTC CT 
TGA CAG TAA GTG AAG ATA AAG TGT GTC
SNORD- 44 EC GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA GTC AG 
ACT GAA CAT GAA GGT CTT AAT TAG CTC
SNORD- 47 EC GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA CCT CA 
GAT ATC ACT GTA AAA CCG TTC CAT TTT G
hsa-miR 93 EC GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC TAC CT 
GCT CGC AAA GTG CTG TTC GT 
hsa-miR 124 Vaginal 
Material 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACG GCA TT  
T AAG GCC GCG GTG  
hsa-miR 124* Saliva GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATA
CGACATCAAG 
CGTGTTCACAGCGGAC  
hsa-miR 135a Semen GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT CAC AT (50 bp)  
TAT GGC TTT TTA TTC  
hsa-miR 135b Semen GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT CAC AT 
TATGGCTTTTCATTC 
hsa-miR 138-2 Saliva GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATA
CGACAACCCT 
GCTATTTCACGACAC 
hsa-miR 142-3p Menstrual 
Blood 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT CCA TA (50 bp) 
T GTA GTG TTT CCT AC  
hsa-miR 144-3p Menstrual 
Blood 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA GTA CA (50 bp)  
TACAGTATAGATGATG  
hsa-miR 144-5p Menstrual 
Blood 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC TTA CA (50 bp)  
GGATATCATCATATAC  
hsa-miR 185 -5p Venous 
Blood 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT CAG GA (50 bp)  
TGG AGA GAA AGG CAG   
hsa-miR 199a-5 Menstrual 
Blood 
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATA
CGACGAACAG 
CCCAGTGTTCAGACTAC  
hsa-miR 203a Skin GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC TAG TG (50 bp) 
TGA AAT GTT TAG GAC  
hsa-miR 205 Saliva GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC AGA CT (50 bp) 
TC CTT CAT TCC ACC  
hsa-miR 214-3 Menstrual 
Blood 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA CTG CC 
ACAGCAGGCACAGAC 
hsa-miR 223 Saliva GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT GGG GT   
TGTCAGTTTGTCAAA   
hsa-miR 372-3p Vaginal 
Material 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA CGC TC 
AAAGTGCTGCGAC 
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hsa-miR 412 Menstrual 
Blood 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA CGG CT 
ACTTCACCTGGTCCAC 
hsa-miR 455-3p Skin GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATA
CGACGTGTAT 
CGC GCA CTT CAC CTG GTC CAC 
hsa-miR 507 Semen GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATA
CGACTTCACT 
GCGGCGGTTTTGCACCTTTTGG 
hsa-miR 508 Semen GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC ATG AG 
GCC TGT ACT CCA GAG GGC GT 
hsa-miR 654-5q Vaginal 
Material 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACG CAC AT (50 bp)  
TGGTGGGCCGCAGAAC  
hsa-miR 888-5p Semen GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT GAC TG (50 bp)   
TA CTC AAA AAG CTG TC  
hsa-miR 891a Semen GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT CAG TG (50 bp)  
TGCAACGAACCTGAG  
hsa-miR 891b Semen GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACT CAA TG 
CGC GCG TGC AAC TTA CCT GAG TC
hsa-miR 892a Semen GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATA
CGACCTACGC 
CGC GCG CAC TGT GTC CTT TCT G 
hsa-miR 940   GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATA
CGACGGGGAG 
GCGGCGGAAGGCAGGGCCCCCG 
hsa-miR 1260b Vaginal 
Material 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA TGG TG (50 bp)   
ATCCCACCACTGCCAC   
hsa-miR 2392 Semen GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC ACC TC (50 bp)  
TAG GAT GGG GGT GAG   
hsa-miR 3169 Skin GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATA
CGACCTATGT 
TAGGACTGTGCTTGG 
hsa-miR 3197 Semen GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC GCC TT (50 bp) 
GGAGGCGCAGGCTCG 
hsa-miR 4286 Vaginal 
Material 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACG GTA CC 
ACCCCACTCCTGGTAC  
hsa-miR 16 Venous 
Blood 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACC GCC AA 
T AGC AGC ACG TAAAT 
Only in Neat   
hsa-miR 658 Saliva GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA CCA AC 
GGCGGAGGGAAGTAG 
hsa-miR 617 Vaginal GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACG CCA CC 
A GAC TTC CCA TTT GAA  
hsa-miR 451 Venous 
Blood 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG 
GAT ACG ACA ACT CA 
AAACCGTTACCATTAC 
    
Universal Reverse   GTG CAG GGT CCG AGG T 
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D) R - Heat Map Code 
#set working directory 
setwd("K:/Kimberley/18_R_Studio/Heatmap code/05082016") 
#Install requred package  
install.packages("gplots") 
install.packages("RColorBrewer") 
#load package into session 
library(gplots) 
library(RColorBrewer) 
#import csv file from folder, if columns are labelled, header=TRUE, if not =FALSE  
DNAdat<-read.csv("DNA2.csv", header=FALSE) 
#view data in console  
DNAdat 
#View subset of data 
DNAdat[1:5,] 
#Subset the big data into individual markers 
M1260b<-DNAdat[1:5,2:22] 
M1443<-DNAdat[6:10,2:22] 
M10a<-DNAdat[11:15,2:22] 
M142<-DNAdat[16:20,2:22] 
M124<-DNAdat[21:25,2:22] 
M203a<-DNAdat[26:30,2:22] 
#Set colour scale, colours taken from colour guide, n= step number 
M1260pal<-colorRampPalette(c( "white","purple4"))(n=256) 
 
#Make data matrix 
M1260bM<-data.matrix(M1260b) 
#make heatmap code, data file,  
M1260bHM <-heatmap.2(M1260bM, margins=c(15,5), Rowv=FALSE, Colv=FALSE, colsep=0:21,rowsep=0:5, 
sepcolor = "black", sepwidth = c(0.01, 0.01),  
                     col=M1260pal,tracecol =NULL, density.info="none",  linecol=NULL, hline = NULL, vline=NULL, 
symkey= FALSE,   key=TRUE, keysize = 1.0, key.title = "", key.xlab = "Deltact") 
                     
#Make data matrix 
M1443M<-data.matrix(M1443) 
#Make colour scale 
M1443pal<-colorRampPalette(c("white", "mediumaquamarine")) (n=256) 
#make heatmap code, data file, 
M1443HM <-heatmap.2(M1443M, margins=c(15,5), Rowv=FALSE, Colv=FALSE, colsep=0:21,rowsep=0:5, 
sepcolor = "black", sepwidth = c(0.01, 0.01),  
                    col=M1443pal,tracecol =NULL, density.info="none",  linecol=NULL, hline = NULL, vline=NULL, 
symkey= FALSE,    key=TRUE, keysize = 1.0, key.title = "", key.xlab = "Deltact") 
 
#Make data matrix 
M10aM<-data.matrix(M10a) 
#Make colour scale 
M10apal<-colorRampPalette(c("white", "maroon4")) (n=256) 
#make heatmap code, data file, 
M10aHM <-heatmap.2(M10aM, margins=c(15,5), Rowv=FALSE, Colv=FALSE, colsep=0:21,rowsep=0:5, 
sepcolor = "black", sepwidth = c(0.01, 0.01),  
                   col=M10apal,tracecol =NULL, density.info="none",  linecol=NULL, hline = NULL, vline=NULL, 
symkey= FALSE,                   key=TRUE, keysize = 1.0, key.title = "", key.xlab = "Deltact") 
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E) R - Box and Whisker Plot Code  
#Set working directory  
setwd("K:/phd_data/Intercourse_study/Rstudio") 
#install the plot package 
install.packages("ggplot2") 
#Load the package 
library(ggplot2) 
#Read in the data file 
dataset<-read.csv("data.csv", header=TRUE) 
#Name a plot 'plot1' and tell ggplot to use the dataset  
#aes sets the x axis to column labelled "Time" and y axis to the data in this case column 
Cq.10a 
#Tell it to add the additional categories 'fill' from the column labelled method 
plot1<-ggplot(dataset, aes(x=Time, y=Cq.10a, fill=Method))  
#Tell ggplot to make it a box plot, and set the outliers to black, a diamond shape "18" and 
size "2"   
+geom_boxplot(outlier.colour="black", outlier.shape=18, outlier.size=2)  
# Tell it to label the y axis "deltaCq" 
+ labs(y="ΔCq") 
#Tell it to add a manual scale to the fill the series, with the colours as values 
plot1+scale_fill_manual(values=c("dodgerblue", "darkorchid4", "forestgreen")) 
 
setwd("K:/phd_data/Intercourse_study/Rstudio") 
install.packages("ggplot2") 
library(ggplot2) 
dataset<-read.csv("data.csv", header=TRUE) 
plot1<-ggplot(dataset, aes(x=Time, y=Cq.10a, fill=Method))  
+geom_boxplot(outlier.colour="black", outlier.shape=18, outlier.size=2)  
+ labs(y="ΔCq") 
plot1+scale_fill_manual(values=c("dodgerblue", "darkorchid4", "forestgreen")) 
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F) Volunteer Information 
Unless stated in sample notes all female samples are NO for pregnancy, previous pregnancy, 
disease, contraception, smoking, drugs and have a regular cycle menopause 
UPSI – Unprotected intercourse within the past 7 days 
Grey boxes indicate repeat volunteer. 
Body Fluid     Age Ethnicity Sample notes 
Vaginal material 
Volunteer 1 36 White / British Contraceptive pill  
Volunteer 2 26 White / British Contraceptive pill  
Volunteer 3 22 White / British Condoms,  
Volunteer 4 37 White / British  
Volunteer 5 28 White / British Irregualr cycle, 1 child, breastfed, low alcohol consumption 
Volunteer 6 28 Afro Caribbean  
Volunteer 7 21 White / British Implant 
Volunteer 8 35 Mixed British 1 child 
Volunteer 9 39 White / British 2 pregnancies, implant 
Volunteer 10 23 White / British Contraceptive pill 
Volunteer 11 34 White / British 1 child, Contraceptive injection 
Volunteer 12 28 White / British 2 children, breastfed, Copper coil injection, smoker, average alcohol 
consumption 
Volunteer 13 26 White / British 1 child, miscarriage, stage 1 cervical cancer 
Volunteer 14 31 White / British  
Volunteer 15 21 White / British No menstrual cycle, Contraceptive injection, light smoker, avg. 10unit of 
alcohol p/w 
Volunteer 16 20 White / British Progesterone only pill 
Volunteer 17 22 White / British Cerelle – progesterone only pill 
Volunteer 18 26 Japanese Contraceptive oral pill 
Volunteer 19 22 White / British Progesterone only pill 
Volunteer 20 40 White / British 2 children, contraceptive pill 
Volunteer 21 21 White / British N/A, no previous sexual activity 
Volunteer 22 23 White / British No menstrual cycle, Pill contraceptive 
Volunteer 23 27 White / British Day 6 of cycle 
Volunteer 24 19 White / British Day 5 of cycle 
Volunteer 25 34 White / British No menstrual cycle, Implant contraception, Smoker, 2 previous children  
Volunteer 26 25 White / British No period for 3 years, Implant contraception, Heavy smoker, Previous 
miscarriage, taking medication 
Volunteer 27 40 White / British Full hysterectomy 
Volunteer 28 22 White / British Irregular and very heavy cycke, using IUD 
Volunteer 29 24 White / British Irregular light cycle, using IUD 
Volunteer 30 21 White / British UPSI, Pill contraceptive, day 10 of cycle, contraceptive pill 
Menstrual Blood 
Volunteer 4   Medium stain  
Volunteer 4 38 White / British Very light stain, Pill contraceptive 
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Volunteer 31 36 White / British Very light stain, unpredictable menstrual cycle, currently on day 12 of variable 
flow. 
Volunteer 8   Light stain on menstrual sample 
Volunteer 2   Very heavy stain, Pill contraceptive, day 3 of cycle 
Volunteer 12   Very heavy stain,  
Volunteer 21   Medium stain 
Volunteer 32 30 White / British Very heavy stain, 1 child 
Volunteer 33 21 White / British Very light stain 
Volunteer 13   Very light stain 
Volunteer 34 43 White / British 2 children, going through menopause 
Volunteer 18   Medium stain 
Volunteer 35 35 White / British Light stain  
Volunteer 5   Medium stain 
Volunteer 36 20 Mixed: white and 
Asian   
Very heavy staining, Pill Contraceptive – progesterone only 
Volunteer 37 21 White / British Very light stain, UP, Rod implant 
Volunteer 38 41 White / British 3 pregnancies (miscarried first) , breastfed all. Both C section not vaginal birth. 
Regular although altering recently possible due to onset of menopause 
Volunteer 39 48 IC4 - African Day 3 of cycle, regular and heavy cycle. Heavy stain. Suffered from 
endometriosis. On medication for anaemia. 
Saliva 
Volunteer 40 22 White / British No red stains observed 
Volunteer 41 26 Italian  No red stains observed
Volunteer 42 27 White / British No red stains observed
Volunteer 43 26 White British No red stains observed
Volunteer 2   No red stains observed
Volunteer 44 21 Asian (Indian) No red stains observed
Volunteer 15   No red stains observed
Volunteer 5   No red stains observed
Volunteer 45   No red stains observed
Volunteer 12   No red stains observed
Blood 
Volunteer 41    
Volunteer 44 21 Asian (Indian)  
Volunteer 12   Heavy stain 
Volunteer 5    
Volunteer 40    
Volunteer 2   Heavy stain 
Volunteer 43    
Volunteer 15    
Volunteer 45    
Volunteer 42   Light stain 
Semen 
Volunteer 42   Sperm count unknown, no vasectomy normal consistency 
Volunteer 41   Sperm count unknown, no vasectomy 
Volunteer 43 26 White British Sperm count unknown, no vasectomy 
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Volunteer 46 26 White British Sperm count unknown, no vasectomy, very thick  
Volunteer 47 29 White British Sperm count unknown, no vasectomy 
Volunteer 48 52 Afro Caribbean Sperm count unknown, no vasectomy, normal consistency  
Volunteer 49 21 White / British Sperm count unknown, no vasectomy 
Volunteer 40   Sperm count unknown, no vasectomy 
Volunteer 50 26 White British Sperm count unknown, no vasectomy, thick and goopy 
 
Volunteer 51 25 White British Sperm count unknown, no vasectomy 
Volunteer 52 21 White British Sperm count unknown, no vasectomy normal consistency 
Volunteer 53 22 White British Limitited volume sample normal consistency 
Volunteer 54 30 White British Sperm count unknown, no vasectomy 
Volunteer 55 24 White British Sperm count unknown, no vasectomy 
Volunteer 56 27 Asian Limited volume sample, quite clear and fluid 
Volunteer 57 24 White / British Sperm count unknown, no vasectomy 
Volunteer 58 21 White / British Sperm count unknown, no vasectomy normal consistency 
Volunteer 59 24 White / British Large volume samples, fairly fluid 
Volunteer 45 24 White / British Sperm count unknown, no vasectomy 
Volunteer 60 21 White / British Sperm count unknown, no vasectomy 
Vasectomised/ 
Seminal Fluid 
 
Volunteer 61 51 White / British Vasectomised 
Volunteer 62 42 White / British Vasectomised 
Volunteer 63 55 White/ Dutch Vasectomised 
Volunteer 64 52 White / British Vasectomised : Known zero sperm count: Almost clear in appearance 
Volunteer 65 46 White / British Vasectomised: Almost clear in appearance 
Volunteer 66 45 White / British Vasectomised: very ‘goopy’ 
Skin 
Volunteer 2    
Volunteer 41    
Volunteer 15    
Volunteer 5    
Volunteer 47    
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G) Limit of Detection of hsa-mir-888 in Vaginal 
Material 
Figure 10.1: Δ1Cq values + SEM obtained from hsa-mir-888 within six vaginal material samples  
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